Current Protein Identity:P07900 New Search
Main Difference Dimensions in This Set
Different construct Different mutation/modification Different assembly state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics

Difference tags compare only the current result set; every original PDB and assembly record remains separate.

Related-Structure Differences

Each row represents one biological assembly in one PDB entry; multiple monomers of the same protein are listed separately.

PDB Entry Assembly / Oligomeric State Construct Mutations and Modifications Ligands, Ions and Non-polymers Experimental Method Experimental Conditions Structure Quality
1BYQ HSP90 N-TERMINAL DOMAIN BOUND TO ADP-MG Deposited 1998-10-19 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 8–235(228 aa) Fragment:RESIDUES 9 - 236
Not recorded MG MAGNESIUM ION × 1 ADP ADENOSINE-5'-DIPHOSPHATE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8.5;pH 8.50
Resolution 1.50 Å R-free 0.247
1OSF Human Hsp90 in complex with 17-desmethoxy-17-N,N-Dimethylaminoethylamino-Geldanamycin Deposited 2003-03-19 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–223(215 aa) Fragment:Residues 9-223
Not recorded KOS 17-DESMETHOXY-17-N,N-DIMETHYLAMINOETHYLAMINO-GELDANAMYCIN × 1 MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 2 ACY ACETIC ACID × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;VAPOR DIFFUSION, HANGING DROP
Resolution 1.75 Å R-free 0.219
1UY6 Human Hsp90-alpha with 9-Butyl-8-(3,4,5-trimethoxy-benzyl)-9H-purin-6-ylamine Deposited 2004-03-02 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–235(235 aa) Fragment:N-TERMINAL DOMAIN, RESIDUES 1-235
Not recorded PU3 9-BUTYL-8-(3,4,5-TRIMETHOXYBENZYL)-9H-PURIN-6-AMINE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;25% PEG MME 2000, 0.1M NA CACODYLATE, PH6.5, 0.2M MGCL2., pH 6.50
Resolution 1.90 Å R-free 0.231
1UY7 Human Hsp90-alpha with 9-Butyl-8-(4-methoxy-benzyl)-9H-purin-6-ylamine Deposited 2004-03-02 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–235(235 aa) Fragment:N-TERMINAL DOMAIN, RESIDUES 1-235
Not recorded PU4 9-BUTYL-8-(4-METHOXYBENZYL)-9H-PURIN-6-AMINE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;25% PEG MME 2000, 0.1M NA CACODYLATE, PH6.5, 0.2M MGCL2., pH 6.50
Resolution 1.90 Å R-free 0.223
1UY8 Human Hsp90-alpha with 9-Butyl-8-(3-trimethoxy-benzyl)-9H-purin-6ylamine Deposited 2004-03-02 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–235(235 aa) Fragment:N-TERMINAL DOMAIN, RESIDUES 1-235
Not recorded PU5 9-BUTYL-8-(3-METHOXYBENZYL)-9H-PURIN-6-AMINE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;25% PEG MME 2000, 0.1M NA CACODYLATE, PH6.5, 0.2M MGCL2., pH 6.50
Resolution 1.98 Å R-free 0.204
1UY9 Human Hsp90-alpha with 8-Benzo[1,3]dioxol-,5-ylmethyl-9-butyl-9H-purin-6-ylamine Deposited 2004-03-02 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–235(235 aa) Fragment:N-TERMINAL DOMAIN, RESIDUES 1-235
Not recorded PU6 8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H- × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;25% PEG MME 2000, 0.1M NA CACODYLATE, PH6.5, 0.2M MGCL2., pH 6.50
Resolution 2.00 Å R-free 0.218
1UYC Human Hsp90-alpha with 9-Butyl-8-(2,5-dimethoxy-benzyl)-9H-purin-6-ylamine Deposited 2004-03-02 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–235(235 aa) Fragment:N-TERMINAL DOMAIN, RESIDUES 1-235
Not recorded PU7 9-BUTYL-8-(2,5-DIMETHOXY-BENZYL)-9H-PURIN-6-YLAMINE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;25% PEG MME 2000, 0.1M NA CACODYLATE, PH6.5, 0.2M MGCL2., pH 6.50
Resolution 2.00 Å R-free 0.248
1UYD Human Hsp90-alpha with 9-Butyl-8-(2-chloro-3,4,5-trimethoxy-benzyl)-9H-purin-6-ylamine Deposited 2004-03-02 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–235(235 aa) Fragment:N-TERMINAL DOMAIN, RESIDUES 1-235
Not recorded PU8 9-BUTYL-8-(2-CHLORO-3,4,5-TRIMETHOXY-BENZYL)-9H-PURIN-6-YLAMINE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;25% PEG MME 2000, 0.1M NA CACODYLATE, PH6.5, 0.2M MGCL2., pH 6.50
Resolution 2.20 Å R-free 0.218
1UYE Human Hsp90-alpha with 8-(2-chloro-3,4,5-trimethoxy-benzyl)-9-pent-4-ylnyl-9H-purin-6-ylamine Deposited 2004-03-02 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–235(235 aa) Fragment:N-TERMINAL DOMAIN, RESIDUES 1-235
Not recorded PU9 8-(2-CHLORO-3,4,5-TRIMETHOXY-BENZYL)-9-PENT-4-YLNYL-9H-PURIN-6-YLAMINE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;25% PEG MME 2000, 0.1M NA CACODYLATE, PH6.5, 0.2M MGCL2., pH 6.50
Resolution 2.00 Å R-free 0.218
1UYF Human Hsp90-alpha with 8-(2-chloro-3,4,5-trimethoxy-benzyl)-2-fluoro-9-pent-4-ylnyl-9H-purin-6-ylamine Deposited 2004-03-02 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–235(235 aa) Fragment:N-TERMINAL DOMAIN, RESIDUES 1-235
Not recorded PU1 8-(2-CHLORO-3,4,5-TRIMETHOXY-BENZYL)-2-FLUORO-9-PENT-4-YLNYL-9H-PURIN-6-YLAMINE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;25% PEG MME 2000, 0.1M NA CACODYLATE, PH6.5, 0.2M MGCL2., pH 6.50
Resolution 2.00 Å R-free 0.263
1UYG Human Hsp90-alpha with 8-(2,5-dimethoxy-benzyl)-2-fluoro-9H-purin-6-ylamine Deposited 2004-03-02 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–235(235 aa) Fragment:N-TERMINAL DOMAIN, RESIDUES 1-235
Not recorded PU2 8-(2,5-DIMETHOXY-BENZYL)-2-FLUORO-9H-PURIN-6-YLAMINE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;25% PEG MME 2000, 0.1M NA CACODYLATE, PH6.5, 0.2M MGCL2., pH 6.50
Resolution 2.00 Å R-free 0.218
1UYH Human Hsp90-alpha with 9-Butyl-8-(2,5-dimethoxy-benzyl)-2-fluoro-9H-purin-6-ylamine Deposited 2004-03-02 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–235(235 aa) Fragment:N-TERMINAL DOMAIN, RESIDUES 1-235
Not recorded PU0 9-BUTYL-8-(2,5-DIMETHOXY-BENZYL)-2-FLUORO-9H-PURIN-6-YLAMINE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;25% PEG MME 2000, 0.1M NA CACODYLATE, PH6.5, 0.2M MGCL2., pH 6.50
Resolution 2.20 Å R-free 0.326
1UYI Human Hsp90-alpha with 8-(2,5-dimethoxy-benzyl)-2-fluoro-9-pent-9H-purin-6-ylamine Deposited 2004-03-02 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–235(235 aa) Fragment:N-TERMINAL DOMAIN, RESIDUES 1-235
Not recorded PUZ 8-(2,5-DIMETHOXY-BENZYL)-2-FLUORO-9-PENT-9H-PURIN-6-YLAMINE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;25% PEG MME 2000, 0.1M NA CACODYLATE, PH6.5, 0.2M MGCL2., pH 6.50
Resolution 2.20 Å R-free 0.218
1UYK Human Hsp90-alpha with 8-Benzo[1,3]dioxol-,5-ylmethyl-9-butyl-2-fluoro-9H-purin-6-ylamine Deposited 2004-03-02 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–235(235 aa) Fragment:N-TERMINAL DOMAIN, RESIDUES 1-235
Not recorded PUX 8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-2-FLUORO-9H-PURIN-6-YLAMINE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;25% PEG MME 2000, 0.1M NA CACODYLATE, PH6.5, 0.2M MGCL2., pH 6.50
Resolution 2.20 Å R-free 0.218
1UYL Structure-Activity Relationships in purine-based inhibitor binding to HSP90 isoforms Deposited 2004-03-02 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–235(235 aa) Fragment:N-TERMINAL DOMAIN, RESIDUES 1-235
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;25% PEG MME 2000, 0.1M NA CACODYLATE, PH6.5, 0.2M MGCL2., pH 6.50
Resolution 1.40 Å R-free 0.227
1YC1 Crystal Structures of human HSP90alpha complexed with dihydroxyphenylpyrazoles Deposited 2004-12-21 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 8–235(228 aa) Fragment:N-terminal ATP binding domain residues 9-223
Mutation:no 4BC 4-(1,3-BENZODIOXOL-5-YL)-5-(5-ETHYL-2,4-DIHYDROXYPHENYL)-2H-PYRAZOLE-3-CARBOXYLIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 9;277 K;PEG 6000, LiCl, pH 9.0, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 1.70 Å R-free 0.227
1YC3 Crystal Structure of human HSP90alpha complexed with dihydroxyphenylpyrazoles Deposited 2004-12-21 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 8–235(228 aa) Fragment:sequence database residues 8-222
Not recorded 4BC 4-(1,3-BENZODIOXOL-5-YL)-5-(5-ETHYL-2,4-DIHYDROXYPHENYL)-2H-PYRAZOLE-3-CARBOXYLIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 9;277 K;PEG 6000, LiCl, pH 9.0, VAPOR DIFFUSION, HANGING DROP, temperature 277K, pH 9.00
Resolution 2.12 Å R-free 0.259
1YC4 Crystal structure of human HSP90alpha complexed with dihydroxyphenylpyrazoles Deposited 2004-12-21 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 8–235(228 aa) Fragment:sequence database residues 8-223
Mutation:M12C 43P 4-(1H-IMIDAZOL-4-YL)-3-(5-ETHYL-2,4-DIHYDROXY-PHENYL)-1H-PYRAZOLE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 9;277 K;PEG 6000, LiCl, pH 9.0, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 1.81 Å R-free 0.220
1YER HUMAN HSP90 GELDANAMYCIN-BINDING DOMAIN, "CLOSED" CONFORMATION Deposited 1997-03-25 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 8–235(228 aa) Fragment:RESIDUES 9 - 236
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.65 Å R-free 0.244
1YES HUMAN HSP90 GELDANAMYCIN-BINDING DOMAIN, "OPEN" CONFORMATION Deposited 1997-03-25 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 8–235(228 aa) Fragment:RESIDUES 9 - 236
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.20 Å
1YET GELDANAMYCIN BOUND TO THE HSP90 GELDANAMYCIN-BINDING DOMAIN Deposited 1997-03-25 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 8–235(228 aa) Fragment:RESIDUES 9 - 236
Not recorded GDM GELDANAMYCIN × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.90 Å
21FD Neutron crystal structure of the apo form of the human Hsp90 N-terminal domain Deposited 2025-12-11 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded No recorded non-water small molecule NEUTRON DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.10 Å R-free 0.213
21FE Neutron crystal structure of the ADP bound form of the human Hsp90 N-terminal domain Deposited 2025-12-11 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded No recorded non-water small molecule NEUTRON DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.10 Å R-free 0.226
2BSM Novel, potent small molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design Deposited 2005-05-23 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 1–235(235 aa) Fragment:N-TERMINAL DOMAIN, RESIDUES 1-235
Not recorded BSM 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)-1H-PYRAZOLE-3-CARBOXAMIDE × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;25% PEG MME 2000, 0.1M NA CACODYLATE, PH6.5, 0.2M MGCL2., pH 6.50
Resolution 2.05 Å R-free 0.244
2BT0 Novel, potent small molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design Deposited 2005-05-24 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 1–235(235 aa) Fragment:N-TERMINAL DOMAIN, RESIDUES 1-235
Not recorded CT5 4-[4-(2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)-3-METHYL-1H-PYRAZOL-5-YL]-6-ETHYLBENZENE-1,3-DIOL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;pH 6.50
Resolution 1.90 Å R-free 0.244
2BT0 Novel, potent small molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design Deposited 2005-05-24 Assembly 2 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain B 1–235(235 aa) Fragment:N-TERMINAL DOMAIN, RESIDUES 1-235
Not recorded CT5 4-[4-(2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)-3-METHYL-1H-PYRAZOL-5-YL]-6-ETHYLBENZENE-1,3-DIOL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;pH 6.50
Resolution 1.90 Å R-free 0.244
2BYH 3-(5-chloro-2,4-dihydroxyphenyl)-pyrazole-4-carboxamides as Inhibitors of the Hsp90 Molecular Chaperone Deposited 2005-08-02 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 10–235(226 aa) Fragment:N-TERMINAL DOMAIN, RESIDUES 1-235
Not recorded 2D7 N-(4-ACETYLPHENYL)-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;25% PEG MME 2000, 0.1M NA CACODYLATE, PH6.5, 0.2M MGCL2., pH 6.50
Resolution 1.90 Å R-free 0.211
2BYI 3-(5-chloro-2,4-dihydroxyphenyl)-pyrazole-4-carboxamides as Inhibitors of the Hsp90 Molecular Chaperone Deposited 2005-08-02 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 10–235(226 aa) Fragment:N-TERMINAL DOMAIN, RESIDUES 1-235
Not recorded 2DD 3-(5-CHLORO-2,4-DIHYDROXY-PHENYL)-1H-PYRAZOLE-4-CARBOXYLIC ACID 4-SULFAMOYL-BENZYLAMIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 5.5;25% PEG MME 2000, 0.1M NA CACODYLATE, PH6.5, 0.2M MGCL2, pH 5.50
Resolution 1.60 Å R-free 0.242
2BZ5 Structure-based Discovery of a New Class of Hsp90 Inhibitors Deposited 2005-08-11 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–235(235 aa) Fragment:N-TERMINAL DOMAIN, RESIDUES 1-235
Not recorded AB4 2,5-DICHLORO-N-[4-HYDROXY-3-(2-HYDROXY-1-NAPHTHYL)PHENYL]BENZENESULFONAMIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;CRYSTALLIZATION CONDITIONS: 25% PEG MME 2000, 0.1M NA CACODYLATE, PH6.5, 0.2M MGCL2., pH 6.50
Resolution 1.90 Å R-free 0.254
2BZ5 Structure-based Discovery of a New Class of Hsp90 Inhibitors Deposited 2005-08-11 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–235(235 aa) Fragment:N-TERMINAL DOMAIN, RESIDUES 1-235
Not recorded AB4 2,5-DICHLORO-N-[4-HYDROXY-3-(2-HYDROXY-1-NAPHTHYL)PHENYL]BENZENESULFONAMIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;CRYSTALLIZATION CONDITIONS: 25% PEG MME 2000, 0.1M NA CACODYLATE, PH6.5, 0.2M MGCL2., pH 6.50
Resolution 1.90 Å R-free 0.254
2CCS HUMAN HSP90 WITH 4-CHLORO-6-(4-PIPERAZIN-1-YL-1H-PYRAZOL-3-YL)- BENZENE-1,2-DIOL Deposited 2006-01-18 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa) Fragment:N-TERMINAL DOMAIN RESIDUES 1-236
Not recorded 4BH 4-CHLORO-6-(4-PIPERAZIN-1-YL-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;pH 6.50
Resolution 1.79 Å R-free 0.277
2CCT HUMAN HSP90 WITH 5-(5-CHLORO-2,4-DIHYDROXY-PHENYL)-4-PIPERAZIN-1-YL- 2H-PYRAZOLE-3-CARBOXYLIC ACID ETHYLAMIDE Deposited 2006-01-18 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa) Fragment:N-TERMINAL DOMAIN RESIDUES 1-236
Not recorded 2E1 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-PIPERAZIN-1-YL-1H-PYRAZOLE-3-CARBOXAMIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;pH 6.50
Resolution 2.30 Å R-free 0.299
2CCU HUMAN HSP90 WITH 4-CHLORO-6-(4-(4-(4-METHANESULPHONYL-BENZYL)- PIERAZIN-1-YL)-1H-PYRAZOL-3-YL)-BENZENE-1,3-DIOL Deposited 2006-01-18 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa) Fragment:N-TERMINAL DOMAIN RESIDUES 1-236
Not recorded 2D9 4-CHLORO-6-(4-{4-[4-(METHYLSULFONYL)BENZYL]PIPERAZIN-1-YL}-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;pH 6.50
Resolution 2.70 Å R-free 0.313
2JJC Hsp90 alpha ATPase domain with bound small molecule fragment Deposited 2008-03-31 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–15(7 aa) Fragment:N-TERMINAL ATPASE DOMAIN, RESIDUES 9-15,17-223
Chain A 17–223(207 aa) Fragment:N-TERMINAL ATPASE DOMAIN, RESIDUES 9-15,17-223
Not recorded DMS DIMETHYL SULFOXIDE × 2 LGA PYRIMIDIN-2-AMINE × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.8;0.1M SODIUM CACODYLATE PH 6.8 0.2M MAGNESIUM CHLORIDE 20%(W/V) MPEG 2000
Resolution 1.95 Å R-free 0.217
2K5B Human CDC37-HSP90 docking model based on NMR Deposited 2008-06-26 Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 14–223(210 aa) Fragment:residues 14-223
Not recorded No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 7.4;298 K;Ionic strength (raw mmCIF value) 100;Pressure ambient
NMR sample composition 0.8mM [U-100% 15N] human HSP90, 0.8mM [U-100% 15N] human CDC37, 50mM HEPES, 100mM sodium chloride, 1mM DTT, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition 0.8mM [U-100% 15N, U-100% 2H] human HSP90, 0.8mM human CDC37, 50mM HEPES, 100mM sodium chloride, 1mM DTT, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition 0.8mM human HSP90, 0.8mM [U-100% 15N, U-100% 2H] human CDC37, 50mM HEPES, 100mM sodium chloride, 1mM DTT, 90% H2O/10% D2O | 90% H2O/10% D2O
Resolution not provided
2QF6 HSP90 complexed with A56322 Deposited 2007-06-26 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 17–223(207 aa)
Not recorded A56 6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;22 %(w/v) PEG 8000, 0.1 M Na cacodylate, 0.2 M Ammonium Sulfate, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 3.10 Å R-free 0.284
2QF6 HSP90 complexed with A56322 Deposited 2007-06-26 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 17–223(207 aa)
Not recorded A56 6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;22 %(w/v) PEG 8000, 0.1 M Na cacodylate, 0.2 M Ammonium Sulfate, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 3.10 Å R-free 0.284
2QF6 HSP90 complexed with A56322 Deposited 2007-06-26 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 17–223(207 aa)
Not recorded A56 6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;22 %(w/v) PEG 8000, 0.1 M Na cacodylate, 0.2 M Ammonium Sulfate, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 3.10 Å R-free 0.284
2QF6 HSP90 complexed with A56322 Deposited 2007-06-26 Assembly 4 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain D 17–223(207 aa)
Not recorded A56 6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;22 %(w/v) PEG 8000, 0.1 M Na cacodylate, 0.2 M Ammonium Sulfate, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 3.10 Å R-free 0.284
2QFO HSP90 complexed with A143571 and A516383 Deposited 2007-06-27 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 17–223(207 aa) Fragment:UNP residues 17-223
Not recorded A13 4-METHYL-6-(TRIFLUOROMETHYL)PYRIMIDIN-2-AMINE × 1 A51 (3E)-3-[(phenylamino)methylidene]dihydrofuran-2(3H)-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8.5;277 K;Protein at 35 mg/ml with a reservoir of 22-30 % (w/v) PEG4000, 0.1 M Tris-HCl PH 8.5, 0.2 M MgCl2, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 1.68 Å R-free 0.237
2QFO HSP90 complexed with A143571 and A516383 Deposited 2007-06-27 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 17–223(207 aa) Fragment:UNP residues 17-223
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8.5;277 K;Protein at 35 mg/ml with a reservoir of 22-30 % (w/v) PEG4000, 0.1 M Tris-HCl PH 8.5, 0.2 M MgCl2, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 1.68 Å R-free 0.237
2QG0 HSP90 complexed with A943037 Deposited 2007-06-28 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 17–223(207 aa)
Chain B 17–223(207 aa)
Not recorded A94 N-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)METHYL]-3-{[(E)-(2-OXODIHYDROFURAN-3(2H)-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;40 mg/ml protein with a reservoir solution of 20-28 %(w/v)PEG 3350, 0.1 M Bis-Tris-Propane PH 6.5, 0.2 M Sodium chloride, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 1.85 Å R-free 0.285
2QG2 HSP90 complexed with A917985 Deposited 2007-06-28 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 17–223(207 aa)
Not recorded A91 3-({2-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)ETHYNYL]BENZYL}AMINO)-1,3-OXAZOL-2(3H)-ONE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;40 mg/ml protein with a reservoir solution of 8-18 %(w/v) PMME 2000, 0.1 M sodium cacodylate PH 6.5, 0.2 M MgCl2, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 1.80 Å R-free 0.234
2UWD Inhibition of the HSP90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole, isoxazole amide analogs Deposited 2007-03-20 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 1–235(235 aa)
Not recorded MG MAGNESIUM ION × 4 SO4 SULFATE ION × 2 2GG 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)ISOXAZOLE-3-CARBOXAMIDE × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;pH 6.50
Resolution 1.90 Å R-free 0.259
2VCI 4,5 Diaryl Isoxazole Hsp90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer Deposited 2007-09-24 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 1–236(236 aa) Fragment:N-TERMINAL DOMAIN, RESIDUES 1-236
Not recorded 2GJ 5-[2,4-DIHYDROXY-5-(1-METHYLETHYL)PHENYL]-N-ETHYL-4-[4-(MORPHOLIN-4-YLMETHYL)PHENYL]ISOXAZOLE-3-CARBOXAMIDE × 2 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.00 Å R-free 0.278
2VCJ 4,5 Diaryl Isoxazole Hsp90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer Deposited 2007-09-24 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 1–236(236 aa) Fragment:N-TERMINAL DOMAIN, RESIDUES 1-236
Not recorded 2EQ 5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]isoxazole-3-carboxamide × 2 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.50 Å R-free 0.305
2WI1 Orally Active 2-Amino Thienopyrimidine Inhibitors of the Hsp90 Chaperone Deposited 2009-05-08 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa) Fragment:N-TERMINAL ATP-BINDING DOMAIN, RESIDUES 1-236
Not recorded MG MAGNESIUM ION × 1 ZZ2 4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;pH 6.5
Resolution 2.30 Å R-free 0.321
2WI2 Orally Active 2-Amino Thienopyrimidine Inhibitors of the Hsp90 Chaperone Deposited 2009-05-08 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa) Fragment:N-TERMINAL ATP-BINDING DOMAIN, RESIDUES 1-236
Not recorded DMS DIMETHYL SULFOXIDE × 1 ZZ3 4-METHYL-6-(METHYLSULFANYL)-1,3,5-TRIAZIN-2-AMINE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;pH 6.5
Resolution 2.09 Å R-free 0.289
2WI2 Orally Active 2-Amino Thienopyrimidine Inhibitors of the Hsp90 Chaperone Deposited 2009-05-08 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–236(236 aa) Fragment:N-TERMINAL ATP-BINDING DOMAIN, RESIDUES 1-236
Not recorded ZZ3 4-METHYL-6-(METHYLSULFANYL)-1,3,5-TRIAZIN-2-AMINE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;pH 6.5
Resolution 2.09 Å R-free 0.289
2WI3 Orally Active 2-Amino Thienopyrimidine Inhibitors of the Hsp90 Chaperone Deposited 2009-05-08 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa) Fragment:N-TERMINAL ATP-BINDING DOMAIN, RESIDUES 1-236
Not recorded MG MAGNESIUM ION × 1 ZZ3 4-METHYL-6-(METHYLSULFANYL)-1,3,5-TRIAZIN-2-AMINE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;pH 6.5
Resolution 1.90 Å R-free 0.242
2WI4 Orally Active 2-Amino Thienopyrimidine Inhibitors of the Hsp90 Chaperone Deposited 2009-05-08 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa) Fragment:N-TERMINAL ATP-BINDING DOMAIN, RESIDUES 1-236
Not recorded ZZ4 4-(2,4-dichlorophenyl)-5-phenyldiazenyl-pyrimidin-2-amine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;pH 6.5
Resolution 2.40 Å R-free 0.285
2WI5 Orally Active 2-Amino Thienopyrimidine Inhibitors of the Hsp90 Chaperone Deposited 2009-05-08 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa) Fragment:N-TERMINAL ATP-BINDING DOMAIN, RESIDUES 1-236
Not recorded ZZ5 3,6-DIAMINO-5-CYANO-4-(4-ETHOXYPHENYL)THIENO[2,3-B]PYRIDINE-2-CARBOXAMIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;pH 6.5
Resolution 2.10 Å R-free 0.302
2WI6 Orally Active 2-Amino Thienopyrimidine Inhibitors of the Hsp90 Chaperone Deposited 2009-05-08 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa) Fragment:N-TERMINAL ATP-BINDING DOMAIN, RESIDUES 1-236
Not recorded ZZ6 2-AMINO-4-(2,4-DICHLOROPHENYL)-N-ETHYLTHIENO[2,3-D]PYRIMIDINE-6-CARBOXAMIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;pH 6.5
Resolution 2.18 Å R-free 0.304
2WI7 Orally Active 2-Amino Thienopyrimidine Inhibitors of the Hsp90 Chaperone Deposited 2009-05-08 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa) Fragment:N-TERMINAL ATP-BINDING DOMAIN, RESIDUES 1-236
Not recorded 2KL 2-amino-4-[2,4-dichloro-5-(2-pyrrolidin-1-ylethoxy)phenyl]-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;pH 6.5
Resolution 2.50 Å R-free 0.281
2XAB Structure of HSP90 with an inhibitor bound Deposited 2010-03-30 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:RESIDUES 9-236
Not recorded VHD 4-(1,3-DIHYDRO-2H-ISOINDOL-2-YLCARBONYL)-6-(1-METHYLETHYL)BENZENE-1,3-DIOL × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.90 Å R-free 0.236
2XAB Structure of HSP90 with an inhibitor bound Deposited 2010-03-30 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 9–236(228 aa) Fragment:RESIDUES 9-236
Not recorded VHD 4-(1,3-DIHYDRO-2H-ISOINDOL-2-YLCARBONYL)-6-(1-METHYLETHYL)BENZENE-1,3-DIOL × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.90 Å R-free 0.236
2XDK Structure of HSP90 with small molecule inhibitor bound Deposited 2010-05-04 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:RESIDUES 9-236
Not recorded XDK 2-AMINO-4-PYRIDYL-PYRIMIDINE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.97 Å R-free 0.240
2XDL Structure of HSP90 with small molecule inhibitor bound Deposited 2010-05-04 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–236(228 aa) Fragment:RESIDUES 9-236
Not recorded 2DL 2-METHYL-4-DIETHYLAMIDE-PHENOL × 2 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.98 Å R-free 0.252
2XDS Structure of HSP90 with small molecule inhibitor bound Deposited 2010-05-07 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:RESIDUES 9-236
Not recorded DMS DIMETHYL SULFOXIDE × 1 MT0 1-CHLORO-4-METHYLPHTHALAZINE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.97 Å R-free 0.248
2XDU Structure of HSP90 with small molecule inhibitor bound Deposited 2010-05-07 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 14–224(211 aa) Fragment:RESIDUES 14-224
Not recorded MG MAGNESIUM ION × 1 DMS DIMETHYL SULFOXIDE × 1 LGA PYRIMIDIN-2-AMINE × 1 MT0 1-CHLORO-4-METHYLPHTHALAZINE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.74 Å R-free 0.222
2XDX Structure of HSP90 with small molecule inhibitor bound Deposited 2010-05-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:RESIDUES 9-236
Not recorded WOE 4-CHLORO-6-(2-METHOXYPHENYL)PYRIMIDIN-2-AMINE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.42 Å R-free 0.330
2XHR Structure of HSP90 with small molecule inhibitor bound Deposited 2010-06-21 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-TERMINAL DOMAIN (9-236)
Not recorded C0P 4-CHLORO-6-[2,4-DICHLORO-5-(2-MORPHOLIN-4-YLETHOXY)PHENYL]PYRIMIDIN-2-AMINE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.20 Å R-free 0.304
2XHT Structure of HSP90 with small molecule inhibitor bound Deposited 2010-06-21 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:RESIDUES 9-236
Not recorded C0Y (3-TERT-BUTYL-4-HYDROXYPHENYL)MORPHOLIN-4-YL-METHANONE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.27 Å R-free 0.297
2XHX Structure of HSP90 with small molecule inhibitor bound Deposited 2010-06-21 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-TERMINAL DOMAIN (9-236)
Not recorded T5M 2-TERT-BUTYL-4-(1,3-DIHYDRO-2H-ISOINDOL-2-YLCARBONYL)PHENOL × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.80 Å R-free 0.407
2XJG Structure of HSP90 with small molecule inhibitor bound Deposited 2010-07-06 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:RESIDUES 9-236
Not recorded XJG 1,3-DIHYDROISOINDOL-2-YL-(2-HYDROXY-4-METHOXY-5-PROPAN-2-YL-PHENYL)METHANONE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.25 Å R-free 0.281
2XJJ Structure of HSP90 with small molecule inhibitor bound Deposited 2010-07-06 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:RESIDUES 9-236
Not recorded GOL GLYCEROL × 1 L81 1,3-DIHYDROISOINDOL-2-YL-(6-HYDROXY-3,3-DIMETHYL-1,2-DIHYDROINDOL-5-YL)METHANONE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.90 Å R-free 0.233
2XJJ Structure of HSP90 with small molecule inhibitor bound Deposited 2010-07-06 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 9–236(228 aa) Fragment:RESIDUES 9-236
Not recorded GOL GLYCEROL × 1 L81 1,3-DIHYDROISOINDOL-2-YL-(6-HYDROXY-3,3-DIMETHYL-1,2-DIHYDROINDOL-5-YL)METHANONE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.90 Å R-free 0.233
2XJX Structure of HSP90 with small molecule inhibitor bound Deposited 2010-07-06 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:RESIDUES 9-236
Not recorded XJX Onalespib × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.66 Å R-free 0.208
2XK2 Structure of HSP90 with small molecule inhibitor bound Deposited 2010-07-07 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:RESIDUES 9-236
Not recorded MG MAGNESIUM ION × 1 ADP ADENOSINE-5'-DIPHOSPHATE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.95 Å R-free 0.257
2YE2 HSP90 inhibitors and drugs from fragment and virtual screening Deposited 2011-03-25 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-TERMINAL ATP-BINDING DOMAIN, RESIDUES 9-236
Not recorded SO4 SULFATE ION × 2 XQI METHYL 2-(3,5-DIHYDROXYPHENYL)ETHANOATE × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;pH 6.5
Resolution 1.90 Å R-free 0.221
2YE3 HSP90 inhibitors and drugs from fragment and virtual screening Deposited 2011-03-25 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-TERMINAL ATP-BINDING DOMAIN, RESIDUES 9-236
Not recorded VXX METHYL VANILLATE × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;pH 6.5
Resolution 1.95 Å R-free 0.237
2YE4 HSP90 inhibitors and drugs from fragment and virtual screening Deposited 2011-03-25 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-TERMINAL ATP-BINDING DOMAIN, RESIDUES 9-236
Not recorded 2FY 1-(2,4-DIHYDROXY-PHENYL)-PROPAN-1-ONE × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;pH 6.5
Resolution 2.30 Å R-free 0.288
2YE5 HSP90 inhibitors and drugs from fragment and virtual screening Deposited 2011-03-25 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-TERMINAL ATP-BINDING DOMAIN, RESIDUES 9-236
Not recorded 2A7 5-METHOXY-BENZENE-1,3-DIOL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;pH 6.5
Resolution 1.73 Å R-free 0.292
2YE6 HSP90 inhibitors and drugs from fragment and virtual screening Deposited 2011-03-25 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-TERMINAL ATP-BINDING DOMAIN, RESIDUES 9-236
Not recorded 2AE 2-AMINO-BENZAMIDE × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;pH 6.5
Resolution 2.56 Å R-free 0.290
2YE7 HSP90 inhibitors and drugs from fragment and virtual screening Deposited 2011-03-25 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-TERMINAL ATP-BINDING DOMAIN, RESIDUES 9-236
Not recorded 2GA 2-[(3,5-DIMETHYL-1H-PYRAZOL-4-YL)SULFANYL]-5-METHYLSULFANYL-1,3,4-THIADIAZOLE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;pH 6.5
Resolution 2.20 Å R-free 0.245
2YE8 HSP90 inhibitors and drugs from fragment and virtual screening Deposited 2011-03-25 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-TERMINAL ATP-BINDING DOMAIN, RESIDUES 9-236
Not recorded MG MAGNESIUM ION × 2 2D3 METHYL 3-ISOXAZOL-5-YL-5-METHYL-1H-PYRAZOLE-4-CARBOXYLATE × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;pH 6.5
Resolution 2.30 Å R-free 0.283
2YE9 HSP90 inhibitors and drugs from fragment and virtual screening Deposited 2011-03-25 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-TERMINAL ATP-BINDING DOMAIN, RESIDUES 1-236
Not recorded 2D4 N-[4-HYDROXY-3-(2-HYDROXYNAPHTHALEN-1-YL)PHENYL]THIOPHENE-2-SULFONAMIDE × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;pH 6.5
Resolution 2.20 Å R-free 0.289
2YEA HSP90 inhibitors and drugs from fragment and virtual screening Deposited 2011-03-25 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-TERMINAL ATP-BINDING DOMAIN, RESIDUES 9-236
Not recorded 2A9 5-(HYDROXYMETHYL)-2-METHOXYPHENOL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;pH 6.5
Resolution 1.73 Å R-free 0.300
2YEB HSP90 inhibitors and drugs from fragment and virtual screening Deposited 2011-03-25 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-TERMINAL ATP-BINDING DOMAIN, RESIDUES 9-236
Not recorded 2K4 1H-INDAZOL-6-OL × 2 CL CHLORIDE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;pH 6.5
Resolution 2.40 Å R-free 0.311
2YEC HSP90 inhibitors and drugs from fragment and virtual screening Deposited 2011-03-25 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-TERMINAL ATP-BINDING DOMAIN, RESIDUES 9-236
Not recorded SO4 SULFATE ION × 4 XQ0 3-METHYL-1H-INDAZOL-6-OL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;pH 6.5
Resolution 2.10 Å R-free 0.282
2YED HSP90 inhibitors and drugs from fragment and virtual screening Deposited 2011-03-25 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-TERMINAL ATP-BINDING DOMAIN, RESIDUES 9-236
Not recorded CL CHLORIDE ION × 2 ADE ADENINE × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;pH 6.5
Resolution 2.10 Å R-free 0.258
2YEE HSP90 inhibitors and drugs from fragment and virtual screening Deposited 2011-03-25 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-TERMINAL ATP-BINDING DOMAIN, RESIDUES 9-236
Not recorded SO4 SULFATE ION × 4 2EC 9-ETHYL-9H-PURIN-6-YLAMINE × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;pH 6.5
Resolution 2.30 Å R-free 0.307
2YEF HSP90 inhibitors and drugs from fragment and virtual screening Deposited 2011-03-25 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-TERMINAL ATP-BINDING DOMAIN, RESIDUES 9-236
Not recorded MG MAGNESIUM ION × 1 ANP PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;pH 6.5
Resolution 1.55 Å R-free 0.219
2YEG HSP90 inhibitors and drugs from fragment and virtual screening Deposited 2011-03-25 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-TERMINAL ATP-BINDING DOMAIN, RESIDUES 9-236
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;pH 6.5
Resolution 2.50 Å R-free 0.324
2YEG HSP90 inhibitors and drugs from fragment and virtual screening Deposited 2011-03-25 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 9–236(228 aa) Fragment:N-TERMINAL ATP-BINDING DOMAIN, RESIDUES 9-236
Not recorded XQG 6-METHYLSULFANYL-9H-PURINE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;pH 6.5
Resolution 2.50 Å R-free 0.324
2YEH HSP90 inhibitors and drugs from fragment and virtual screening Deposited 2011-03-25 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-TERMINAL ATP-BINDING DOMAIN, RESIDUES 9-236
Not recorded SO4 SULFATE ION × 1 2KU N-(3-METHOXYPROPYL)-9H-PURIN-6-AMINE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;pH 6.5
Resolution 2.10 Å R-free 0.291
2YEI HSP90 inhibitors and drugs from fragment and virtual screening Deposited 2011-03-25 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-TERMINAL ATP-BINDING DOMAIN, RESIDUES 9-236
Not recorded XQK METHYL 5-ISOXAZOL-5-YL-3-METHYL-1H-PYRAZOLE-4-CARBOXYLATE × 1 XQI METHYL 2-(3,5-DIHYDROXYPHENYL)ETHANOATE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;pH 6.5
Resolution 2.20 Å R-free 0.390
2YEJ HSP90 inhibitors and drugs from fragment and virtual screening Deposited 2011-03-25 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-TERMINAL ATP-BINDING DOMAIN, RESIDUES 9-236
Not recorded MG MAGNESIUM ION × 1 XQK METHYL 5-ISOXAZOL-5-YL-3-METHYL-1H-PYRAZOLE-4-CARBOXYLATE × 1 ZZ3 4-METHYL-6-(METHYLSULFANYL)-1,3,5-TRIAZIN-2-AMINE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;pH 6.5
Resolution 2.20 Å R-free 0.349
2YI0 Structural characterization of 5-Aryl-4-(5-substituted-2-4- dihydroxyphenyl)-1,2,3-thiadiazole Hsp90 inhibitors. Deposited 2011-05-10 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 1–229(229 aa) Fragment:N-TERMINAL DOMAIN, RESIDUES 1-229
Not recorded YI0 4-CHLORO-6-[5-(4-METHOXYPHENYL)-1,2,3-THIADIAZOL-4-YL]BENZENE-1,3-DIOL × 2 MG MAGNESIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7;pH 7
Resolution 1.60 Å R-free 0.234
2YI5 Structural characterization of 5-Aryl-4-(5-substituted-2-4- dihydroxyphenyl)-1,2,3-thiadiazole Hsp90 inhibitors. Deposited 2011-05-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–229(229 aa) Fragment:N-TERMINAL DOMAIN, RESIDUES 1-229
Not recorded YI5 4-CHLORO-6-[5-(3,4-DIMETHOXYPHENYL)-1,2,3-THIADIAZOL-4-YL]BENZENE-1,3-DIOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7;pH 7
Resolution 2.50 Å R-free 0.289
2YI6 Structural characterization of 5-Aryl-4-(5-substituted-2-4- dihydroxyphenyl)-1,2,3-thiadiazole Hsp90 inhibitors. Deposited 2011-05-10 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 1–229(229 aa) Fragment:N-TERMINAL DOMAIN, RESIDUES 1-229
Not recorded 6QM 4-[5-(4-ETHOXYPHENYL)-1,2,3-THIADIAZOL-4-YL]-6-ETHYLBENZENE-1,3-DIOL × 2 MG MAGNESIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7;pH 7
Resolution 1.80 Å R-free 0.238
2YI7 Structural characterization of 5-Aryl-4-(5-substituted-2-4- dihydroxyphenyl)-1,2,3-thiadiazole Hsp90 inhibitors. Deposited 2011-05-10 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 1–229(229 aa) Fragment:N-TERMINAL DOMAIN, RESIDUES 1-229
Not recorded BZ8 4-CHLORO-6-[5-(4-ETHOXYPHENYL)-1,2,3-THIADIAZOL-4-YL BENZENE-1,3-DIOL × 2 MG MAGNESIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7;pH 7
Resolution 1.40 Å R-free 0.196
2YJW Tricyclic series of Hsp90 inhibitors Deposited 2011-05-24 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 18–223(206 aa) Fragment:N-DOMAIN, RESIDUES 18-233
Not recorded YJW 4-(5-METHYL-4-PHENYLISOXAZOL-3-YL)BENZENE-1,3-DIOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5;NA CITRATE 1.3 M., pH 7.5
Resolution 1.61 Å R-free 0.210
2YJX Tricyclic series of Hsp90 inhibitors Deposited 2011-05-24 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 18–223(206 aa) Fragment:N-DOMAIN, RESIDUES 18-233
Not recorded YJX 1-(3H-imidazo[4,5-c]pyridin-2-yl)-3,4-dihydropyrido[2,1-a]isoindol-6(2H)-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5;pH 7.5
Resolution 1.83 Å R-free 0.199
2YK2 Tricyclic series of Hsp90 inhibitors Deposited 2011-05-25 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 18–223(206 aa) Fragment:N-DOMAIN, RESIDUES 18-223
Not recorded YJW 4-(5-METHYL-4-PHENYLISOXAZOL-3-YL)BENZENE-1,3-DIOL × 1 YJX 1-(3H-imidazo[4,5-c]pyridin-2-yl)-3,4-dihydropyrido[2,1-a]isoindol-6(2H)-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5;pH 7.5
Resolution 1.74 Å R-free 0.211
2YK9 Tricyclic series of Hsp90 inhibitors Deposited 2011-05-26 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 18–223(206 aa) Fragment:N-DOMAIN, RESIDUES 18-223
Not recorded YK9 4-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)FLUOREN-9-ONE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5;pH 7.5
Resolution 1.32 Å R-free 0.195
2YKB Tricyclic series of Hsp90 inhibitors Deposited 2011-05-26 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 18–223(206 aa) Fragment:N-DOMAIN, RESIDUES 18-233
Not recorded YKB N-[4-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-9H-FLUOREN-9-YL]-SUCCINAMIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5;pH 7.5
Resolution 1.93 Å R-free 0.241
2YKC Tricyclic series of Hsp90 inhibitors Deposited 2011-05-26 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 18–223(206 aa) Fragment:N-DOMAIN, RESIDUES 18-233
Not recorded YKC N-[4-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-9H-FLUOREN-9-YL-ISONICOTINAMIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5;pH 7.5
Resolution 1.67 Å R-free 0.210
2YKE Tricyclic series of Hsp90 inhibitors Deposited 2011-05-26 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 18–223(206 aa) Fragment:N-DOMAIN, RESIDUES 18-233
Not recorded YKE N-[(4R)-4-(3H-imidazo[4,5-c]pyridin-2-yl)-4H-fluoren-9-yl]quinoline-5-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5;pH 7.5
Resolution 1.43 Å R-free 0.185
2YKI Tricyclic series of Hsp90 inhibitors Deposited 2011-05-27 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 18–223(206 aa) Fragment:N-DOMAIN, RESIDUES 18-233
Not recorded YKI 1-H-PYRROLO[2,3-B]PYRIDINE-4-CARBOXYLIC ACID [4-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-9H-FLUOREN-9-YL]-AMIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5;pH 7.5
Resolution 1.67 Å R-free 0.258
2YKJ Tricyclic series of Hsp90 inhibitors Deposited 2011-05-27 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 18–223(206 aa) Fragment:N-DOMAIN, RESIDUES 18-233
Not recorded YKJ 2-AMINO-N-[4-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)--9H-FLUOREN-9-YL]-ISONICOTINAMIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5;pH 7.5
Resolution 1.46 Å R-free 0.252
3B24 Hsp90 alpha N-terminal domain in complex with an aminotriazine fragment molecule Deposited 2011-07-21 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-terminal domain
Not recorded MG MAGNESIUM ION × 1 B2J 4-(ethylsulfanyl)-6-methyl-1,3,5-triazin-2-amine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8;277 K;27%(w/v) PEG 3350, 0.3M MgCl2, 0.1M Tris-Cl, pH 8.0, vapor diffusion, hanging drop, temperature 277K
Resolution 1.70 Å R-free 0.188
3B24 Hsp90 alpha N-terminal domain in complex with an aminotriazine fragment molecule Deposited 2011-07-21 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 9–236(228 aa) Fragment:N-terminal domain
Not recorded B2J 4-(ethylsulfanyl)-6-methyl-1,3,5-triazin-2-amine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8;277 K;27%(w/v) PEG 3350, 0.3M MgCl2, 0.1M Tris-Cl, pH 8.0, vapor diffusion, hanging drop, temperature 277K
Resolution 1.70 Å R-free 0.188
3B24 Hsp90 alpha N-terminal domain in complex with an aminotriazine fragment molecule Deposited 2011-07-21 Assembly 3 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-terminal domain
Not recorded MG MAGNESIUM ION × 2 B2J 4-(ethylsulfanyl)-6-methyl-1,3,5-triazin-2-amine × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8;277 K;27%(w/v) PEG 3350, 0.3M MgCl2, 0.1M Tris-Cl, pH 8.0, vapor diffusion, hanging drop, temperature 277K
Resolution 1.70 Å R-free 0.188
3B24 Hsp90 alpha N-terminal domain in complex with an aminotriazine fragment molecule Deposited 2011-07-21 Assembly 4 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain B 9–236(228 aa) Fragment:N-terminal domain
Not recorded B2J 4-(ethylsulfanyl)-6-methyl-1,3,5-triazin-2-amine × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8;277 K;27%(w/v) PEG 3350, 0.3M MgCl2, 0.1M Tris-Cl, pH 8.0, vapor diffusion, hanging drop, temperature 277K
Resolution 1.70 Å R-free 0.188
3B25 Hsp90 alpha N-terminal domain in complex with an inhibitor CH4675194 Deposited 2011-07-21 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-terminal domain
Not recorded B2K 4-Methyl-6-(toluene-4-sulfonyl)-pyrimidin-2-ylamine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8;277 K;18%(w/v) PEG3350, 0.4M MgCl2, 0.1M Tris-Cl, pH 8.0, vapor diffusion, hanging drop, temperature 277K
Resolution 1.75 Å R-free 0.203
3B25 Hsp90 alpha N-terminal domain in complex with an inhibitor CH4675194 Deposited 2011-07-21 Assembly 2 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-terminal domain
Not recorded B2K 4-Methyl-6-(toluene-4-sulfonyl)-pyrimidin-2-ylamine × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8;277 K;18%(w/v) PEG3350, 0.4M MgCl2, 0.1M Tris-Cl, pH 8.0, vapor diffusion, hanging drop, temperature 277K
Resolution 1.75 Å R-free 0.203
3B26 Hsp90 alpha N-terminal domain in complex with an inhibitor Ro1127850 Deposited 2011-07-21 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-terminal domain
Not recorded B2L 4-(1H,3H-benzo[de]isochromen-6-yl)-6-methylpyrimidin-2-amine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8;277 K;24%(w/v) PEG3350, 0.3M MgCl2, 0.1M Tris-Cl, pH 8.0, vapor diffusion, hanging drop, temperature 277K
Resolution 2.10 Å R-free 0.205
3B26 Hsp90 alpha N-terminal domain in complex with an inhibitor Ro1127850 Deposited 2011-07-21 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 9–236(228 aa) Fragment:N-terminal domain
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8;277 K;24%(w/v) PEG3350, 0.3M MgCl2, 0.1M Tris-Cl, pH 8.0, vapor diffusion, hanging drop, temperature 277K
Resolution 2.10 Å R-free 0.205
3B26 Hsp90 alpha N-terminal domain in complex with an inhibitor Ro1127850 Deposited 2011-07-21 Assembly 3 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-terminal domain
Not recorded B2L 4-(1H,3H-benzo[de]isochromen-6-yl)-6-methylpyrimidin-2-amine × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8;277 K;24%(w/v) PEG3350, 0.3M MgCl2, 0.1M Tris-Cl, pH 8.0, vapor diffusion, hanging drop, temperature 277K
Resolution 2.10 Å R-free 0.205
3B26 Hsp90 alpha N-terminal domain in complex with an inhibitor Ro1127850 Deposited 2011-07-21 Assembly 4 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain B 9–236(228 aa) Fragment:N-terminal domain
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8;277 K;24%(w/v) PEG3350, 0.3M MgCl2, 0.1M Tris-Cl, pH 8.0, vapor diffusion, hanging drop, temperature 277K
Resolution 2.10 Å R-free 0.205
3B27 Hsp90 alpha N-terminal domain in complex with an inhibitor Ro4919127 Deposited 2011-07-21 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-terminal domain
Not recorded B2T 4-(2-chlorophenyl)-6-(methylsulfanyl)-1,3,5-triazin-2-amine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8;277 K;21%(w/v) PEG3350, 0.3M MgCl2, 0.1M Tris-Cl, pH 8.0, vapor diffusion, hanging drop, temperature 277K
Resolution 1.50 Å R-free 0.208
3B28 Hsp90 alpha N-terminal domain in complex with an inhibitor CH5015765 Deposited 2011-07-21 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-terminal domain
Not recorded GOL GLYCEROL × 1 B2X 4-(5-chloro-1H,3H-benzo[de]isochromen-6-yl)-6-(methylsulfanyl)-1,3,5-triazin-2-amine × 1 MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;278 K;22%(w/v) PEG2000 MME, 0.2M MgCl2, 0.1M MES-Na, pH 6.5, vapor diffusion, hanging drop, temperature 278K
Resolution 1.35 Å R-free 0.181
3B28 Hsp90 alpha N-terminal domain in complex with an inhibitor CH5015765 Deposited 2011-07-21 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 9–236(228 aa) Fragment:N-terminal domain
Not recorded B2X 4-(5-chloro-1H,3H-benzo[de]isochromen-6-yl)-6-(methylsulfanyl)-1,3,5-triazin-2-amine × 1 MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;278 K;22%(w/v) PEG2000 MME, 0.2M MgCl2, 0.1M MES-Na, pH 6.5, vapor diffusion, hanging drop, temperature 278K
Resolution 1.35 Å R-free 0.181
3B28 Hsp90 alpha N-terminal domain in complex with an inhibitor CH5015765 Deposited 2011-07-21 Assembly 3 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-terminal domain
Not recorded GOL GLYCEROL × 2 B2X 4-(5-chloro-1H,3H-benzo[de]isochromen-6-yl)-6-(methylsulfanyl)-1,3,5-triazin-2-amine × 2 MG MAGNESIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;278 K;22%(w/v) PEG2000 MME, 0.2M MgCl2, 0.1M MES-Na, pH 6.5, vapor diffusion, hanging drop, temperature 278K
Resolution 1.35 Å R-free 0.181
3B28 Hsp90 alpha N-terminal domain in complex with an inhibitor CH5015765 Deposited 2011-07-21 Assembly 4 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain B 9–236(228 aa) Fragment:N-terminal domain
Not recorded B2X 4-(5-chloro-1H,3H-benzo[de]isochromen-6-yl)-6-(methylsulfanyl)-1,3,5-triazin-2-amine × 2 MG MAGNESIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;278 K;22%(w/v) PEG2000 MME, 0.2M MgCl2, 0.1M MES-Na, pH 6.5, vapor diffusion, hanging drop, temperature 278K
Resolution 1.35 Å R-free 0.181
3BM9 Discovery of Benzisoxazoles as Potent Inhibitors of Chaperone Hsp90 Deposited 2007-12-12 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 10–236(227 aa) Fragment:N-terminal domain, UNP RESIDUES 10-236
Not recorded BXZ 4-bromo-6-(6-hydroxy-1,2-benzisoxazol-3-yl)benzene-1,3-diol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;277 K;20% PEG3350, 0.2M MAGNESIUM ACETATE, PH 7.5, TEMPERATURE 277K; FROZEN BY 1-STEP TRANSFER TO 25% GLYCEROL, 15% PEG3350, 0.15M MAGNESIUM ACETATE, VAPOR DIFFUSION, HANGING DROP
Resolution 1.60 Å R-free 0.186
3BMY Discovery of Benzisoxazoles as Potent Inhibitors of Chaperone Hsp90 Deposited 2007-12-13 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 10–236(227 aa) Fragment:N-terminal domain, UNP residues 10-236
Not recorded CXZ 4-chloro-6-{5-[(2-morpholin-4-ylethyl)amino]-1,2-benzisoxazol-3-yl}benzene-1,3-diol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;277 K;24% PEG 1500, 20% glycerol, pH 7.5, temperature 277K; frozen by 1-step transfer to 18% PEG 1500, 40% glycerol; VAPOR DIFFUSION, HANGING DROP
Resolution 1.60 Å R-free 0.196
3D0B Crystal Structure of Benzamide Tetrahydro-4H-carbazol-4-one bound to Hsp90 Deposited 2008-05-01 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–232(232 aa) Fragment:N-Terminal Domain residues 1-232
Not recorded SNX 2-[(2-methoxyethyl)amino]-4-(4-oxo-1,2,3,4-tetrahydro-9H-carbazol-9-yl)benzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 6.5;277 K;Crystals were grown in 0.2M MgCl2, 0.1M Bis-Tris pH 6.5, and 20% PEG 3350. Crystals were generated by adding 0.5ul protein to 0.5ul of reservoir in a sitting drop and incubating at 277K, VAPOR DIFFUSION, SITTING DROP
Resolution 1.74 Å R-free 0.228
3EKO Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone Deposited 2008-09-19 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–225(217 aa) Fragment:N-terminal domain: UNP residues 9-225
Not recorded PYU 2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 4.4;286 K;34 % Ethylene glycol, 0.1 M Phoshpate-citrate pH 4.4, 5 mM TCEP, VAPOR DIFFUSION, HANGING DROP, temperature 286K
Resolution 1.55 Å R-free 0.206
3EKO Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone Deposited 2008-09-19 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 9–225(217 aa) Fragment:N-terminal domain: UNP residues 9-225
Not recorded PYU 2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol × 1 PO4 PHOSPHATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 4.4;286 K;34 % Ethylene glycol, 0.1 M Phoshpate-citrate pH 4.4, 5 mM TCEP, VAPOR DIFFUSION, HANGING DROP, temperature 286K
Resolution 1.55 Å R-free 0.206
3EKO Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone Deposited 2008-09-19 Assembly 3 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–225(217 aa) Fragment:N-terminal domain: UNP residues 9-225
Chain B 9–225(217 aa) Fragment:N-terminal domain: UNP residues 9-225
Not recorded PYU 2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol × 2 PO4 PHOSPHATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 4.4;286 K;34 % Ethylene glycol, 0.1 M Phoshpate-citrate pH 4.4, 5 mM TCEP, VAPOR DIFFUSION, HANGING DROP, temperature 286K
Resolution 1.55 Å R-free 0.206
3EKR Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone Deposited 2008-09-19 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–225(217 aa) Fragment:N-terminal domain: UNP residues 9-225
Not recorded PY9 4-{[(2R)-2-(2-methylphenyl)pyrrolidin-1-yl]carbonyl}benzene-1,3-diol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 4.4;295 K;18 % Ethylene glycol, 0.1 M Phosphate-citrate pH 4.4, 10 mM TCEP, VAPOR DIFFUSION, HANGING DROP, temperature 295K
Resolution 2.00 Å R-free 0.223
3EKR Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone Deposited 2008-09-19 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 9–225(217 aa) Fragment:N-terminal domain: UNP residues 9-225
Not recorded PY9 4-{[(2R)-2-(2-methylphenyl)pyrrolidin-1-yl]carbonyl}benzene-1,3-diol × 1 PO4 PHOSPHATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 4.4;295 K;18 % Ethylene glycol, 0.1 M Phosphate-citrate pH 4.4, 10 mM TCEP, VAPOR DIFFUSION, HANGING DROP, temperature 295K
Resolution 2.00 Å R-free 0.223
3EKR Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone Deposited 2008-09-19 Assembly 3 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–225(217 aa) Fragment:N-terminal domain: UNP residues 9-225
Chain B 9–225(217 aa) Fragment:N-terminal domain: UNP residues 9-225
Not recorded PY9 4-{[(2R)-2-(2-methylphenyl)pyrrolidin-1-yl]carbonyl}benzene-1,3-diol × 2 PO4 PHOSPHATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 4.4;295 K;18 % Ethylene glycol, 0.1 M Phosphate-citrate pH 4.4, 10 mM TCEP, VAPOR DIFFUSION, HANGING DROP, temperature 295K
Resolution 2.00 Å R-free 0.223
3FT5 Structure of HSP90 bound with a novel fragment Deposited 2009-01-12 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-terminal domain
Not recorded MO8 4-methyl-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidin-2-amine × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;100mM sodium cacodylate pH 6.5, 19-23% PEG2000 monoethylether, 175 -225mM MgCl2, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 1.90 Å R-free 0.264
3FT8 Structure of HSP90 bound with a noval fragment. Deposited 2009-01-12 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-terminal domain
Not recorded MOJ (5E,7S)-2-amino-7-(4-fluoro-2-pyridin-3-ylphenyl)-4-methyl-7,8-dihydroquinazolin-5(6H)-one oxime × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;100mM sodium cacodylate pH 6.5, 19-23% PEG2000 monoethylether, 175 -225mM MgCl2, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.00 Å R-free 0.298
3HEK HSP90 N-terminal domain in complex with 1-{4-[(2R)-1-(5-chloro-2,4-dihydroxybenzoyl)pyrrolidin-2-yl]benzyl}-3,3-difluoropyrrolidinium Deposited 2009-05-08 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–225(217 aa) Fragment:N-terminal domain (UNP residues 9 to 225)
Chain B 9–225(217 aa) Fragment:N-terminal domain (UNP residues 9 to 225)
Not recorded BD0 [(2~{R})-2-[4-[[3,3-bis(fluoranyl)pyrrolidin-1-yl]methyl]phenyl]pyrrolidin-1-yl]-[5-chloranyl-2,4-bis(oxidanyl)phenyl]methanone × 2 PO4 PHOSPHATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 4.4;286 K;15 % ethylene glycol, 0.1 M phosphate-citrate, pH 4.4, 20 mM TCEP, VAPOR DIFFUSION, HANGING DROP, temperature 286K
Resolution 1.95 Å R-free 0.237
3HHU Human heat-shock protein 90 (HSP90) in complex with {4-[3-(2,4-dihydroxy-5-isopropyl-phenyl)-5-thioxo- 1,5-dihydro-[1,2,4]triazol-4-yl]-benzyl}-carbamic acid ethyl ester {ZK 2819} Deposited 2009-05-17 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–224(224 aa) Fragment:UNP residues 1-224
Not recorded 819 ethyl (4-{3-[2,4-dihydroxy-5-(1-methylethyl)phenyl]-5-sulfanyl-4H-1,2,4-triazol-4-yl}benzyl)carbamate × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8.5;278 K;0.2 M MgCl, 30% PEG4000,0.1M Tris, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 278K
Resolution 1.59 Å R-free 0.225
3HHU Human heat-shock protein 90 (HSP90) in complex with {4-[3-(2,4-dihydroxy-5-isopropyl-phenyl)-5-thioxo- 1,5-dihydro-[1,2,4]triazol-4-yl]-benzyl}-carbamic acid ethyl ester {ZK 2819} Deposited 2009-05-17 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–224(224 aa) Fragment:UNP residues 1-224
Not recorded 819 ethyl (4-{3-[2,4-dihydroxy-5-(1-methylethyl)phenyl]-5-sulfanyl-4H-1,2,4-triazol-4-yl}benzyl)carbamate × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8.5;278 K;0.2 M MgCl, 30% PEG4000,0.1M Tris, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 278K
Resolution 1.59 Å R-free 0.225
3HYY Crystal structure of Hsp90 with fragment 37-D04 Deposited 2009-06-23 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-terminal nucleotide binding domain
Not recorded 37D methyl 5-furan-2-yl-3-methyl-1H-pyrazole-4-carboxylate × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;0.2M Magnesium chloride, 0.1M Sodium cacodylate, 19-23% PEG2000 MME, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 1.90 Å R-free 0.238
3HYY Crystal structure of Hsp90 with fragment 37-D04 Deposited 2009-06-23 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-terminal nucleotide binding domain
Not recorded 37D methyl 5-furan-2-yl-3-methyl-1H-pyrazole-4-carboxylate × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;0.2M Magnesium chloride, 0.1M Sodium cacodylate, 19-23% PEG2000 MME, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 1.90 Å R-free 0.238
3HYZ Crystal structure of Hsp90 with fragment 42-C03 Deposited 2009-06-23 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-terminal domain
Not recorded 42C N,N-dimethyl-7H-purin-6-amine × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;0.2M Magnesium chloride, 0.1M sodium cacodylate, 19-23% PEG2000 MME, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.30 Å R-free 0.305
3HYZ Crystal structure of Hsp90 with fragment 42-C03 Deposited 2009-06-23 Assembly 2 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain B 9–236(228 aa) Fragment:N-terminal domain
Not recorded 42C N,N-dimethyl-7H-purin-6-amine × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;0.2M Magnesium chloride, 0.1M sodium cacodylate, 19-23% PEG2000 MME, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.30 Å R-free 0.305
3HZ1 Crystal structure of Hsp90 with fragments 37-D04 and 42-C03 Deposited 2009-06-23 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-terminal domain
Not recorded 42C N,N-dimethyl-7H-purin-6-amine × 2 37D methyl 5-furan-2-yl-3-methyl-1H-pyrazole-4-carboxylate × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;0.2M Magnesium chloride, 0.1M sodium cacodylate, 19-23% PEG2000 MME, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.30 Å R-free 0.265
3HZ1 Crystal structure of Hsp90 with fragments 37-D04 and 42-C03 Deposited 2009-06-23 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-terminal domain
Not recorded 42C N,N-dimethyl-7H-purin-6-amine × 1 37D methyl 5-furan-2-yl-3-methyl-1H-pyrazole-4-carboxylate × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;0.2M Magnesium chloride, 0.1M sodium cacodylate, 19-23% PEG2000 MME, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.30 Å R-free 0.265
3HZ5 Crystal structure of Hsp90 with fragment Z064 Deposited 2009-06-23 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-terminal domain
Not recorded Z64 N-[4-(5-furan-2-yl-3-methyl-1H-pyrazol-4-yl)butyl]-N-methyl-7H-purin-6-amine × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;0.2M Magnesium Chloride, 0.1M Sodium cacodylate, 19-23% PEG2000 MME, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 1.90 Å R-free 0.254
3HZ5 Crystal structure of Hsp90 with fragment Z064 Deposited 2009-06-23 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-terminal domain
Not recorded Z64 N-[4-(5-furan-2-yl-3-methyl-1H-pyrazol-4-yl)butyl]-N-methyl-7H-purin-6-amine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;0.2M Magnesium Chloride, 0.1M Sodium cacodylate, 19-23% PEG2000 MME, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 1.90 Å R-free 0.254
3INW HSP90 N-TERMINAL DOMAIN with pochoxime A Deposited 2009-08-13 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 10–236(227 aa) Fragment:UNP residues 10-236, N-terminal domain
Not recorded DMS DIMETHYL SULFOXIDE × 1 JZB (5E,9E,11E)-13-chloro-14,16-dihydroxy-3,4,7,8-tetrahydro-1H-2-benzoxacyclotetradecine-1,11(12H)-dione 11-[O-(2-oxo-2-piperidin-1-ylethyl)oxime] × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;273 K;22-31 % (w/v) PEG 4000, 200 mM Na-Acetate, 100 mM Tris-HCl, pH 7.5-9.0, VAPOR DIFFUSION, HANGING DROP, temperature 273K
Resolution 1.95 Å R-free 0.242
3INX HSP90 N-TERMINAL DOMAIN with pochoxime B Deposited 2009-08-13 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 10–236(227 aa) Fragment:UNP residues 10-236, N-terminal domain
Not recorded DMS DIMETHYL SULFOXIDE × 2 JZC (5E,9E,11E)-14,16-dihydroxy-3,4,7,8-tetrahydro-1H-2-benzoxacyclotetradecine-1,11(12H)-dione 11-[O-(2-oxo-2-piperidin-1-ylethyl)oxime] × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;273 K;22-31 % (w/v) PEG 4000, 200 mM Na-Acetate, 100 mM Tris-HCl, pH 7.5-9.0, VAPOR DIFFUSION, HANGING DROP, temperature 273K
Resolution 1.75 Å R-free 0.217
3K97 HSP90 N-terminal domain in complex with 4-chloro-6-{[(2R)-2-(2-methylphenyl)pyrrolidin-1-yl]carbonyl}benzene-1,3-diol Deposited 2009-10-15 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-terminal domain (UNP residues 9-236)
Not recorded 4CD 4-chloro-6-{[(2R)-2-(2-methylphenyl)pyrrolidin-1-yl]carbonyl}benzene-1,3-diol × 1 DMS DIMETHYL SULFOXIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277 K;19% PEG 3350, 0.2 M MgCl2, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 1.95 Å R-free 0.222
3K98 HSP90 N-terminal domain in complex with (1R)-2-(5-chloro-2,4-dihydroxybenzoyl)-N-ethylisoindoline-1-carboxamide Deposited 2009-10-15 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–225(217 aa) Fragment:HSP90 N-terminal domain (UNP residues 9-225)
Not recorded 1RC (1R)-2-[(5-chloro-2,4-dihydroxyphenyl)carbonyl]-N-ethyl-2,3-dihydro-1H-isoindole-1-carboxamide × 1 PO4 PHOSPHATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 4.2;295 K;16 % ehtylene glycol, 0.1 M phosphate-citrate, pH 4.2, 30 mM TCEP, VAPOR DIFFUSION, HANGING DROP, temperature 295K
Resolution 2.40 Å R-free 0.263
3K98 HSP90 N-terminal domain in complex with (1R)-2-(5-chloro-2,4-dihydroxybenzoyl)-N-ethylisoindoline-1-carboxamide Deposited 2009-10-15 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 9–225(217 aa) Fragment:HSP90 N-terminal domain (UNP residues 9-225)
Not recorded 1RC (1R)-2-[(5-chloro-2,4-dihydroxyphenyl)carbonyl]-N-ethyl-2,3-dihydro-1H-isoindole-1-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 4.2;295 K;16 % ehtylene glycol, 0.1 M phosphate-citrate, pH 4.2, 30 mM TCEP, VAPOR DIFFUSION, HANGING DROP, temperature 295K
Resolution 2.40 Å R-free 0.263
3K98 HSP90 N-terminal domain in complex with (1R)-2-(5-chloro-2,4-dihydroxybenzoyl)-N-ethylisoindoline-1-carboxamide Deposited 2009-10-15 Assembly 3 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–225(217 aa) Fragment:HSP90 N-terminal domain (UNP residues 9-225)
Chain B 9–225(217 aa) Fragment:HSP90 N-terminal domain (UNP residues 9-225)
Not recorded 1RC (1R)-2-[(5-chloro-2,4-dihydroxyphenyl)carbonyl]-N-ethyl-2,3-dihydro-1H-isoindole-1-carboxamide × 2 PO4 PHOSPHATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 4.2;295 K;16 % ehtylene glycol, 0.1 M phosphate-citrate, pH 4.2, 30 mM TCEP, VAPOR DIFFUSION, HANGING DROP, temperature 295K
Resolution 2.40 Å R-free 0.263
3K98 HSP90 N-terminal domain in complex with (1R)-2-(5-chloro-2,4-dihydroxybenzoyl)-N-ethylisoindoline-1-carboxamide Deposited 2009-10-15 Assembly 4 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–225(217 aa) Fragment:HSP90 N-terminal domain (UNP residues 9-225)
Chain B 9–225(217 aa) Fragment:HSP90 N-terminal domain (UNP residues 9-225)
Not recorded 1RC (1R)-2-[(5-chloro-2,4-dihydroxyphenyl)carbonyl]-N-ethyl-2,3-dihydro-1H-isoindole-1-carboxamide × 2 PO4 PHOSPHATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 4.2;295 K;16 % ehtylene glycol, 0.1 M phosphate-citrate, pH 4.2, 30 mM TCEP, VAPOR DIFFUSION, HANGING DROP, temperature 295K
Resolution 2.40 Å R-free 0.263
3K99 HSP90 N-terminal domain in complex with 4-(1,3-dihydro-2H-isoindol-2-ylcarbonyl)benzene-1,3-diol Deposited 2009-10-15 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–225(217 aa) Fragment:N-terminal domain (UNP residues 9-225)
Not recorded PFT 4-(1,3-dihydro-2H-isoindol-2-ylcarbonyl)benzene-1,3-diol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 4.2;295 K;16% ethylene glycol, 0.1 M phosphate-citrate, pH 4.2, 30 mM TCEP, VAPOR DIFFUSION, HANGING DROP, temperature 295K
Resolution 2.10 Å R-free 0.245
3K99 HSP90 N-terminal domain in complex with 4-(1,3-dihydro-2H-isoindol-2-ylcarbonyl)benzene-1,3-diol Deposited 2009-10-15 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 9–225(217 aa) Fragment:N-terminal domain (UNP residues 9-225)
Not recorded PFT 4-(1,3-dihydro-2H-isoindol-2-ylcarbonyl)benzene-1,3-diol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 4.2;295 K;16% ethylene glycol, 0.1 M phosphate-citrate, pH 4.2, 30 mM TCEP, VAPOR DIFFUSION, HANGING DROP, temperature 295K
Resolution 2.10 Å R-free 0.245
3K99 HSP90 N-terminal domain in complex with 4-(1,3-dihydro-2H-isoindol-2-ylcarbonyl)benzene-1,3-diol Deposited 2009-10-15 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 9–225(217 aa) Fragment:N-terminal domain (UNP residues 9-225)
Not recorded PFT 4-(1,3-dihydro-2H-isoindol-2-ylcarbonyl)benzene-1,3-diol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 4.2;295 K;16% ethylene glycol, 0.1 M phosphate-citrate, pH 4.2, 30 mM TCEP, VAPOR DIFFUSION, HANGING DROP, temperature 295K
Resolution 2.10 Å R-free 0.245
3K99 HSP90 N-terminal domain in complex with 4-(1,3-dihydro-2H-isoindol-2-ylcarbonyl)benzene-1,3-diol Deposited 2009-10-15 Assembly 4 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain D 9–225(217 aa) Fragment:N-terminal domain (UNP residues 9-225)
Not recorded PFT 4-(1,3-dihydro-2H-isoindol-2-ylcarbonyl)benzene-1,3-diol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 4.2;295 K;16% ethylene glycol, 0.1 M phosphate-citrate, pH 4.2, 30 mM TCEP, VAPOR DIFFUSION, HANGING DROP, temperature 295K
Resolution 2.10 Å R-free 0.245
3K99 HSP90 N-terminal domain in complex with 4-(1,3-dihydro-2H-isoindol-2-ylcarbonyl)benzene-1,3-diol Deposited 2009-10-15 Assembly 5 Protein homooligomer Homooligomer;Protein × 4 PDB declaration: tetrameric(4) Consistent with protein count
Chain A 9–225(217 aa) Fragment:N-terminal domain (UNP residues 9-225)
Chain B 9–225(217 aa) Fragment:N-terminal domain (UNP residues 9-225)
Chain C 9–225(217 aa) Fragment:N-terminal domain (UNP residues 9-225)
Chain D 9–225(217 aa) Fragment:N-terminal domain (UNP residues 9-225)
Not recorded PFT 4-(1,3-dihydro-2H-isoindol-2-ylcarbonyl)benzene-1,3-diol × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 4.2;295 K;16% ethylene glycol, 0.1 M phosphate-citrate, pH 4.2, 30 mM TCEP, VAPOR DIFFUSION, HANGING DROP, temperature 295K
Resolution 2.10 Å R-free 0.245
3MNR Crystal Structure of Benzamide SNX-1321 bound to Hsp90 Deposited 2010-04-22 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain P 1–232(232 aa) Fragment:UNP residues 1-232, N-TERMINAL DOMAIN
Not recorded SD1 2-[(3,4,5-trimethoxyphenyl)amino]-4-(2,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions LIQUID DIFFUSION;pH 6.5;277 K;Crystallized in 0.2M MgCl2, 0.1M Bis-Tris pH 6.5, and 20% PEG 3350 and were cryo-protected by adding 25% Ethylene Glycol to the mother liquor and passing the crystal through the solution immediately before flash freezing it in liquid nitrogen. The drops were setup by hand, adding 0.5ul protein to 0.5ul of reservoir in a sitting drop 192-well corning crystallization plate and incubated at 277K. , LIQUID DIFFUSION
Resolution 1.90 Å R-free 0.235
3OW6 Crystal Structure of HSP90 with N-Aryl-benzimidazolone I Deposited 2010-09-17 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 17–223(207 aa)
Not recorded MEX 1-(2,4-dihydroxyphenyl)-1,3-dihydro-2H-benzimidazol-2-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;pH 6.5, VAPOR DIFFUSION, HANGING DROP
Resolution 1.80 Å R-free 0.220
3OWB Crystal Structure of HSP90 with VER-49009 Deposited 2010-09-17 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 17–223(207 aa)
Not recorded BSM 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)-1H-PYRAZOLE-3-CARBOXAMIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.05 Å R-free 0.200
3OWD Crystal Structure of HSP90 with N-Aryl-benzimidazolone II Deposited 2010-09-17 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 17–223(207 aa)
Not recorded MEY N-{[1-(5-chloro-2,4-dihydroxyphenyl)-2-oxo-2,3-dihydro-1H-benzimidazol-5-yl]methyl}naphthalene-1-sulfonamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;0.2M NaCl, 26 % PEG 3350, BTP, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 1.63 Å R-free 0.199
3Q6M Crystal Structure of Human MC-HSP90 in C2221 Space Group Deposited 2011-01-03 Assembly 1 Protein homooligomer Homooligomer;Protein × 6 PDB declaration: hexameric(6) Consistent with protein count
Chain A 293–732(440 aa) Fragment:Middle and C-terminal domain, UNP residues 293-732
Chain B 293–732(440 aa) Fragment:Middle and C-terminal domain, UNP residues 293-732
Chain C 293–732(440 aa) Fragment:Middle and C-terminal domain, UNP residues 293-732
Not recorded SO4 SULFATE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;298 K;2.5M ammonium sulfate, 0.1M Tris-sodium citrate, 0.1mM cis-dichloro(ethylenediamine)platinum (II), pH 5.4-5.8, VAPOR DIFFUSION, SITTING DROP, temperature 298.0K
Resolution 3.00 Å R-free 0.252
3Q6N Crystal Structure of Human MC-HSP90 in P21 space group Deposited 2011-01-03 Assembly 1 Protein homooligomer Homooligomer;Protein × 6 PDB declaration: hexameric(6) Consistent with protein count
Chain A 293–732(440 aa) Fragment:Middle and C-terminal domain, UNP residues 293-732
Chain B 293–732(440 aa) Fragment:Middle and C-terminal domain, UNP residues 293-732
Chain C 293–732(440 aa) Fragment:Middle and C-terminal domain, UNP residues 293-732
Chain D 293–732(440 aa) Fragment:Middle and C-terminal domain, UNP residues 293-732
Chain E 293–732(440 aa) Fragment:Middle and C-terminal domain, UNP residues 293-732
Chain F 293–732(440 aa) Fragment:Middle and C-terminal domain, UNP residues 293-732
Not recorded SO4 SULFATE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;298 K;1.0M ammonium sulfate, 0.04M Tris-sodium citrate, 0.04 mM cisplatin, pH 5.4-5.8, VAPOR DIFFUSION, SITTING DROP, temperature 298K
Resolution 3.05 Å R-free 0.259
3QDD HSP90A N-terminal domain in complex with BIIB021 Deposited 2011-01-18 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa) Fragment:N-terminal domain (UNP residues 1-236)
Not recorded 94M 6-chloro-9-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-9H-purin-2-amine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 6.5;277 K;0.1 M sodium cacodylate, 20% PEG2000 MME, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 1.79 Å R-free 0.209
3QTF Design and SAR of macrocyclic Hsp90 inhibitors with increased metabolic stability and potent cell-proliferation activity Deposited 2011-02-22 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 10–236(227 aa) Fragment:N-terminal domain (UNP RESIDUES 10-236)
Not recorded 05S (6S)-6,15,15,18-tetramethyl-17-oxo-2,3,4,5,6,7,14,15,16,17-decahydro-1H-8,12-(metheno)[1,4,9]triazacyclotetradecino[9,8-a]indole-9-carboxamide × 1 DMS DIMETHYL SULFOXIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;277 K;18.4% PEG3350, 0.2M MAGNESIUM NITRATE, PROTEIN @ 13.5 MG/ML, TEMPERATURE 277K; FROZEN BY 1-STEP TRANSFER TO 25% GLYCEROL, 14% PEG3350, 0.15M MAGNESIUM NITRATE, pH 7.5, VAPOR DIFFUSION, HANGING DROP
Resolution 1.57 Å R-free 0.204
3R4M Optimization of Potent, Selective, and Orally Bioavailable Pyrrolodinopyrimidine-containing Inhibitors of Heat Shock Protein 90. Identification of Development Candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide Deposited 2011-03-17 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:unp residues 9-236
Not recorded WOE 4-CHLORO-6-(2-METHOXYPHENYL)PYRIMIDIN-2-AMINE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 5.2;286 K;30 % PEG MME 550, 0.1 M CaCl2, 0.1 M cacodylate, pH 5.2, VAPOR DIFFUSION, HANGING DROP, temperature 286K
Resolution 1.70 Å R-free 0.223
3R4N Optimization of Potent, Selective, and Orally Bioavailable Pyrrolodinopyrimidine-containing Inhibitors of Heat Shock Protein 90. Identification of Development Candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide Deposited 2011-03-17 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–225(217 aa) Fragment:unp residues 9-225
Not recorded FU5 4-[2-chloro-6-(4,4,4-trifluorobutoxy)phenyl]-6-methylpyrimidin-2-amine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 4.5;286 K;20 % Ethylene glycol, 0.1 M citrate phosphate, 20 mM TCEP, pH 4.5, VAPOR DIFFUSION, HANGING DROP, temperature 286K
Resolution 2.00 Å R-free 0.220
3R4N Optimization of Potent, Selective, and Orally Bioavailable Pyrrolodinopyrimidine-containing Inhibitors of Heat Shock Protein 90. Identification of Development Candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide Deposited 2011-03-17 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 9–225(217 aa) Fragment:unp residues 9-225
Not recorded FU5 4-[2-chloro-6-(4,4,4-trifluorobutoxy)phenyl]-6-methylpyrimidin-2-amine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 4.5;286 K;20 % Ethylene glycol, 0.1 M citrate phosphate, 20 mM TCEP, pH 4.5, VAPOR DIFFUSION, HANGING DROP, temperature 286K
Resolution 2.00 Å R-free 0.220
3R4N Optimization of Potent, Selective, and Orally Bioavailable Pyrrolodinopyrimidine-containing Inhibitors of Heat Shock Protein 90. Identification of Development Candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide Deposited 2011-03-17 Assembly 3 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–225(217 aa) Fragment:unp residues 9-225
Chain B 9–225(217 aa) Fragment:unp residues 9-225
Not recorded FU5 4-[2-chloro-6-(4,4,4-trifluorobutoxy)phenyl]-6-methylpyrimidin-2-amine × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 4.5;286 K;20 % Ethylene glycol, 0.1 M citrate phosphate, 20 mM TCEP, pH 4.5, VAPOR DIFFUSION, HANGING DROP, temperature 286K
Resolution 2.00 Å R-free 0.220
3R4O Optimization of Potent, Selective, and Orally Bioavailable Pyrrolodinopyrimidine-containing Inhibitors of Heat Shock Protein 90. Identification of Development Candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide Deposited 2011-03-17 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–225(217 aa) Fragment:unp residues 9-225
Not recorded FU3 2-amino-N-cyclobutyl-4-[2,4-dichloro-6-(4,4,4-trifluorobutoxy)phenyl]-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 4.5;286 K;5 % Ethylene glycol, 0.1 M phosphate-citrate, pH 4.5, 20 mM TCEP, VAPOR DIFFUSION, HANGING DROP, temperature 286K
Resolution 2.65 Å R-free 0.285
3R4O Optimization of Potent, Selective, and Orally Bioavailable Pyrrolodinopyrimidine-containing Inhibitors of Heat Shock Protein 90. Identification of Development Candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide Deposited 2011-03-17 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 9–225(217 aa) Fragment:unp residues 9-225
Not recorded FU3 2-amino-N-cyclobutyl-4-[2,4-dichloro-6-(4,4,4-trifluorobutoxy)phenyl]-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 4.5;286 K;5 % Ethylene glycol, 0.1 M phosphate-citrate, pH 4.5, 20 mM TCEP, VAPOR DIFFUSION, HANGING DROP, temperature 286K
Resolution 2.65 Å R-free 0.285
3R4O Optimization of Potent, Selective, and Orally Bioavailable Pyrrolodinopyrimidine-containing Inhibitors of Heat Shock Protein 90. Identification of Development Candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide Deposited 2011-03-17 Assembly 3 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–225(217 aa) Fragment:unp residues 9-225
Chain B 9–225(217 aa) Fragment:unp residues 9-225
Not recorded FU3 2-amino-N-cyclobutyl-4-[2,4-dichloro-6-(4,4,4-trifluorobutoxy)phenyl]-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 4.5;286 K;5 % Ethylene glycol, 0.1 M phosphate-citrate, pH 4.5, 20 mM TCEP, VAPOR DIFFUSION, HANGING DROP, temperature 286K
Resolution 2.65 Å R-free 0.285
3R4P Optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitors of heat shock protein 90. identification of development candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide Deposited 2011-03-17 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–225(217 aa) Fragment:unp residues 9-225
Not recorded FU7 2-amino-4-{2,4-dichloro-6-[2-(1H-pyrazol-1-yl)ethoxy]phenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide × 1 PO4 PHOSPHATE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 4.3;286 K;5 % Ethylene glycol, 0.1 M phosphate-citrate, pH 4.3, 20 mM TCEP, VAPOR DIFFUSION, HANGING DROP, temperature 286K
Resolution 1.70 Å R-free 0.212
3R4P Optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitors of heat shock protein 90. identification of development candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide Deposited 2011-03-17 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 9–225(217 aa) Fragment:unp residues 9-225
Not recorded FU7 2-amino-4-{2,4-dichloro-6-[2-(1H-pyrazol-1-yl)ethoxy]phenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 4.3;286 K;5 % Ethylene glycol, 0.1 M phosphate-citrate, pH 4.3, 20 mM TCEP, VAPOR DIFFUSION, HANGING DROP, temperature 286K
Resolution 1.70 Å R-free 0.212
3R4P Optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitors of heat shock protein 90. identification of development candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide Deposited 2011-03-17 Assembly 3 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–225(217 aa) Fragment:unp residues 9-225
Chain B 9–225(217 aa) Fragment:unp residues 9-225
Not recorded FU7 2-amino-4-{2,4-dichloro-6-[2-(1H-pyrazol-1-yl)ethoxy]phenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide × 2 PO4 PHOSPHATE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 4.3;286 K;5 % Ethylene glycol, 0.1 M phosphate-citrate, pH 4.3, 20 mM TCEP, VAPOR DIFFUSION, HANGING DROP, temperature 286K
Resolution 1.70 Å R-free 0.212
3R91 Macrocyclic lactams as potent Hsp90 inhibitors with excellent tumor exposure and extended biomarker activity. Deposited 2011-03-24 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 10–236(227 aa) Fragment:N-terminal domain, UNP RESIDUES 10-236
Mutation:Delta 16 06H (6S)-4,6,15,15,18-pentamethyl-5,17-dioxo-2,3,4,5,6,7,14,15,16,17-decahydro-1H-12,8-(metheno)[1,4,9]triazacyclotetradecino[9,8-a]indole-9-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;277 K;22% PEG3350, 0.175 M MAGNESIUM NITRATE, pH 7.5, TEMPERATURE 277K; FROZEN BY 1-STEP TRANSFER TO 25% GLYCEROL, 17% PEG3350, 0.13M MAGNESIUM NITRATE, VAPOR DIFFUSION, HANGING DROP
Resolution 1.58 Å R-free 0.199
3R92 Discovery of a macrocyclic o-aminobenzamide Hsp90 inhibitor with heterocyclic tether that shows extended biomarker activity and in vivo efficacy in a mouse xenograft model. Deposited 2011-03-24 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 10–236(227 aa) Fragment:N-terminal domain, UNP RESIDUES 10-236
Not recorded 06J (3aR)-13,13,16-trimethyl-15-oxo-1,2,3,3a,4,5,12,14,15,17,18,19-dodecahydro-13H-10,6-(metheno)pyrrolo[2',1':3,4][1,4,9]triazacyclotetradecino[9,8-a]indole-7-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;25% PEG3000, 0.1 M MES, pH 6.5, TEMPERATURE 277K; FROZEN BY 1-STEP TRANSFER TO 25% GLYCEROL, 19% PEG3000, 0.075M MES, VAPOR DIFFUSION, HANGING DROP
Resolution 1.58 Å R-free 0.194
3RKZ Discovery of a stable macrocyclic o-aminobenzamide Hsp90 inhibitor capable of significantly decreasing tumor volume in a mouse xenograft model. Deposited 2011-04-18 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 10–236(227 aa) Fragment:N-terminal domain, UNP RESIDUES 10-236
Mutation:Delta 16 06T (5R,6S)-3-(L-alanyl)-5,6,15,15,18-pentamethyl-17-oxo-2,3,4,5,6,7,14,15,16,17-decahydro-1H-12,8-(metheno)[1,5,9]triazacyclotetradecino[1,2-a]indole-9-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;277 K;20% PEG3350, 0.200 M MAGNESIUM FORMATE, pH 7.5, TEMPERATURE 277K; FROZEN BY 1-STEP TRANSFER TO 25% GLYCEROL, 15% PEG3350, 0.15M MAGNESIUM FORMATE, VAPOR DIFFUSION, HANGING DROP
Resolution 1.57 Å R-free 0.188
3RLP Co-crystal structure of the HSP90 ATP binding domain in complex with 4-(2,4-dichloro-5-methoxyphenyl)-6-methylpyrimidin-2-amine Deposited 2011-04-20 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–225(217 aa) Fragment:ATP binding domain (UNP Residues 9-225)
Not recorded 3RP 4-(2,4-dichloro-5-methoxyphenyl)-6-methylpyrimidin-2-amine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 4.3;286 K;5% Ethylene glycol, 0.1 M phosphate-citrate, pH 4.3, 20 mM TCEP, 13 C, VAPOR DIFFUSION, HANGING DROP, temperature 286K
Resolution 1.70 Å R-free 0.219
3RLP Co-crystal structure of the HSP90 ATP binding domain in complex with 4-(2,4-dichloro-5-methoxyphenyl)-6-methylpyrimidin-2-amine Deposited 2011-04-20 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 9–225(217 aa) Fragment:ATP binding domain (UNP Residues 9-225)
Not recorded 3RP 4-(2,4-dichloro-5-methoxyphenyl)-6-methylpyrimidin-2-amine × 1 PO4 PHOSPHATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 4.3;286 K;5% Ethylene glycol, 0.1 M phosphate-citrate, pH 4.3, 20 mM TCEP, 13 C, VAPOR DIFFUSION, HANGING DROP, temperature 286K
Resolution 1.70 Å R-free 0.219
3RLP Co-crystal structure of the HSP90 ATP binding domain in complex with 4-(2,4-dichloro-5-methoxyphenyl)-6-methylpyrimidin-2-amine Deposited 2011-04-20 Assembly 3 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–225(217 aa) Fragment:ATP binding domain (UNP Residues 9-225)
Chain B 9–225(217 aa) Fragment:ATP binding domain (UNP Residues 9-225)
Not recorded 3RP 4-(2,4-dichloro-5-methoxyphenyl)-6-methylpyrimidin-2-amine × 2 PO4 PHOSPHATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 4.3;286 K;5% Ethylene glycol, 0.1 M phosphate-citrate, pH 4.3, 20 mM TCEP, 13 C, VAPOR DIFFUSION, HANGING DROP, temperature 286K
Resolution 1.70 Å R-free 0.219
3RLQ Co-crystal structure of the HSP90 ATP binding domain in complex with 4-(2,4-dichloro-5-methoxyphenyl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5- carbonitrile Deposited 2011-04-20 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–225(217 aa) Fragment:ATP binding domain (UNP Residues 9-225)
Not recorded 3RQ 4-(2,4-dichloro-5-methoxyphenyl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile × 1 PO4 PHOSPHATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 4.3;286 K;30% Ethylene glycol, 0.1 M phosphate-citrate, pH 4.3, 20 mM TCEP, 13 C, VAPOR DIFFUSION, HANGING DROP, temperature 286K
Resolution 1.90 Å R-free 0.223
3RLQ Co-crystal structure of the HSP90 ATP binding domain in complex with 4-(2,4-dichloro-5-methoxyphenyl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5- carbonitrile Deposited 2011-04-20 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 9–225(217 aa) Fragment:ATP binding domain (UNP Residues 9-225)
Not recorded 3RQ 4-(2,4-dichloro-5-methoxyphenyl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 4.3;286 K;30% Ethylene glycol, 0.1 M phosphate-citrate, pH 4.3, 20 mM TCEP, 13 C, VAPOR DIFFUSION, HANGING DROP, temperature 286K
Resolution 1.90 Å R-free 0.223
3RLQ Co-crystal structure of the HSP90 ATP binding domain in complex with 4-(2,4-dichloro-5-methoxyphenyl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5- carbonitrile Deposited 2011-04-20 Assembly 3 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–225(217 aa) Fragment:ATP binding domain (UNP Residues 9-225)
Chain B 9–225(217 aa) Fragment:ATP binding domain (UNP Residues 9-225)
Not recorded 3RQ 4-(2,4-dichloro-5-methoxyphenyl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile × 2 PO4 PHOSPHATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 4.3;286 K;30% Ethylene glycol, 0.1 M phosphate-citrate, pH 4.3, 20 mM TCEP, 13 C, VAPOR DIFFUSION, HANGING DROP, temperature 286K
Resolution 1.90 Å R-free 0.223
3RLR Co-crystal structure of the HSP90 ATP binding domain in complex with 4-(2,4-dichloro-5-methoxyphenyl)-2,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile Deposited 2011-04-20 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–225(217 aa) Fragment:ATP binding domain (UNP Residues 9-225)
Not recorded 3RR 4-(2,4-dichloro-5-methoxyphenyl)-2,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile × 1 PO4 PHOSPHATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 4.3;286 K;5% Ethylene glycol, 0.1 M phosphate-citrate, pH 4.3, 20 mM TCEP, 21 C, VAPOR DIFFUSION, HANGING DROP, temperature 286K
Resolution 1.70 Å R-free 0.207
3RLR Co-crystal structure of the HSP90 ATP binding domain in complex with 4-(2,4-dichloro-5-methoxyphenyl)-2,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile Deposited 2011-04-20 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 9–225(217 aa) Fragment:ATP binding domain (UNP Residues 9-225)
Not recorded 3RR 4-(2,4-dichloro-5-methoxyphenyl)-2,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 4.3;286 K;5% Ethylene glycol, 0.1 M phosphate-citrate, pH 4.3, 20 mM TCEP, 21 C, VAPOR DIFFUSION, HANGING DROP, temperature 286K
Resolution 1.70 Å R-free 0.207
3RLR Co-crystal structure of the HSP90 ATP binding domain in complex with 4-(2,4-dichloro-5-methoxyphenyl)-2,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile Deposited 2011-04-20 Assembly 3 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–225(217 aa) Fragment:ATP binding domain (UNP Residues 9-225)
Chain B 9–225(217 aa) Fragment:ATP binding domain (UNP Residues 9-225)
Not recorded 3RR 4-(2,4-dichloro-5-methoxyphenyl)-2,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile × 2 PO4 PHOSPHATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 4.3;286 K;5% Ethylene glycol, 0.1 M phosphate-citrate, pH 4.3, 20 mM TCEP, 21 C, VAPOR DIFFUSION, HANGING DROP, temperature 286K
Resolution 1.70 Å R-free 0.207
3T0H Structure insights into mechanisms of ATP hydrolysis and the activation of human Hsp90 Deposited 2011-07-20 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:UNP RESIDUES 9-236
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;20-25% (w/v) PEG 2000 monomethyl ether, 200mM magnesium chloride, 100mM sodium cacodylate, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 1.20 Å R-free 0.171
3T0H Structure insights into mechanisms of ATP hydrolysis and the activation of human Hsp90 Deposited 2011-07-20 Assembly 2 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–236(228 aa) Fragment:UNP RESIDUES 9-236
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;20-25% (w/v) PEG 2000 monomethyl ether, 200mM magnesium chloride, 100mM sodium cacodylate, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 1.20 Å R-free 0.171
3T0Z Hsp90 N-terminal domain bound to ATP Deposited 2011-07-21 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:UNP RESIDUES 9-236
Not recorded ATP ADENOSINE-5'-TRIPHOSPHATE × 1 MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;15~20% PEG 3350, 5mM magnesium chloride, 500mM ammonium phosphate, 100mM Bis-Tris pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.19 Å R-free 0.258
3T10 HSP90 N-terminal domain bound to ACP Deposited 2011-07-21 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:UNP RESIDUES 9-236
Not recorded ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 1 MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;20~25% (w/v) PEG 2000 monomethyl ether, 200mM magnesium chloride, 100mM sodium cacodylate pH 6.5,, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 1.24 Å R-free 0.172
3T1K HSP90 N-terminal domain bound to ANP Deposited 2011-07-22 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:UNP RESIDUES 9-236
Not recorded ANP PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER × 1 MG MAGNESIUM ION × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.50 Å R-free 0.189
3T1K HSP90 N-terminal domain bound to ANP Deposited 2011-07-22 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 9–236(228 aa) Fragment:UNP RESIDUES 9-236
Not recorded ANP PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER × 1 MG MAGNESIUM ION × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.50 Å R-free 0.189
3T2S HSP90 N-terminal domain bound to AGS Deposited 2011-07-23 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:UNP RESIDUES 9-236
Not recorded AGS PHOSPHOTHIOPHOSPHORIC ACID-ADENYLATE ESTER × 1 MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8.5;20~25% PEG 4000, 200mM magnesium chloride, 100mM Tris pH 8.5, VAPOR DIFFUSION, HANGING DROP
Resolution 1.50 Å R-free 0.226
3T2S HSP90 N-terminal domain bound to AGS Deposited 2011-07-23 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 9–236(228 aa) Fragment:UNP RESIDUES 9-236
Not recorded AGS PHOSPHOTHIOPHOSPHORIC ACID-ADENYLATE ESTER × 1 MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8.5;20~25% PEG 4000, 200mM magnesium chloride, 100mM Tris pH 8.5, VAPOR DIFFUSION, HANGING DROP
Resolution 1.50 Å R-free 0.226
3TUH Crystal Structure of the N-terminal domain of an HSP90 in the presence of an the inhibitor ganetespib Deposited 2011-09-16 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 16–224(209 aa) Fragment:UNP residues 16-224
Not recorded TUH 5-[2,4-dihydroxy-5-(propan-2-yl)phenyl]-4-(1-methyl-1H-indol-5-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.80 Å R-free 0.212
3TUH Crystal Structure of the N-terminal domain of an HSP90 in the presence of an the inhibitor ganetespib Deposited 2011-09-16 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 16–224(209 aa) Fragment:UNP residues 16-224
Not recorded TUH 5-[2,4-dihydroxy-5-(propan-2-yl)phenyl]-4-(1-methyl-1H-indol-5-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.80 Å R-free 0.212
3VHA Hsp90 alpha N-terminal domain in complex with a macrocyclic inhibitor Deposited 2011-08-24 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-terminal domain
Not recorded MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1 VHA 22-methyl-13,18-dioxa-7-thia-3,5-diazatetracyclo[17.3.1.1~2,6~.1~8,12~]pentacosa-1(23),2(25),3,5,8(24),9,11,19,21-nonaen-4-amine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6;277 K;32%(w/v) PEG 3350, 0.3M KCl, 0.1M Na-MES, pH 6.0, vapor diffusion, hanging drop, temperature 277K
Resolution 1.39 Å R-free 0.216
3VHC Hsp90 alpha N-terminal domain in complex with a macrocyclic inhibitor Deposited 2011-08-24 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-terminal domain
Not recorded VHC 4-amino-20,22-dimethyl-13-oxa-7-thia-3,5,17-triazatetracyclo[17.3.1.1~2,6~.1~8,12~]pentacosa-1(23),2(25),3,5,8(24),9,11,19,21-nonaen-18-one × 1 MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8.5;277 K;33%(w/v) PEG 2000 MME, 0.1M MgCl2, 0.1M Tris-Cl, pH 8.5, vapor diffusion, hanging drop, temperature 277K
Resolution 1.41 Å R-free 0.220
3VHD Hsp90 alpha N-terminal domain in complex with a macrocyclic inhibitor, CH5164840 Deposited 2011-08-24 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-terminal domain
Not recorded VHE 4-amino-18,20-dimethyl-7-thia-3,5,11,15-tetraazatricyclo[15.3.1.1(2,6)]docosa-1(20),2,4,6(22),17(21),18-hexaene-10,16-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;31%(w/v) PEG 5000 MME, 0.2M MgCl2, 5%(v/v) Glycerol, 0.1M Na-MES, pH 6.5, vapor diffusion, hanging drop, temperature 277K
Resolution 1.52 Å R-free 0.196
3VHD Hsp90 alpha N-terminal domain in complex with a macrocyclic inhibitor, CH5164840 Deposited 2011-08-24 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 9–236(228 aa) Fragment:N-terminal domain
Not recorded VHE 4-amino-18,20-dimethyl-7-thia-3,5,11,15-tetraazatricyclo[15.3.1.1(2,6)]docosa-1(20),2,4,6(22),17(21),18-hexaene-10,16-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;31%(w/v) PEG 5000 MME, 0.2M MgCl2, 5%(v/v) Glycerol, 0.1M Na-MES, pH 6.5, vapor diffusion, hanging drop, temperature 277K
Resolution 1.52 Å R-free 0.196
3WHA Hsp90 alpha N-terminal domain in complex with a tricyclic inhibitor Deposited 2013-08-23 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:UNP residues 9-236
Not recorded GOL GLYCEROL × 1 WHA 4-{[4-amino-6-(5-chloro-1H,3H-benzo[de]isochromen-6-yl)-1,3,5-triazin-2-yl]sulfanyl}butanamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 6.5;278 K;22%(w/v) PEG 3350, 0.2M MgCl2, 0.1M Na-MES, pH 6.5, vapor diffusion, sitting drop, temperature 278K
Resolution 1.30 Å R-free 0.200
3WHA Hsp90 alpha N-terminal domain in complex with a tricyclic inhibitor Deposited 2013-08-23 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 9–236(228 aa) Fragment:UNP residues 9-236
Not recorded WHA 4-{[4-amino-6-(5-chloro-1H,3H-benzo[de]isochromen-6-yl)-1,3,5-triazin-2-yl]sulfanyl}butanamide × 1 MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 6.5;278 K;22%(w/v) PEG 3350, 0.2M MgCl2, 0.1M Na-MES, pH 6.5, vapor diffusion, sitting drop, temperature 278K
Resolution 1.30 Å R-free 0.200
3WHA Hsp90 alpha N-terminal domain in complex with a tricyclic inhibitor Deposited 2013-08-23 Assembly 3 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–236(228 aa) Fragment:UNP residues 9-236
Not recorded GOL GLYCEROL × 2 WHA 4-{[4-amino-6-(5-chloro-1H,3H-benzo[de]isochromen-6-yl)-1,3,5-triazin-2-yl]sulfanyl}butanamide × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 6.5;278 K;22%(w/v) PEG 3350, 0.2M MgCl2, 0.1M Na-MES, pH 6.5, vapor diffusion, sitting drop, temperature 278K
Resolution 1.30 Å R-free 0.200
3WHA Hsp90 alpha N-terminal domain in complex with a tricyclic inhibitor Deposited 2013-08-23 Assembly 4 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain B 9–236(228 aa) Fragment:UNP residues 9-236
Not recorded WHA 4-{[4-amino-6-(5-chloro-1H,3H-benzo[de]isochromen-6-yl)-1,3,5-triazin-2-yl]sulfanyl}butanamide × 2 MG MAGNESIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 6.5;278 K;22%(w/v) PEG 3350, 0.2M MgCl2, 0.1M Na-MES, pH 6.5, vapor diffusion, sitting drop, temperature 278K
Resolution 1.30 Å R-free 0.200
3WQ9 Crystal structure of Hsp90-alpha N-terminal domain in complex with 2-(4-Hydroxy-cyclohexylamino)-4-[5-(4-phenyl-imidazol-1-yl)-isoquinolin-1-yl]-benzamide Deposited 2014-01-23 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa) Fragment:N-TERMINAL DOMAIN, UNP RESIDUES 1-236
Not recorded YUK 2-[(trans-4-hydroxycyclohexyl)amino]-4-[5-(4-phenyl-1H-imidazol-1-yl)isoquinolin-1-yl]benzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;277 K;PEG 6000, 200mM NaCl, 50mM Tris pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 1.80 Å R-free 0.264
3WQ9 Crystal structure of Hsp90-alpha N-terminal domain in complex with 2-(4-Hydroxy-cyclohexylamino)-4-[5-(4-phenyl-imidazol-1-yl)-isoquinolin-1-yl]-benzamide Deposited 2014-01-23 Assembly 2 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 1–236(236 aa) Fragment:N-TERMINAL DOMAIN, UNP RESIDUES 1-236
Not recorded YUK 2-[(trans-4-hydroxycyclohexyl)amino]-4-[5-(4-phenyl-1H-imidazol-1-yl)isoquinolin-1-yl]benzamide × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;277 K;PEG 6000, 200mM NaCl, 50mM Tris pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 1.80 Å R-free 0.264
4AIF AIP TPR domain in complex with human Hsp90 peptide Deposited 2012-02-09 Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain D 726–732(7 aa) Fragment:C-TERMINAL PEPTIDE SRMEEVD, RESIDUES 726-732
Not recorded SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions 1 M AMMONIUM SULFATE, 0.1 M BIS-TRIS PH 5.5, 1% PEG 3350
Resolution 2.01 Å R-free 0.236
4AIF AIP TPR domain in complex with human Hsp90 peptide Deposited 2012-02-09 Assembly 2 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain E 726–732(7 aa) Fragment:C-TERMINAL PEPTIDE SRMEEVD, RESIDUES 726-732
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions 1 M AMMONIUM SULFATE, 0.1 M BIS-TRIS PH 5.5, 1% PEG 3350
Resolution 2.01 Å R-free 0.236
4AWO Complex of HSP90 ATPase domain with tropane derived inhibitors Deposited 2012-06-05 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–236(228 aa) Fragment:ATPASE DOMAIN, RESIDUES 9-236
Chain B 9–236(228 aa) Fragment:ATPASE DOMAIN, RESIDUES 9-236
Not recorded 99B 5-[(2R)-butan-2-ylamino]-N-{(3-endo)-8-[5-(cyclopropylcarbonyl)pyridin-2-yl]-8-azabicyclo[3.2.1]oct-3-yl}-2-methylbenzene-1,4-dicarboxamide × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8;pH 8.0
Resolution 1.70 Å R-free 0.251
4AWP Complex of HSP90 ATPase domain with tropane derived inhibitors Deposited 2012-06-05 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–236(228 aa) Fragment:ATPASE DOMAIN, RESIDUES 9-236
Chain B 9–236(228 aa) Fragment:ATPASE DOMAIN, RESIDUES 9-236
Not recorded 99A N-{(3-endo)-8-[5-(benzylcarbamoyl)pyridin-2-yl]-8-azabicyclo[3.2.1]oct-3-yl}-2,5-dimethylbenzene-1,4-dicarboxamide × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8;pH 8
Resolution 1.82 Å R-free 0.246
4AWQ Complex of HSP90 ATPase domain with tropane derived inhibitors Deposited 2012-06-05 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–236(228 aa) Fragment:ATPASE DOMAIN, RESIDUES 9-236
Chain B 9–236(228 aa) Fragment:ATPASE DOMAIN, RESIDUES 9-236
Not recorded 592 N-benzyl-6-[(3-endo)-3-{[(3-methoxy-2-methylphenyl)carbonyl]amino}-8-azabicyclo[3.2.1]oct-8-yl]pyridine-3-carboxamide × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8;pH 8.0
Resolution 1.60 Å R-free 0.262
4B7P Structure of HSP90 with NMS-E973 inhibitor bound Deposited 2012-08-21 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-TERMINAL DOMAIN, RESIDUES 9-236
Not recorded 9UN 5-[2,4-dihydroxy-6-(4-nitrophenoxy)phenyl]-N-(1-methylpiperidin-4-yl)-1,2-oxazole-3-carboxamide × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.70 Å R-free 0.197
4BQJ structure of HSP90 with an inhibitor bound Deposited 2013-05-30 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-TERMINAL DOMAIN, RESIDUES 9-236
Not recorded XKL 5-[2,4-dihydroxy-6-(4-nitrophenoxy)phenyl]-N-ethyl-1,2-oxazole-3-carboxamide × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.00 Å R-free 0.221
4CGQ Full length Tah1 bound to HSP90 peptide SRMEEVD Deposited 2013-11-26 Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain Q 726–732(7 aa) Fragment:C-TERMINAL PEPTIDE, RESIDUES 726-732
Not recorded CL CHLORIDE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7;pH 7
Resolution 2.00 Å R-free 0.210
4CGU Full length Tah1 bound to yeast PIH1 and HSP90 peptide SRMEEVD Deposited 2013-11-26 Assembly 1 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric(3) Consistent with protein count
Chain C 726–732(7 aa) Fragment:C-TERMINAL PEPTIDE, RESIDUES 726-732
Not recorded GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7;pH 7
Resolution 2.11 Å R-free 0.210
4CGV First TPR of Spaghetti (RPAP3) bound to HSP90 peptide SRMEEVD Deposited 2013-11-26 Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain F 726–732(7 aa) Fragment:C-TERMINAL PEPTIDE, RESIDUES 726-732
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions pH 7;pH 7
Resolution 2.54 Å R-free 0.267
4CGV First TPR of Spaghetti (RPAP3) bound to HSP90 peptide SRMEEVD Deposited 2013-11-26 Assembly 3 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain E 726–732(7 aa) Fragment:C-TERMINAL PEPTIDE, RESIDUES 726-732
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions pH 7;pH 7
Resolution 2.54 Å R-free 0.267
4CGW Second TPR of Spaghetti (RPAP3) bound to HSP90 peptide SRMEEVD Deposited 2013-11-26 Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain C 726–732(7 aa) Fragment:C-TERMINAL PEPTIDE, RESIDUES 726-732
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions pH 7;pH 7
Resolution 3.00 Å R-free 0.291
4CGW Second TPR of Spaghetti (RPAP3) bound to HSP90 peptide SRMEEVD Deposited 2013-11-26 Assembly 2 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain D 726–732(7 aa) Fragment:C-TERMINAL PEPTIDE, RESIDUES 726-732
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions pH 7;pH 7
Resolution 3.00 Å R-free 0.291
4CWF Human HSP90 alpha N-terminal domain in complex with an Aminotriazoloquinazoline inhibitor Deposited 2014-04-02 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-TERMINAL DOMAIN, RESIDUES 9-236
Not recorded H05 5-propyl[1,2,4]triazolo[1,5-c]quinazolin-2-amine × 2 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.00 Å R-free 0.233
4CWN Human HSP90 alpha N-terminal domain in complex with an Aminotriazoloquinazoline inhibitor Deposited 2014-04-03 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-TERMINAL DOMAIN, RESIDUES 9-236
Not recorded 6LV 5-(3,5-dimethoxybenzyl)[1,2,4]triazolo[1,5-c]quinazolin-2-amine × 2 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.80 Å R-free 0.228
4CWO Human HSP90 alpha N-terminal domain in complex with an Aminotriazoloquinazoline inhibitor Deposited 2014-04-03 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-TERMINAL DOMAIN, RESIDUES 9-236
Not recorded T62 5-(2-amino-[1,2,4]triazolo[1,5-c]quinazolin-5-ylmethyl)-benzene-1,3-diol × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.31 Å R-free 0.253
4CWP Human HSP90 alpha N-terminal domain in complex with an Aminotriazoloquinazoline inhibitor Deposited 2014-04-03 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-TERMINAL DOMAIN, RESIDUES 9-236
Not recorded TV2 5-(1,3-benzodioxol-5-ylmethyl)[1,2,4]triazolo[1,5-c]quinazolin-2-amine × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.95 Å R-free 0.216
4CWQ Human HSP90 alpha N-terminal domain in complex with an Aminotriazoloquinazoline inhibitor Deposited 2014-04-03 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-TERMINAL DOMAIN, RESIDUES 9-236
Not recorded W2D 2-amino-5-(1,3-benzodioxol-5-ylmethyl)[1,2,4]triazolo[1,5-c]quinazoline-8-sulfonamide × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.00 Å R-free 0.240
4CWR Human HSP90 alpha N-terminal domain in complex with an Aminotriazoloquinazoline inhibitor Deposited 2014-04-03 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-TERMINAL DOMAIN, RESIDUES 9-236
Not recorded HAJ 5-(1,3-benzodioxol-5-ylmethyl)-10-fluoro[1,2,4]triazolo[1,5-c]quinazolin-2-amine × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.00 Å R-free 0.215
4CWS Human HSP90 alpha N-terminal domain in complex with an Aminotriazoloquinazoline inhibitor Deposited 2014-04-03 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-TERMINAL DOMAIN, RESIDUES 9-236
Not recorded G3R 2-{[2-amino-5-(1,3-benzodioxol-5-ylmethyl)[1,2,4]triazolo[1,5-c]quinazolin-8-yl]amino}ethanol × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.30 Å R-free 0.264
4CWT Human HSP90 alpha N-terminal domain in complex with an Aminotriazoloquinazoline inhibitor Deposited 2014-04-03 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-TERMINAL DOMAIN, RESIDUES 9-236
Not recorded IK9 2-{[(2Z)-5-(1,3-benzodioxol-5-ylmethyl)-8-fluoro-2-imino-2,3-dihydro[1,2,4]triazolo[1,5-c]quinazolin-10-yl]amino}ethanol × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.90 Å R-free 0.228
4EEH Hsp90 Alpha N-terminal Domain in Complex with an Inhibitor 3-(4-Hydroxy-phenyl)-1H-indazol-6-ol Deposited 2012-03-28 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-TERMINAL DOMAIN
Not recorded HH6 3-(4-hydroxyphenyl)-1H-indazol-6-ol × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;Na-Cacodylate, 30% PEG8000, 0.2M Ammonium Sulfate, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 1.60 Å R-free 0.212
4EEH Hsp90 Alpha N-terminal Domain in Complex with an Inhibitor 3-(4-Hydroxy-phenyl)-1H-indazol-6-ol Deposited 2012-03-28 Assembly 2 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-TERMINAL DOMAIN
Not recorded HH6 3-(4-hydroxyphenyl)-1H-indazol-6-ol × 2 SO4 SULFATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;Na-Cacodylate, 30% PEG8000, 0.2M Ammonium Sulfate, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 1.60 Å R-free 0.212
4EFT Hsp90 Alpha N-terminal Domain in Complex with an Inhibitor 3-Cyclohexyl-2-(6-hydroxy-1H-indazol-3-yl)-propionitrile Deposited 2012-03-30 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-TERMINAL DOMAIN
Not recorded EFT (2R)-3-cyclohexyl-2-(6-hydroxy-1H-indazol-3-yl)propanenitrile × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;Na-Cacodylate, 30% PEG8000, 0.2M Ammonium Sulfate, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.12 Å R-free 0.230
4EFT Hsp90 Alpha N-terminal Domain in Complex with an Inhibitor 3-Cyclohexyl-2-(6-hydroxy-1H-indazol-3-yl)-propionitrile Deposited 2012-03-30 Assembly 2 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-TERMINAL DOMAIN
Not recorded EFT (2R)-3-cyclohexyl-2-(6-hydroxy-1H-indazol-3-yl)propanenitrile × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;Na-Cacodylate, 30% PEG8000, 0.2M Ammonium Sulfate, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.12 Å R-free 0.230
4EFU Hsp90 Alpha N-terminal Domain in Complex with an Inhibitor 6-Hydroxy-3-(3-methyl-benzyl)-1H-indazole-5-carboxylic acid benzyl-methyl-amide Deposited 2012-03-30 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-TERMINAL DOMAIN
Not recorded EFU N-benzyl-6-hydroxy-N-methyl-3-(3-methylbenzyl)-1H-indazole-5-carboxamide × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;Na-Cacodylate, 30% PEG8000, 0.2M Ammonium Sulfate , pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.00 Å R-free 0.223
4EGH Hsp90-alpha ATPase domain in complex with (4-Hydroxyphenyl)morpholin-4-yl methanone Deposited 2012-03-30 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-terminal domain, residues 9-236
Not recorded MG MAGNESIUM ION × 1 0OY (4-hydroxyphenyl)(morpholin-4-yl)methanone × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.2;273 K;0.2M MgCl2, 0.1M HEPES, 20%w/v PEG2000, pH 7.2, VAPOR DIFFUSION, HANGING DROP, temperature 273K
Resolution 1.60 Å R-free 0.226
4EGH Hsp90-alpha ATPase domain in complex with (4-Hydroxyphenyl)morpholin-4-yl methanone Deposited 2012-03-30 Assembly 2 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-terminal domain, residues 9-236
Not recorded MG MAGNESIUM ION × 2 0OY (4-hydroxyphenyl)(morpholin-4-yl)methanone × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.2;273 K;0.2M MgCl2, 0.1M HEPES, 20%w/v PEG2000, pH 7.2, VAPOR DIFFUSION, HANGING DROP, temperature 273K
Resolution 1.60 Å R-free 0.226
4EGI Hsp90-alpha ATPase domain in complex with 2-Amino-4-ethylthio-6-methyl-1,3,5-triazine Deposited 2012-03-31 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-terminal domain, residues 9-236
Not recorded B2J 4-(ethylsulfanyl)-6-methyl-1,3,5-triazin-2-amine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.2;273 K;0.2M MgCl2, 0.1M HEPE, 20%w/v PEG2000, pH 7.2, VAPOR DIFFUSION, HANGING DROP, temperature 273K
Resolution 1.79 Å R-free 0.236
4EGK Human Hsp90-alpha ATPase domain bound to Radicicol Deposited 2012-03-31 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-terminal domain, residues 9-236
Not recorded RDC RADICICOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.2;273 K;0.2M MgCl2, 0.1M HEPES, 20%w/v PEG2000, pH 7.2, VAPOR DIFFUSION, HANGING DROP, temperature 273K
Resolution 1.69 Å R-free 0.243
4FCP Targetting conserved water molecules: Design of 4-aryl-5-cyanopyrrolo [2,3-d] pyrimidine Hsp90 inhibitors using fragment-based screening and structure-based optimization Deposited 2012-05-25 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 1–236(236 aa)
Chain B 1–236(236 aa)
Not recorded 42C N,N-dimethyl-7H-purin-6-amine × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;298 K;25% PEG MME 2000, 0.1M NA CACODYLATE 6.5, 0.2M MGCL2, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.00 Å R-free 0.292
4FCP Targetting conserved water molecules: Design of 4-aryl-5-cyanopyrrolo [2,3-d] pyrimidine Hsp90 inhibitors using fragment-based screening and structure-based optimization Deposited 2012-05-25 Assembly 2 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 1–236(236 aa)
Not recorded 42C N,N-dimethyl-7H-purin-6-amine × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;298 K;25% PEG MME 2000, 0.1M NA CACODYLATE 6.5, 0.2M MGCL2, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.00 Å R-free 0.292
4FCP Targetting conserved water molecules: Design of 4-aryl-5-cyanopyrrolo [2,3-d] pyrimidine Hsp90 inhibitors using fragment-based screening and structure-based optimization Deposited 2012-05-25 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–236(236 aa)
Not recorded 42C N,N-dimethyl-7H-purin-6-amine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;298 K;25% PEG MME 2000, 0.1M NA CACODYLATE 6.5, 0.2M MGCL2, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.00 Å R-free 0.292
4FCQ Targeting conserved water molecules: Design of 4-aryl-5-cyanopyrrolo[2,3-d]pyrimidine Hsp90 inhibitors using fragment-based screening and structure-based optimization Deposited 2012-05-25 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa) Fragment:UNP Residues 1-236
Not recorded 2N6 4-(2,4-dimethylphenyl)-2-(methylsulfanyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;298 K;25% PEG MME 2000, 0.1M Na Cacodylate, PH6.5, 0.2M MGCl2, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.15 Å R-free 0.247
4FCQ Targeting conserved water molecules: Design of 4-aryl-5-cyanopyrrolo[2,3-d]pyrimidine Hsp90 inhibitors using fragment-based screening and structure-based optimization Deposited 2012-05-25 Assembly 2 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 1–236(236 aa) Fragment:UNP Residues 1-236
Not recorded 2N6 4-(2,4-dimethylphenyl)-2-(methylsulfanyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;298 K;25% PEG MME 2000, 0.1M Na Cacodylate, PH6.5, 0.2M MGCl2, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.15 Å R-free 0.247
4FCR Targeting conserved water molecules: Design of 4-aryl-5-cyanopyrrolo[2,3-d]pyrimidine Hsp90 inhibitors using fragment-based screening and structure-based optimization Deposited 2012-05-25 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa)
Not recorded 0TM 2-{[4-(2-chloro-4,5-dimethoxyphenyl)-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-2-yl]sulfanyl}-N,N-dimethylacetamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;298 K;25% PEG MME 2000, 0.1M Na Cacodylate, PH6.5, 0.2M MgCl2, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 1.70 Å R-free 0.243
4FCR Targeting conserved water molecules: Design of 4-aryl-5-cyanopyrrolo[2,3-d]pyrimidine Hsp90 inhibitors using fragment-based screening and structure-based optimization Deposited 2012-05-25 Assembly 2 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 1–236(236 aa)
Not recorded 0TM 2-{[4-(2-chloro-4,5-dimethoxyphenyl)-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-2-yl]sulfanyl}-N,N-dimethylacetamide × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;298 K;25% PEG MME 2000, 0.1M Na Cacodylate, PH6.5, 0.2M MgCl2, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 1.70 Å R-free 0.243
4HY6 Crystal Structure of the human Hsp90-alpha N-domain bound to the hsp90 inhibitor FJ1 Deposited 2012-11-13 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-Terminal domain, UNP residues 9-236
Not recorded FJ1 6,6-dimethyl-3-(trifluoromethyl)-1,5,6,7-tetrahydro-4H-indazol-4-one × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.65 Å R-free 0.216
4JQL Synthesis of Benzoquinone-Ansamycin-Inspired Macrocyclic Lactams from Shikimic Acid Deposited 2013-03-20 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded VJ6 valerjesomycin × 1 MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION;pH 8.5;277 K;0.1 M Tris HCl, 0.2 M MgCl2, 30% PEG4000, pH 8.5, VAPOR DIFFUSION, temperature 277K
Resolution 1.72 Å R-free 0.196
4L8Z Crystal structure of Human Hsp90 with RL1 Deposited 2013-06-18 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:UNP residues 9-236
Not recorded RL1 [5-(6-bromo[1,2,4]triazolo[4,3-a]pyridin-3-yl)-2,4-dihydroxyphenyl](3,4-dihydroisoquinolin-2(1H)-yl)methanone × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;25%(w/v) PEG 2000 monomethyl ether, 200mM magnesium chloride, 100mM sodium cacodylate, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 1.70 Å R-free 0.218
4L90 Crystal structure of Human Hsp90 with RL3 Deposited 2013-06-18 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:UNP residues 9-236
Not recorded RL3 [5-(6-bromo[1,2,4]triazolo[4,3-a]pyridin-3-yl)-2,4-dihydroxyphenyl](4-methylpiperazin-1-yl)methanone × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.00 Å R-free 0.219
4L91 Crystal structure of Human Hsp90 with X29 Deposited 2013-06-18 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:UNP residues 9-236
Not recorded X29 4-(6-bromo[1,2,4]triazolo[4,3-a]pyridin-3-yl)-6-chlorobenzene-1,3-diol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;25%(w/v) PEG 2000 monomethyl ether, 200mM magnesium chloride, 100mM sodium cacodylate, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 1.75 Å R-free 0.211
4L93 Crystal structure of Human Hsp90 with S36 Deposited 2013-06-18 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–236(228 aa) Fragment:UNP residues 9-236
Not recorded S36 3,4-dihydroisoquinolin-2(1H)-yl[2,4-dihydroxy-5-(propan-2-yl)phenyl]methanone × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;20%-25%(w/v) PEG 2000 monomethyl ether, 200mM magnesium chloride, 100mM sodium cacodylate, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 1.84 Å R-free 0.260
4L93 Crystal structure of Human Hsp90 with S36 Deposited 2013-06-18 Assembly 2 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain B 9–236(228 aa) Fragment:UNP residues 9-236
Not recorded S36 3,4-dihydroisoquinolin-2(1H)-yl[2,4-dihydroxy-5-(propan-2-yl)phenyl]methanone × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;20%-25%(w/v) PEG 2000 monomethyl ether, 200mM magnesium chloride, 100mM sodium cacodylate, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 1.84 Å R-free 0.260
4L94 Crystal structure of Human Hsp90 with S46 Deposited 2013-06-18 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:UNP residues 9-236
Not recorded S46 (4-hydroxyphenyl)(4-methylpiperazin-1-yl)methanone × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;20%-25%(w/v) PEG 2000 monomethyl ether, 200mM magnesium chloride, 100mM sodium cacodylate, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 1.65 Å R-free 0.213
4L94 Crystal structure of Human Hsp90 with S46 Deposited 2013-06-18 Assembly 2 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–236(228 aa) Fragment:UNP residues 9-236
Not recorded S46 (4-hydroxyphenyl)(4-methylpiperazin-1-yl)methanone × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;20%-25%(w/v) PEG 2000 monomethyl ether, 200mM magnesium chloride, 100mM sodium cacodylate, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 1.65 Å R-free 0.213
4LWE Crystal Structure of the human Hsp90-alpha N-domain bound to the hsp90 inhibitor FJ2 Deposited 2013-07-27 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 17–224(208 aa) Fragment:UNP RESIDUES 17-224
Not recorded FJ2 N-[3-(5-chloro-2,4-dihydroxyphenyl)-4-(4-methoxyphenyl)-1,2-oxazol-5-yl]acetamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;0.1M Sodium cacodylate 6.5, 0.2M Mgcl2, 20-25% PEG2000 MME, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 1.50 Å R-free 0.195
4LWF Crystal Structure of the human Hsp90-alpha N-domain bound to the hsp90 inhibitor FJ3 Deposited 2013-07-27 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 17–224(208 aa) Fragment:UNP RESIDUES 17-224
Not recorded FJ3 4-(5-amino-1,2-oxazol-3-yl)-6-(propan-2-yl)benzene-1,3-diol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;20-25% (w/v) PEG 2000 monomethyl ether, 200mM magnesium chloride, 100mM sodium cacodylate pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 1.75 Å R-free 0.209
4LWG Crystal Structure of the human Hsp90-alpha N-domain bound to the hsp90 inhibitor FJ4 Deposited 2013-07-27 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 17–224(208 aa) Fragment:UNP RESIDUES 17-224
Not recorded FJ4 1-(5-chloro-2,4-dihydroxyphenyl)-2-(4-methoxyphenyl)ethanone × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;20-25% (w/v) PEG 2000 monomethyl ether, 200mM magnesium chloride, 100mM sodium cacodylate pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 1.60 Å R-free 0.210
4LWH Crystal Structure of the human Hsp90-alpha N-domain bound to the hsp90 inhibitor FJ5 Deposited 2013-07-27 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 16–224(209 aa) Fragment:UNP RESIDUES 16-224
Not recorded FJ5 N-{3-[2,4-dihydroxy-5-(propan-2-yl)phenyl]-4-[4-(morpholin-4-ylmethyl)phenyl]-1,2-oxazol-5-yl}cyclopropanecarboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;20-25% (w/v) PEG 2000 monomethyl ether, 200mM magnesium chloride, 100mM sodium cacodylate pH 6.5,, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 1.70 Å R-free 0.204
4LWI Crystal Structure of the human Hsp90-alpha N-domain bound to the hsp90 inhibitor FJ6 Deposited 2013-07-27 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 17–224(208 aa) Fragment:UNP RESIDUES 17-224
Not recorded FJ6 N-{3-[2,4-dihydroxy-5-(propan-2-yl)phenyl]-4-(4-methoxyphenyl)-1,2-oxazol-5-yl}cyclopropanecarboxamide × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.70 Å R-free 0.213
4NH7 Correlation between chemotype-dependent binding conformations of HSP90 alpha/beta and isoform selectivity Deposited 2013-11-04 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 131–358(228 aa) Fragment:UNP residues 9-236
Not recorded E0G 4-[6,6-dimethyl-4-oxidanylidene-3-(trifluoromethyl)-5,7-dihydroindazol-1-yl]-2-[(4-oxidanylcyclohexyl)amino]benzamide × 1 GOL GLYCEROL × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;20-25% PEGMME 2000, 100mM cacodylate pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.00 Å R-free 0.243
4NH7 Correlation between chemotype-dependent binding conformations of HSP90 alpha/beta and isoform selectivity Deposited 2013-11-04 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 131–358(228 aa) Fragment:UNP residues 9-236
Not recorded E0G 4-[6,6-dimethyl-4-oxidanylidene-3-(trifluoromethyl)-5,7-dihydroindazol-1-yl]-2-[(4-oxidanylcyclohexyl)amino]benzamide × 1 GOL GLYCEROL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;20-25% PEGMME 2000, 100mM cacodylate pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.00 Å R-free 0.243
4NH8 Correlation between chemotype-dependent binding conformations of HSP90 alpha/beta and isoform selectivity Deposited 2013-11-04 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:UNP residues 9-236
Not recorded 2LC 2-fluoro-6-[(3S)-tetrahydrofuran-3-ylamino]-4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;20-25% PEGMME2K, 100mM MgCl2, 100mM cacodylate pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 1.65 Å R-free 0.187
4O04 Identification of novel HSP90/isoform selective inhibitors using structure-based drug design. Demonstration of potential utility in treating CNS disorders such as Huntington's disease Deposited 2013-12-13 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:UNP residues 9-236
Not recorded 2Q8 4-(2,7,7-trimethyl-5-oxo-1,2,3,4,5,6,7,8-octahydro-9H-beta-carbolin-9-yl)benzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;20-25%PEGMME2K, 0.2M MgCl2,0.1M cacodylate pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 1.82 Å R-free 0.205
4O05 Identification of novel HSP90/isoform selective inhibitors using structure-based drug design. Demonstration of potential utility in treating CNS disorders such as Huntington's disease Deposited 2013-12-13 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:UNP residues 9-236
Not recorded 2Q9 2,7,7-trimethyl-9-[1-oxo-8-(propan-2-ylamino)-1,2,3,4-tetrahydroisoquinolin-6-yl]-1,2,3,4,6,7,8,9-octahydro-5H-beta-carbolin-5-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;20-25$PEGMME2K, 100mM cacodylate pH 6.5, 200mM MgCl2, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 1.79 Å R-free 0.215
4O07 Identification of novel HSP90/isoform selective inhibitors using structure-based drug design. Demonstration of potential utility in treating CNS disorders such as Huntington's disease Deposited 2013-12-13 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:UNP residues 9-236
Not recorded FGH 2,7,7-trimethyl-9-[8-(2-methylpropyl)-1-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl]-1,2,3,4,6,7,8,9-octahydro-5H-beta-carbolin-5-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;20-25%PEGMME2K, 100mM cacodylate pH 6.5, 200mM MgCl2, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 1.86 Å R-free 0.209
4O09 Identification of novel HSP90 / isoform selective inhibitors using structure-based drug design. Demonstration of potential utility in treating CNS disorders such as Huntington s disease Deposited 2013-12-13 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:UNP residues 9-236
Not recorded 2R6 8-(2-methylpropyl)-6-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)-3,4-dihydroisoquinolin-1(2H)-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;20-25%PEGMME2K, 100mM cacodylate 6.5, 200mM magnesium chloride, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 1.96 Å R-free 0.228
4O0B Identification of novel HSP90/isoform selective inhibitors using structure-based drug design. Demonstration of potential utility in treating CNS disorders such as Huntington's disease Deposited 2013-12-13 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:UNP residues 9-236
Not recorded 2QA 8-cyclopentyl-6-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)-3,4-dihydroisoquinolin-1(2H)-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;20-25%PEGMME2K, 100mM cacodylate pH 6.5, 200mM MgCl2, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 1.93 Å R-free 0.218
4R3M Crystal structure of Human Hsp90 with JR9 Deposited 2014-08-16 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 16–224(209 aa) Fragment:UNP RESIDUES 16-223
Not recorded JR9 N~3~-benzyl-2-[(6-bromo-1,3-benzodioxol-5-yl)methyl]imidazo[1,2-a]pyrazine-3,8-diamine × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.80 Å R-free 0.234
4U93 Crystal Structure of Hsp90-alpha N-domain Bound to the Inhibitor NVP-HSP990 Deposited 2014-08-05 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa) Fragment:ATP-binding domain, UNP residues 1-236
Not recorded 990 (7R)-2-amino-7-[4-fluoro-2-(6-methoxypyridin-2-yl)phenyl]-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;298 K;Protein is used at 10mg/ml. Crystallant is: 10-20% (w/v) PEG2K MME, 50-200 mM magnesium chloride, 100 mM sodium cacodylate Equal ratio of protein to crystallant use for drops
Resolution 1.55 Å R-free 0.213
4W7T Crystal Structure of Hsp90-alpha N-domain Bound to the Inhibitor NVP-HSP990 Deposited 2014-08-22 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 123–358(236 aa)
Not recorded 3JC (7S)-2-amino-4-methyl-7-phenyl-7,8-dihydroquinazolin-5(6H)-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;298 K;Protein is used at 12mg/ml crystallant is: 20% (w/v) PEG2K MME, 200 mM magnesium chloride, 100 mM sodium cacodylate Apo crystals are grown with equal volumes of protein to crystallant. Compound is dissolved to 200mM in equal volumes of EtOH:PEG400:DMI, then diluted into crystallant for a working stock of 4mM. 1ul of compound working stock is added to a drop containing Apo Hsp90 crystals. Soak for 3 days.
Resolution 1.80 Å R-free 0.210
4XIP Discovery of novel oxazepine and diazepine carboxamides as two new classes of heat shock protein 90 inhibitors Deposited 2015-01-07 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 131–358(228 aa) Fragment:residues 131-358
Not recorded 40W 4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;20-25% PEGMME2K, 100MM MGCL2, 100mM cacodylate buffer pH 6.5
Resolution 1.70 Å R-free 0.214
4XIP Discovery of novel oxazepine and diazepine carboxamides as two new classes of heat shock protein 90 inhibitors Deposited 2015-01-07 Assembly 2 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 131–358(228 aa) Fragment:residues 131-358
Not recorded 40W 4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;20-25% PEGMME2K, 100MM MGCL2, 100mM cacodylate buffer pH 6.5
Resolution 1.70 Å R-free 0.214
4XIQ Discovery of novel oxazepine and diazepine carboxamides as two new classes of heat shock protein 90 inhibitors Deposited 2015-01-07 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 131–358(228 aa) Fragment:residues 131-358
Not recorded 40Y 8,11,11-trimethyl-9-oxo-6,7,9,10,11,12-hexahydroindolo[2,1-d][1,5]benzoxazepine-3-carboxamide × 1 GOL GLYCEROL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;20-25% PEGMME2K, 100MM MGCL2, 100MM CACODYLATE PH 6.5
Resolution 1.84 Å R-free 0.206
4XIQ Discovery of novel oxazepine and diazepine carboxamides as two new classes of heat shock protein 90 inhibitors Deposited 2015-01-07 Assembly 2 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 131–358(228 aa) Fragment:residues 131-358
Not recorded 40Y 8,11,11-trimethyl-9-oxo-6,7,9,10,11,12-hexahydroindolo[2,1-d][1,5]benzoxazepine-3-carboxamide × 2 GOL GLYCEROL × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;20-25% PEGMME2K, 100MM MGCL2, 100MM CACODYLATE PH 6.5
Resolution 1.84 Å R-free 0.206
4XIR Discovery of novel oxazepine and diazepine carboxamides as two new classes of heat shock protein 90 inhibitors Deposited 2015-01-07 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 131–358(228 aa) Fragment:residues 131-358
Not recorded 40X (6S)-2-chloro-8,11,11-trimethyl-9-oxo-6-propyl-6,7,9,10,11,12-hexahydroindolo[2,1-d][1,5]benzoxazepine-3-carboxamide × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;20-25% PEGMME2K, 100MM MGCL2, 100MM REMARK 280 CACODYLATE PH 6.5
Resolution 1.70 Å R-free 0.221
4XIT Discovery of novel oxazepine and diazepine carboxamides as two new classes of heat shock protein 90 inhibitors Deposited 2015-01-07 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 131–358(228 aa) Fragment:residues 131-358
Not recorded 40Z 2-chloro-5-(furan-2-ylmethyl)-8,11,11-trimethyl-9-oxo-6,7,9,10,11,12-hexahydro-5H-indolo[1,2-a][1,5]benzodiazepine-3-carboxamide × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277 K;20-25% PEGMME2K, 100MM MGCL2, 100MM REMARK 280 CACODYLATE PH 6.5
Resolution 1.86 Å R-free 0.223
4YKQ Heat Shock Protein 90 Bound to CS301 Deposited 2015-03-04 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 2–236(235 aa) Fragment:UNP residues 2-236
Not recorded 4EO 1-(5-ethyl-2,4-dihydroxyphenyl)-1,3-dihydro-2H-benzimidazol-2-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8;277 K;26% Peg 4000, 0.2 M MgCl2, 0.1 M Tris pH 8.0, cryo conditions: 35% Peg 4000, 10% glycerol
Resolution 1.91 Å R-free 0.201
4YKR Heat Shock Protein 90 Bound to CS302 Deposited 2015-03-04 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 2–236(235 aa) Fragment:UNP residues 2-236
Not recorded 4EP 1-(2,4-dihydroxy-5-propylphenyl)-1,3-dihydro-2H-benzimidazol-2-one × 1 GOL GLYCEROL × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8;277 K;26% Peg 4000, 0.2 M MgCl2, 0.1 M Tris pH 8.0, Cryo Conditions: 35% Peg 4000, 10% glycerol
Resolution 1.61 Å R-free 0.195
4YKT Heat Shock Protein 90 Bound to CS307 Deposited 2015-03-04 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 2–236(235 aa) Fragment:UNP residues 2-236
Not recorded 4EQ 1-(5-chloro-2,4-dihydroxyphenyl)-5-({[dihydroxy(pyridin-3-yl)-lambda~4~-sulfanyl]amino}methyl)-1,3-dihydro-2H-benzimidazol-2-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8;277 K;26% Peg 4000, 0.2 M MgCl2, 0.1 M Tris pH 8.0, Cryo Conditions: 35% Peg 4000, 10% glycerol
Resolution 1.85 Å R-free 0.214
4YKU Heat Shock Protein 90 Bound to CS311 Deposited 2015-03-04 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 2–236(235 aa) Fragment:UNP residues 2-236
Not recorded 4ER 6-(2-chlorophenyl)-1,3,5-triazine-2,4-diamine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8;277 K;26% Peg 4000, 0.2 M MgCl2, 0.1 M Tris pH 8.0, Cryo Conditions: 35% Peg 4000, 10% glycerol
Resolution 1.70 Å R-free 0.196
4YKW Heat Shock Protein 90 Bound to CS312 Deposited 2015-03-04 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 2–236(235 aa) Fragment:UNP residues 2-236
Not recorded 4ES 4-(2-chloro-4-nitrophenyl)-6-methylpyrimidin-2-amine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;20% Peg 1000, 0.1 M Tris pH 7.0, Cryo Conditions: 35% Peg 4000, 10% glycerol
Resolution 1.85 Å R-free 0.229
4YKW Heat Shock Protein 90 Bound to CS312 Deposited 2015-03-04 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 2–236(235 aa) Fragment:UNP residues 2-236
Not recorded 4ES 4-(2-chloro-4-nitrophenyl)-6-methylpyrimidin-2-amine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;20% Peg 1000, 0.1 M Tris pH 7.0, Cryo Conditions: 35% Peg 4000, 10% glycerol
Resolution 1.85 Å R-free 0.229
4YKX Heat Shock Protein 90 Bound to CS318 Deposited 2015-03-04 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 2–236(235 aa) Fragment:UNP residues 2-236
Not recorded 4ET (5-chloro-2-hydroxyphenyl)(4-hydroxyphenyl)methanone × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8;277 K;26% Peg 4000, 0.2 M MgCl2, 0.1 M Tris pH 8.0, Cryo Conditions: 35% Peg 4000, 10% glycerol
Resolution 1.80 Å R-free 0.189
4YKY Heat Shock Protein 90 Bound to CS319 Deposited 2015-03-04 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 2–236(235 aa) Fragment:UNP residues 2-236
Not recorded 4EU (2,4-dihydroxyphenyl)(4-hydroxyphenyl)methanone × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8;277 K;26% Peg 4000, 0.2 M MgCl2, 0.1 M Tris pH 8.0, Cryo conditions: 35% Peg 4000, 10% glycerol
Resolution 1.78 Å R-free 0.188
4YKZ Heat Shock Protein 90 Bound to CS320 Deposited 2015-03-04 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 2–236(235 aa) Fragment:UNP residues 2-236
Not recorded 4EV (2,4-dihydroxyphenyl)(3-hydroxyphenyl)methanone × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8;277 K;26% Peg 4000, 0.2 M MgCl2, 0.1 M Tris pH 8.0, Cryo conditions: 35% Peg 4000, 10% glycerol
Resolution 1.85 Å R-free 0.206
5CF0 Crystal Structure of the human Hsp90-alpha N-domain bound to the hsp90 inhibitor FJ6 Deposited 2015-07-08 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:N-terminal domain, UNP residues 9-236
Not recorded FJS N-{3-[2,4-dihydroxy-5-(isoquinolin-4-yl)phenyl]-4-(4-methoxyphenyl)-1,2-oxazol-5-yl}cyclopropanecarboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8.5;277 K;100 mM Tris-HCl, 20% PEG 4000, 200 mM MgCl2
Resolution 1.80 Å R-free 0.222
5FNC Dynamic Undocking and the Quasi-Bound State as tools for Drug Design Deposited 2015-11-13 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 1–236(236 aa) Fragment:N-TERMINAL ATP-BINDING DOMAIN, RESIDUES 1-236
Not recorded IEE 6-CHLORO-4-N-[(4-METHYLPHENYL)METHYL]PYRIMIDINE- 2,4-DIAMINE × 2 SO4 SULFATE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;pH 6.5
Resolution 2.20 Å R-free 0.240
5FND Dynamic Undocking and the Quasi-Bound State as tools for Drug Design Deposited 2015-11-13 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 1–236(236 aa) Fragment:N-TERMINAL ATP-BINDING DOMAIN, RESIDUES 1-236
Not recorded IQ5 N-(2-AZANYL-6-METHYL-1,3-BENZOTHIAZOL-5-YL)ETHANAMIDE × 2 SO4 SULFATE ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;pH 6.5
Resolution 2.00 Å R-free 0.308
5FNF Dynamic Undocking and the Quasi-Bound State as tools for Drug Design Deposited 2015-11-13 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa) Fragment:N-TERMINAL ATP-BINDING DOMAIN, RESIDUES 1-236
Not recorded SO4 SULFATE ION × 2 TQL 4-[(E)-N-oxidanyl-C-pyridin-3-yl-carbonimidoyl]benzene-1,3-diol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;pH 6.5
Resolution 2.10 Å R-free 0.276
5GGZ Crystal structure of novel inhibitor bound with Hsp90 Deposited 2016-06-16 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain B 16–225(210 aa) Fragment:UNP residues 16-225
Chain D 16–225(210 aa) Fragment:UNP residues 16-225
Not recorded 6TN [2,4-bis(oxidanyl)-5-propan-2-yl-phenyl]-(2-ethoxy-7,8-dihydro-5~{H}-pyrido[4,3-d]pyrimidin-6-yl)methanone × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8.5;277 K;0.1 M Tris, 0.2 M MgCl2, 26% Peg 4000
Resolution 2.02 Å R-free 0.265
5GGZ Crystal structure of novel inhibitor bound with Hsp90 Deposited 2016-06-16 Assembly 2 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 16–225(210 aa) Fragment:UNP residues 16-225
Chain C 16–225(210 aa) Fragment:UNP residues 16-225
Not recorded 6TN [2,4-bis(oxidanyl)-5-propan-2-yl-phenyl]-(2-ethoxy-7,8-dihydro-5~{H}-pyrido[4,3-d]pyrimidin-6-yl)methanone × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8.5;277 K;0.1 M Tris, 0.2 M MgCl2, 26% Peg 4000
Resolution 2.02 Å R-free 0.265
5J20 HSP90 in complex with 5-[4-(2-Fluoro-phenyl)-5-oxo-4,5-dihydro-1H-[1,2,4]triazol-3-yl]-N-furan-2-ylmethyl-2,4-dihydroxy-N-methyl-benzamide Deposited 2016-03-29 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 139–345(207 aa)
Not recorded 6FJ 5-[4-(2-fluorophenyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]-N-[(furan-2-yl)methyl]-2,4-dihydroxy-N-methylbenzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8.5;277.15 K;0.2 M sodium fluoride 0.1 M Bis Tris propane 20 % w/v PEG 3350
Resolution 1.76 Å R-free 0.221
5J27 HSP90 in complex with 5-[4-(2-Fluoro-phenyl)-5-oxo-4,5-dihydro-1H-[1,2,4]triazol-3-yl]-2,4-dihydroxy-N-methyl-N-propyl-benzenesulfonamide Deposited 2016-03-29 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 138–346(209 aa)
Not recorded 6FF 5-[4-(2-fluorophenyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]-2,4-dihydroxy-N-methyl-N-propylbenzene-1-sulfonamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8.5;277.15 K;0.2 M sodium fluoride 0.1 M Bis Tris propane 20 % w/v PEG 3350
Resolution 1.70 Å R-free 0.217
5J2V Crystal Structure of Hsp90-alpha Apo N-domain Deposited 2016-03-30 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 139–345(207 aa)
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277.15 K;0.2 M sodium fluoride, 0.1 M Bis Tris propane, 20 % w/v PEG 3350
Resolution 1.59 Å R-free 0.203
5J2X Crystal Structure of Hsp90-alpha N-domain in complex with 5-(5-Bromo-2,4-dihydroxy-phenyl)-4-(2-fluoro-phenyl)-2,4-dihydro-[1,2,4]triazol-3-one Deposited 2016-03-30 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 139–346(208 aa)
Not recorded 6DL 5-(5-Bromo-2,4-dihydroxy-phenyl)-4-(2-fluoro-phenyl)-2,4-dihydro-[1,2,4]triazol-3-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277.15 K;0.2 M sodium fluoride, 0.1 M Bis Tris propane pH 8.5, 20 % w/v PEG 3350
Resolution 1.22 Å R-free 0.206
5J64 Crystal Structure of Hsp90-alpha N-domain in complex with 5-(2,4-Dihydroxy-phenyl)-4-(2-fluoro-phenyl)-2,4-dihydro-[1,2,4]triazol-3-one Deposited 2016-04-04 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded 6G7 5-(2,4-dihydroxyphenyl)-4-(2-fluorophenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8.5;277.15 K;0.2 M sodium fluoride, 0.1 M Bis Tris propane, 20 % w/v PEG 3350
Resolution 1.38 Å R-free 0.200
5J6L Crystal Structure of Hsp90-alpha N-domain in complex with N-Butyl-5-[4-(2-fluoro-phenyl)-5-oxo-4,5-dihydro-1H-[1,2,4]triazol-3-yl]-2,4-dihydroxy-N-methyl-benzamide Deposited 2016-04-05 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded 6GC N-butyl-5-[4-(2-fluorophenyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]-2,4-dihydroxy-N-methylbenzamide × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277.15 K;0.2 M sodium fluoride 0.1 M Bis Tris propane pH 8.5 20 % w/v PEG 3350
Resolution 1.75 Å R-free 0.226
5J6M Crystal Structure of Hsp90-alpha N-domain L107 mutant in complex with 5-[4-(2-Fluoro-phenyl)-5-oxo-4,5-dihydro-1H-[1,2,4]triazol-3-yl]-N-furan-2-ylmethyl-2,4-dihydroxy-N-methyl-benzamide Deposited 2016-04-05 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–234(226 aa)
Not recorded 6FJ 5-[4-(2-fluorophenyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]-N-[(furan-2-yl)methyl]-2,4-dihydroxy-N-methylbenzamide × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277.15 K;0.2 M sodium fluoride 0.1 M Bis Tris propane pH 8.5 20 % w/v PEG 3350
Resolution 1.64 Å R-free 0.225
5J6N Crystal Structure of Hsp90-alpha N-domain L107A mutant in complex with 5-[4-(2-Fluoro-phenyl)-5-oxo-4,5-dihydro-1H-[1,2,4]triazol-3-yl]-2,4-dihydroxy-N-methyl-N-propyl-benzenesulfonamide Deposited 2016-04-05 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–234(226 aa)
Not recorded 6FF 5-[4-(2-fluorophenyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]-2,4-dihydroxy-N-methyl-N-propylbenzene-1-sulfonamide × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277.15 K;0.2 M sodium fluoride 0.1 M Bis Tris propane pH 8.5 20 % w/v PEG 3350
Resolution 1.90 Å R-free 0.236
5J80 Crystal Structure of Apo Hsp90-alpha N-domain L107A mutant Deposited 2016-04-07 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–233(225 aa)
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277.15 K;0.2 M sodium fluoride, 0.1 M Bis Tris propane, pH 8.5, 20 % w/v PEG 3350
Resolution 1.17 Å R-free 0.191
5J82 Crystal Structure of Hsp90-alpha N-domain in complex 5-[4-(2-Fluoro-phenyl)-5-oxo-4,5-dihydro-1H-[1,2,4]triazol-3-yl]-2,4-dihydroxy-N-isopropyl-N-methyl-benzenesulfonamide Deposited 2016-04-07 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–233(225 aa)
Not recorded 6GV 5-[4-(2-fluorophenyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]-2,4-dihydroxy-N-methyl-N-(propan-2-yl)benzene-1-sulfonamide × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277.15 K;0.2 M sodium fluoride, 0.1 M Bis Tris propane, pH 8.5, 20 % w/v PEG 3350
Resolution 2.17 Å R-free 0.276
5J86 Crystal Structure of Hsp90-alpha N-domain in complex with 2,4-Dihydroxy-N-methyl-5-(5-oxo-4-o-tolyl-4,5-dihydro-1H-[1,2,4]triazol-3-yl)-N-thiophen-2-ylmethyl-benzamide Deposited 2016-04-07 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–233(225 aa)
Not recorded 6GW 2,4-dihydroxy-N-methyl-5-[4-(2-methylphenyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]-N-[(thiophen-2-yl)methyl]benzamide × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277.15 K;0.2 M sodium fluoride, 0.1 M Bis Tris propane, pH 8.5, 20 % w/v PEG 3350
Resolution 1.87 Å R-free 0.229
5J8M Crystal Structure of Hsp90-alpha N-domain L107A mutant in complex with 5-(5-Bromo-2,4-dihydroxy-phenyl)-4-(2-fluoro-phenyl)-2,4-dihydro-[1,2,4]triazol-3-one Deposited 2016-04-08 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 131–355(225 aa)
Chain B 131–355(225 aa)
Not recorded 6DL 5-(5-Bromo-2,4-dihydroxy-phenyl)-4-(2-fluoro-phenyl)-2,4-dihydro-[1,2,4]triazol-3-one × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277.15 K;0.2 M sodium fluoride 0.1 M Bis Tris propane pH 8.5 20 % w/v PEG 3350
Resolution 1.90 Å R-free 0.213
5J8U Crystal Structure of Hsp90-alpha N-domain L107A mutant in complex with 5-(2,4-Dihydroxy-phenyl)-4-(2-fluoro-phenyl)-2,4-dihydro-[1,2,4]triazol-3-one Deposited 2016-04-08 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 131–355(225 aa)
Chain B 131–355(225 aa)
Not recorded 6DL 5-(5-Bromo-2,4-dihydroxy-phenyl)-4-(2-fluoro-phenyl)-2,4-dihydro-[1,2,4]triazol-3-one × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277.15 K;0.2 M sodium fluoride 0.1 M Bis Tris propane pH 8.5 20 % w/v PEG 3350
Resolution 1.75 Å R-free 0.247
5J9X HSP90 in complex with N-Butyl-5-[4-(2-fluoro-phenyl)-5-oxo-4,5-dihydro-1H-[1,2,4]triazol-3-yl]-2,4-dihydroxy-N-methyl-benzamide Deposited 2016-04-11 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 131–355(225 aa)
Not recorded 6GC N-butyl-5-[4-(2-fluorophenyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]-2,4-dihydroxy-N-methylbenzamide × 2 DMS DIMETHYL SULFOXIDE × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277.15 K;0.2 M sodium fluoride 0.1 M Bis Tris propane pH 8.5 20 % w/v PEG 3350
Resolution 1.80 Å R-free 0.234
5LNY HSP90 WITH indazole derivative Deposited 2016-08-08 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 131–358(228 aa)
Not recorded 70K 6-Hydroxy-3-(piperidine-1-carbonyl)-1H-indazole-5-carboxylic acid methyl-(4-morpholin-4-yl-phenyl)-amide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;30% PEG 4000, 0.1 M Tris HCl pH 8.5, 0.2 M Magnesium Chloride
Resolution 1.88 Å R-free 0.226
5LNZ HSP90 WITH indazole derivative Deposited 2016-08-08 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 131–358(228 aa)
Not recorded 70Z ~{N}3-butyl-~{N}3,~{N}5-dimethyl-~{N}5-(4-morpholin-4-ylphenyl)-6-oxidanyl-2~{H}-indazole-3,5-dicarboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 7.5;277 K;28% PEG 400, 0.1 M Na Hepes pH 7.5, 0.2 M Calcium Chloride
Resolution 1.54 Å R-free 0.198
5LO0 HSP90 WITH indazole derivative Deposited 2016-08-08 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded 70N [2-azanyl-6-[4,5-bis(fluoranyl)-2-(4-methylpiperazin-1-yl)sulfonyl-phenyl]quinazolin-4-yl]-(1,3-dihydroisoindol-2-yl)methanone × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;100 mM BisTris pH 6.5, 250 mM NaF, 21-26% PEG3350
Resolution 2.30 Å R-free 0.227
5LO1 HSP90 WITH indazole derivative Deposited 2016-08-08 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 131–358(228 aa)
Not recorded 70L 1-[2-Amino-4-(1,3-dihydro-isoindole-2-carbonyl)-quinazolin-6-yl]-cyclobutanecarboxylic acid ethylamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;Bis-Tris Propan, pH 6.5 22% PEG 3350 0,2M NaF
Resolution 2.70 Å R-free 0.246
5LO5 HSP90 WITH indole derivative Deposited 2016-08-08 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:ATPASE DOMAIN (8-236)
Not recorded 70M 3-[4-[4-(4-cyanophenyl)piperazin-1-yl]butyl]-6-oxidanyl-1~{H}-indole-5-carbonitrile × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 5.5;277 K;0.1 M Bis Tris pH 5.5, 0.2 M Ammonium actetate, 25 % PEG 3350
Resolution 1.44 Å R-free 0.203
5LO6 HSP90 WITH indazole derivative Deposited 2016-08-08 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:ATPASE DOMAIN (8-236)
Not recorded 70O 3-(3,3-dimethylbutyl)-~{N}-methyl-~{N}-[4-(1-methylpiperidin-4-yl)phenyl]-6-oxidanyl-2~{H}-indazole-5-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;Bis-Tris Propan, pH 6.5, 22% PEG 3350, 0.2M NaF
Resolution 2.40 Å R-free 0.217
5LQ9 CRYSTAL STRUCTURE OF HSP90 IN COMPLEX WITH SAR200323. Deposited 2016-08-16 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 18–223(206 aa)
Not recorded 72K 4-(3-methyl-4-quinolin-3-yl-indazol-1-yl)-2-[(4-oxidanylcyclohexyl)amino]benzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277 K;1.0 to 1.4M Sodium Citrate
Resolution 1.90 Å R-free 0.236
5LR1 CRYSTAL STRUCTURE OF HSP90 IN COMPLEX WITH A003498614A. Deposited 2016-08-18 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 18–223(206 aa)
Not recorded 72Y 4-chloranyl-7-[(4-chloranyl-3,5-dimethyl-pyridin-2-yl)methyl]pyrrolo[2,3-d]pyrimidin-2-amine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277 K;1.0 to 1.4 M Sodium Citrate
Resolution 1.44 Å R-free 0.220
5LR7 CRYSTAL STRUCTURE OF HSP90 IN COMPLEX WITH SAR567530 Deposited 2016-08-18 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 138–345(208 aa)
Not recorded 73J ~{N}-[(9~{R})-4-(5-fluoranyl-1~{H}-benzimidazol-2-yl)-9~{H}-fluoren-9-yl]-1~{H}-pyrrolo[2,3-b]pyridine-4-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277 K;1.0 - 1.4M Sodium Citrate
Resolution 1.86 Å R-free 0.201
5LRL CRYSTAL STRUCTURE OF HSP90 IN COMPLEX WITH A003492875 Deposited 2016-08-19 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 138–345(208 aa)
Not recorded 73S 2-azanyl-5-chloranyl-~{N}-[(9~{R})-4-(1~{H}-imidazo[4,5-c]pyridin-2-yl)-9~{H}-fluoren-9-yl]pyrimidine-4-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277 K;1.0 - 1.4M Sodium Citrate
Resolution 1.33 Å R-free 0.189
5LRZ CRYSTAL STRUCTURE OF HSP90 IN COMPLEX WITH A003643501 Deposited 2016-08-22 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 140–345(206 aa)
Not recorded 73Y 6-bromanyl-~{N}-[(9~{R})-4-quinolin-3-yl-9~{H}-fluoren-9-yl]-3~{H}-imidazo[4,5-b]pyridine-7-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277 K;1.0 to 1.4 M Sodium Citrate
Resolution 2.00 Å R-free 0.249
5LS1 CRYSTAL STRUCTURE OF HSP90 IN COMPLEX WITH SAR166475 Deposited 2016-08-22 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 140–345(206 aa)
Not recorded 73Z 2-[(4-oxidanylidenecyclohexyl)amino]-4-(3,6,6-trimethyl-4-oxidanylidene-5,7-dihydroindol-1-yl)benzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277 K;1.0-1.4M Sodium Citrate
Resolution 1.85 Å R-free 0.213
5M4E Application of Off-Rate Screening in the Identification of Novel Pan-Isoform Inhibitors of Pyruvate Dehydrogenase Kinase Deposited 2016-10-18 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 131–358(228 aa)
Not recorded 7F9 ~{N}-[2-(ethylamino)-2-oxidanylidene-ethyl]-~{N}-(4-methoxyphenyl)-2,4-bis(oxidanyl)benzamide × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION;pH 6.5;277 K;0.1 M Na Cacodylate pH 6.5 25% PEG 2K MME 0.2 M MgCl2
Resolution 1.90 Å R-free 0.218
5M4H Application of Off-Rate Screening in the Identification of Novel Pan-Isoform Inhibitors of Pyruvate Dehydrogenase Kinase Deposited 2016-10-18 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded 7FX [2,4-bis(oxidanyl)phenyl]-[(7~{S})-7-(trifluoromethyl)-6,7-dihydro-5~{H}-pyrazolo[1,5-a]pyrimidin-4-yl]methanone × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;0.1M Na Cacodylate pH 6.5 25% PEG 2K MME 0.2M MgCl2
Resolution 2.00 Å R-free 0.317
5NYH Crystal Structure of Hsp90-alpha N-Domain in complex with Indazole derivative Deposited 2017-05-11 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 131–358(228 aa)
Not recorded 9EK ~{N}-methyl-~{N}-(4-morpholin-4-ylphenyl)-6-oxidanyl-3-pyrrolidin-1-ylcarbonyl-2~{H}-indazole-5-carboxamide × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;277.15 K;0.2 M sodium fluoride, 0.1 M Bis Tris propane, pH 8.5, 20 % w/v PEG 3350
Resolution 1.65 Å R-free 0.226
5NYI Crystal Structure of Hsp90-alpha N-Domain in complex with Resorcinol derivative Deposited 2017-05-11 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–235(227 aa) Fragment:ATPASE DOMAIN (8-236)
Not recorded 2EQ 5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]isoxazole-3-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100 mM Bis-Tris buffer pH 8.5, 20% PEG 3,350, 200 mM NaF
Resolution 1.44 Å R-free 0.200
5OCI Human Heat Shock Protein 90 bound to 6-Hydroxy-3-(3-methyl-benzyl)-1H-indazole-5-carboxylic acid methyl-(4-morpholin-4-yl-phenyl)-amide Deposited 2017-07-03 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded 9R8 6-Hydroxy-3-(3-methyl-benzyl)-1H-indazole-5-carboxylic acid methyl-(4-morpholin-4-yl-phenyl)-amide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277 K;Na-Cacodylate, pH 6.5 28% PEG8000 0,2 M NH4-Sulfate
Resolution 1.62 Å R-free 0.225
5OD7 Hsp90 inhibitor desolvation as a rationale to steer on-rates and impact residence time Deposited 2017-07-04 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded H0T [2-azanyl-6-[2-(4-methylpiperazin-1-yl)sulfonylphenyl]quinazolin-4-yl]-(1,3-dihydroisoindol-2-yl)methanone × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277 K;Na-Cacodylate, pH 6.5 28% PEG8000 0,2 M NH4-Sulfate
Resolution 2.00 Å R-free 0.264
5ODX Crystal Structure of Hsp90-alpha N-Domain in complex with Indazole derivative Deposited 2017-07-07 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded 9RZ 3-[(3~{S})-3-methoxypiperidin-1-yl]carbonyl-~{N}-methyl-~{N}-(4-morpholin-4-ylphenyl)-6-oxidanyl-1~{H}-indazole-5-carboxamide × 1 DMS DIMETHYL SULFOXIDE × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;277.15 K;0.2 M sodium fluoride, 0.1 M Bis Tris propane, pH 8.5, 20 % w/v PEG 3350
Resolution 1.82 Å R-free 0.212
5T21 CRYSTAL STRUCTURE OF HSP90 IN COMPLEX WITH SAR148019. Deposited 2016-08-23 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 18–223(206 aa)
Not recorded 74E 2-[(4-oxidanylcyclohexyl)amino]-4-(3,6,6-trimethyl-4-oxidanylidene-5,7-dihydroindol-1-yl)benzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277 K;1.0 to 1.4M Sodium Citrate
Resolution 2.10 Å R-free 0.216
5VYY Structure of human Hsp90-alpha bound to resorcinylic inhibitor BnIm Deposited 2017-05-26 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 123–358(236 aa)
Not recorded 9QY methyl 2-[2-(1-benzyl-1H-imidazol-2-yl)ethyl]-3-chloro-4,6-dihydroxybenzoate × 1 FMT FORMIC ACID × 2 EDO 1,2-ETHANEDIOL × 1 MG MAGNESIUM ION × 1 NA SODIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;PEG 2000 MME, Sodium formate, Sodium cacodylate
Resolution 1.79 Å R-free 0.218
5VYY Structure of human Hsp90-alpha bound to resorcinylic inhibitor BnIm Deposited 2017-05-26 Assembly 2 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 123–358(236 aa)
Not recorded 9QY methyl 2-[2-(1-benzyl-1H-imidazol-2-yl)ethyl]-3-chloro-4,6-dihydroxybenzoate × 2 FMT FORMIC ACID × 4 EDO 1,2-ETHANEDIOL × 2 MG MAGNESIUM ION × 2 NA SODIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;PEG 2000 MME, Sodium formate, Sodium cacodylate
Resolution 1.79 Å R-free 0.218
5XQD Crystal structure of Human Hsp90 with FS2 Deposited 2017-06-07 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:UNP RESIDUES 9-236
Not recorded 8CF N-[3-[5-chloranyl-2,4-bis(oxidanyl)phenyl]-4-(4-methoxyphenyl)-1,2-oxazol-5-yl]propanamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277 K;20%(w/v) PEG 2000 monomethyl ether, 200mM magnesium chloride, 100mM sodium cacodylate, pH 6.5,
Resolution 1.60 Å R-free 0.200
5XQE Crystal structure of Human Hsp90 with FS3 Deposited 2017-06-07 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:UNP RESIDUES 9-236
Not recorded 8CO N-[3-[5-chloranyl-2,4-bis(oxidanyl)phenyl]-4-(4-methoxyphenyl)-1,2-oxazol-5-yl]-2-methyl-propanamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277 K;25%(w/v) PEG 2000 monomethyl ether, 200mM magnesium chloride, 100mM sodium cacodylate
Resolution 1.70 Å R-free 0.200
5XR5 Crystal structure of Human Hsp90 with FS4 Deposited 2017-06-07 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:UNP RESIDUES 9-236
Not recorded 8CR N-[3-[5-chloranyl-2,4-bis(oxidanyl)phenyl]-4-(4-methoxyphenyl)-1,2-oxazol-5-yl]-2,2-dimethyl-propanamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;15~20% PEG 3350, 5mM magnesium chloride, 500mM ammonium phosphate, 100mM Bis-Tris pH 6.5
Resolution 1.60 Å R-free 0.218
5XR9 Crystal structure of Human Hsp90 with FS6 Deposited 2017-06-08 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:UNP RESIDUES 9-236
Not recorded 8CU N-[3-[5-bromanyl-2,4-bis(oxidanyl)phenyl]-4-(4-methoxyphenyl)-1,2-oxazol-5-yl]ethanamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277 K;20-25%(w/v) PEG 2000 monomethyl ether, 200mM magnesium chloride, 100mM sodium cacodylate, pH 6.5
Resolution 1.50 Å R-free 0.195
5XRB Crystal Structure of the human Hsp90-alpha N-domain bound to the hsp90 inhibitor FJ5 Deposited 2017-06-08 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:UNP RESIDUES 9-236
Not recorded 8DU N-[3-[5-chloranyl-2,4-bis(oxidanyl)phenyl]-4-(4-methoxyphenyl)-1,2-oxazol-5-yl]cyclopropanecarboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP
Resolution 1.65 Å R-free 0.198
5XRD Crystal Structure of the human Hsp90-alpha N-domain bound to the hsp90 inhibitor FS7 Deposited 2017-06-08 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded 9ZC N-{3-[2,4-dihydroxy-5-(propan-2-yl)phenyl]-4-(4-methoxyphenyl)-1H-pyrazol-5-yl}acetamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;15~20% PEG 3350, 5mM magnesium chloride, 500mM ammonium phosphate, 100mM Bis-Tris pH 6.5
Resolution 1.30 Å R-free 0.186
5XRD Crystal Structure of the human Hsp90-alpha N-domain bound to the hsp90 inhibitor FS7 Deposited 2017-06-08 Assembly 2 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded 9ZC N-{3-[2,4-dihydroxy-5-(propan-2-yl)phenyl]-4-(4-methoxyphenyl)-1H-pyrazol-5-yl}acetamide × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;15~20% PEG 3350, 5mM magnesium chloride, 500mM ammonium phosphate, 100mM Bis-Tris pH 6.5
Resolution 1.30 Å R-free 0.186
5XRE Crystal Structure of the human Hsp90-alpha N-domain bound to the hsp90 inhibitor JX1 Deposited 2017-06-08 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa) Fragment:UNP RESIDUES 9-236
Not recorded JX1 N-[4-(4-methoxyphenyl)-3-[5-(8-methylquinolin-5-yl)-2,4-bis(oxidanyl)phenyl]-1,2-oxazol-5-yl]ethanamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;20%-25%(w/v) PEG 2000 monomethyl ether, 200mM magnesium chloride, 100mM sodium cacodylate, pH 6.5
Resolution 1.50 Å R-free 0.196
5ZR3 Crystal structure of Hsp90-alpha N-terminal domain in complex with 4-(3-isopropyl-4-(4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3-methylbenzamide Deposited 2018-04-23 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa)
Not recorded 9J0 3-methyl-4-{4-[4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl}benzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;277 K;PEG 6000, 200mM NaCl, 50mM Tris pH 7.5
Resolution 2.50 Å R-free 0.254
5ZR3 Crystal structure of Hsp90-alpha N-terminal domain in complex with 4-(3-isopropyl-4-(4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3-methylbenzamide Deposited 2018-04-23 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–236(236 aa)
Not recorded 9J0 3-methyl-4-{4-[4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl}benzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;277 K;PEG 6000, 200mM NaCl, 50mM Tris pH 7.5
Resolution 2.50 Å R-free 0.254
5ZR3 Crystal structure of Hsp90-alpha N-terminal domain in complex with 4-(3-isopropyl-4-(4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3-methylbenzamide Deposited 2018-04-23 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain E 1–236(236 aa)
Not recorded 9J0 3-methyl-4-{4-[4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl}benzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;277 K;PEG 6000, 200mM NaCl, 50mM Tris pH 7.5
Resolution 2.50 Å R-free 0.254
5ZR3 Crystal structure of Hsp90-alpha N-terminal domain in complex with 4-(3-isopropyl-4-(4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3-methylbenzamide Deposited 2018-04-23 Assembly 4 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain G 1–236(236 aa)
Not recorded 9J0 3-methyl-4-{4-[4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl}benzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;277 K;PEG 6000, 200mM NaCl, 50mM Tris pH 7.5
Resolution 2.50 Å R-free 0.254
6B99 Hsp90-alpha N-domain bound to NECA Deposited 2017-10-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa)
Not recorded NEC N-ETHYL-5'-CARBOXAMIDO ADENOSINE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.4;277 K;Bis Tris Propane pH 6.4, MgCl2, PEG 2000 MME. Soak with NECA
Resolution 1.60 Å R-free 0.183
6B9A Hsp90-alpha N-domain bound to NPCA Deposited 2017-10-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–236(236 aa)
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.4;277 K;Bis-Tris Propane pH 6.4, MgCl2, PEG 2000 MME. Soak crystals with NPCA
Resolution 1.65 Å R-free 0.191
6B9A Hsp90-alpha N-domain bound to NPCA Deposited 2017-10-10 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa)
Not recorded PA7 N-PROPYL CARBOXYAMIDO ADENOSINE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.4;277 K;Bis-Tris Propane pH 6.4, MgCl2, PEG 2000 MME. Soak crystals with NPCA
Resolution 1.65 Å R-free 0.191
6CEO Structure of Hsp90 NTD with a GRP94-selective resorcinylic inhibitor. Deposited 2018-02-12 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 123–358(236 aa)
Not recorded D57 dimethyl 2-[2-(1-benzyl-1H-imidazol-2-yl)ethyl]-4,6-dihydroxybenzene-1,3-dicarboxylate × 1 MG MAGNESIUM ION × 6 EDO 1,2-ETHANEDIOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277 K;PEG 2000 MME, MgCl2
Resolution 1.90 Å R-free 0.211
6CEO Structure of Hsp90 NTD with a GRP94-selective resorcinylic inhibitor. Deposited 2018-02-12 Assembly 2 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 123–358(236 aa)
Not recorded D57 dimethyl 2-[2-(1-benzyl-1H-imidazol-2-yl)ethyl]-4,6-dihydroxybenzene-1,3-dicarboxylate × 2 MG MAGNESIUM ION × 12 EDO 1,2-ETHANEDIOL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277 K;PEG 2000 MME, MgCl2
Resolution 1.90 Å R-free 0.211
6CYG Hsp90-alpha N-domain bound to NEOCA Deposited 2018-04-05 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa)
Not recorded N5O 5'-N-(2-HYDROXYL)ETHYL CARBOXYAMIDO ADENOSINE × 1 MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.4;277 K;Bis-Tris Propane pH 6.4, MgCl2, PEG 2000 MME. Soak crystals with NEOCA
Resolution 1.50 Å R-free 0.195
6CYG Hsp90-alpha N-domain bound to NEOCA Deposited 2018-04-05 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–236(236 aa)
Not recorded MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.4;277 K;Bis-Tris Propane pH 6.4, MgCl2, PEG 2000 MME. Soak crystals with NEOCA
Resolution 1.50 Å R-free 0.195
6CYH Hsp90-alpha N-domain bound to NEACA Deposited 2018-04-05 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa)
Not recorded N5A 5'-N-[(2-AMINO)ETHYL CARBOXAMIDO] ADENOSINE × 1 MG MAGNESIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.4;277 K;Bis-Tris Propane pH 6.4, MgCl2, PEG 2000 MME. Soak crystals with NEACA
Resolution 1.49 Å R-free 0.182
6CYH Hsp90-alpha N-domain bound to NEACA Deposited 2018-04-05 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–236(236 aa)
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.4;277 K;Bis-Tris Propane pH 6.4, MgCl2, PEG 2000 MME. Soak crystals with NEACA
Resolution 1.49 Å R-free 0.182
6EI5 Estimation of relative drug-target residence times by random acceleration molecular dynamics simulation Deposited 2017-09-17 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 15–223(209 aa)
Not recorded B5Q [2-azanyl-6-[2-(methylaminomethyl)phenyl]quinazolin-4-yl]-(1,3-dihydroisoindol-2-yl)methanone × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277 K;Na-Cacodylate, pH 6.5 30% PEG8000 0.2 M ammonium sulfate
Resolution 2.20 Å R-free 0.217
6EL5 Estimation of relative drug-target residence times by random acceleration molecular dynamics simulation Deposited 2017-09-27 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa)
Not recorded PU1 8-(2-CHLORO-3,4,5-TRIMETHOXY-BENZYL)-2-FLUORO-9-PENT-4-YLNYL-9H-PURIN-6-YLAMINE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277 K;Na-cacodylate, pH 6.5 30% PEG8000 0.2 M ammonium sulfate
Resolution 1.67 Å R-free 0.217
6ELN Estimation of relative drug-target residence times by random acceleration molecular dynamics simulation Deposited 2017-09-29 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 17–223(207 aa)
Not recorded P4A 4-[4-(4-methoxyphenyl)-5-methyl-1H-pyrazol-3-yl]benzene-1,3-diol × 1 SO4 SULFATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;Na-cacodylate, pH 6.5 30% PEG8000 0.2 M ammonium sulfate
Resolution 1.60 Å R-free 0.213
6ELO Estimation of relative drug-target residence times by random acceleration molecular dynamics simulation Deposited 2017-09-29 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa)
Not recorded BAW 4-ethyl-6-[4-(2-fluorophenyl)-3-methyl-1~{H}-pyrazol-5-yl]benzene-1,3-diol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;Na-cacodylate, pH 6.5 30% PEG8000 0.2 M ammonium sulfate
Resolution 1.80 Å R-free 0.238
6ELP Estimation of relative drug-target residence times by random acceleration molecular dynamics simulation Deposited 2017-09-29 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa)
Not recorded BA8 4-[2-(2-chlorophenyl)pyrazol-3-yl]-6-(2-pyridin-2-ylethyl)benzene-1,3-diol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;Na-cacodylate, pH 6.5 30% PEG8000 0.2 M ammonium sulfate
Resolution 1.85 Å R-free 0.202
6EY8 Estimation of relative drug-target residence times by random acceleration molecular dynamics simulation Deposited 2017-11-11 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa)
Not recorded DMS DIMETHYL SULFOXIDE × 1 C4T ~{N}-[(4-chlorophenyl)methyl]-~{N}-methyl-6-oxidanyl-3-(phenylmethyl)-1~{H}-indazole-5-carboxamide × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;0.1 M Na-cacodylateNa, pH 6.5 30% PEG8000 0.2 M ammonium sulfate
Resolution 2.16 Å R-free 0.237
6EY9 Estimation of relative drug-target residence times by random acceleration molecular dynamics simulation Deposited 2017-11-11 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa)
Not recorded SO4 SULFATE ION × 1 C4N ~{N}-[(4-chlorophenyl)methyl]-~{N}-methyl-3-[(3-methylphenyl)methyl]-6-oxidanyl-1~{H}-indazole-5-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277 K;Na-cacodylate, pH 6.5 30% PEG8000 0.2 M ammonium sulfate
Resolution 2.00 Å R-free 0.226
6EYA Estimation of relative drug-target residence times by random acceleration molecular dynamics simulation Deposited 2017-11-11 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa)
Not recorded C4K ~{N}-(1,3-benzodioxol-5-yl)-~{N}-methyl-3-[(3-methylphenyl)methyl]-6-oxidanyl-1~{H}-indazole-5-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;Na-cacodylate, pH 6.5 30% PEG8000 0.2 M ammonium sulfate
Resolution 2.10 Å R-free 0.233
6EYB Estimation of relative drug-target residence times by random acceleration molecular dynamics simulation Deposited 2017-11-11 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa)
Not recorded C3Z 3-(phenylmethyl)-5-(2-phenylpyrazol-3-yl)-2~{H}-indazol-6-ol × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;Na-cacodylate, pH 6.5 30% PEG8000 0.2 M ammonium sulfate
Resolution 1.90 Å R-free 0.227
6F1N Estimation of relative drug-target residence times by random acceleration molecular dynamics simulation Deposited 2017-11-22 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 123–358(236 aa)
Not recorded SO4 SULFATE ION × 1 C8W 4-[5-[2-aminocarbonyl-3,6-bis(azanyl)-5-cyano-thieno[2,3-b]pyridin-4-yl]-2-methoxy-phenoxy]butanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;Na-cacodylate, pH 6.5 30% PEG8000 0.2 M ammonium sulfate
Resolution 2.09 Å R-free 0.213
6FCJ Estimation of Protein-Ligand Unbinding Kinetics Using Non-Equilibrium Targeted Molecular Dynamics Simulations Deposited 2017-12-20 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 131–358(228 aa)
Not recorded D4W 4-[2-(2-chlorophenyl)pyrazol-3-yl]benzene-1,3-diol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277 K;Na-cacodylate, pH 6.5 30% PEG8000 0.2 M ammonium sulfate
Resolution 2.49 Å R-free 0.234
6FDP NMR structure of the second TPR domain of the human RPAP3 protein in complex with HSP90 peptide DTSRMEEVD Deposited 2017-12-26 Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain B 724–732(9 aa) Fragment:UNP residues 724-732
Not recorded No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 6.4;293 K;Ionic strength (raw mmCIF value) 150;Pressure 1
NMR sample composition 1 mM [U-13C; U-15N] RPAP3-TPR2, 1 mM HSP90-pep, 150 mM sodium chloride, 10 mM sodium phosphate, 0.5 mM TCEP, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 1 mM [U-13C; U-15N] RPAP3-TPR2, 1 mM HSP90-pep, 150 mM sodium chloride, 10 mM sodium phosphate, 0.5 mM TCEP, 100% D2O | 100% D2O
Resolution not provided
6GP4 Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112A Deposited 2018-06-05 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa)
Mutation:K112A MG MAGNESIUM ION × 1 CL CHLORIDE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 6.5;291 K;25 % wt/vol PEG 2000, 200 mM MgCl2 and 100 mM sodium cacodylate, pH 6.5
Resolution 1.70 Å R-free 0.205
6GP8 Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112A in complex AMPCPP Deposited 2018-06-05 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa)
Not recorded APC DIPHOSPHOMETHYLPHOSPHONIC ACID ADENOSYL ESTER × 1 MG MAGNESIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 6.5;291 K;Precipitant: 25 % wt/vol PEG 2000,2 200mM MgCl2, 100 mM sodium cacodylate, pH 6.5 Sample: Hsp90a-NTD K112A 20 mg/mL, 10 mM AMPCPP, 500 mM NaCl, 20 mM TRIS, pH 7.5
Resolution 1.75 Å R-free 0.200
6GPF Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112A in complex with AMPPNP Deposited 2018-06-05 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa)
Mutation:K112A ANP PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER × 1 MG MAGNESIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 6.5;291 K;Precipitant: 25 % wt/vol PEG 2000,2 200mM MgCl2, 100 mM sodium cacodylate, pH 6.5 Sample: Hsp90a-NTD K112A 20 mg/mL, 10 mM AMPPNP, 500 mM NaCl, 20 mM TRIS, pH 7.5
Resolution 1.55 Å R-free 0.214
6GPH Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112A in complex with AMPCP Deposited 2018-06-05 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa)
Mutation:K112A A12 PHOSPHOMETHYLPHOSPHONIC ACID ADENOSYL ESTER × 1 MG MAGNESIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 6.5;291 K;Precipitant: 25 % wt/vol PEG 2000,2 200mM MgCl2, 100 mM sodium cacodylate, pH 6.5 Sample: Hsp90a-NTD K112A 20 mg/mL, 10 mM AMPCP, 500 mM NaCl, 20 mM TRIS, pH 7.5
Resolution 1.56 Å R-free 0.198
6GPO Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112A in complex with cAMP Deposited 2018-06-06 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 123–358(236 aa)
Mutation:K112A CMP ADENOSINE-3',5'-CYCLIC-MONOPHOSPHATE × 1 MG MAGNESIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 6.5;291 K;Precipitant: 25 % wt/vol PEG 2000,2 200mM MgCl2, 100 mM sodium cacodylate, pH 6.5 Sample: Hsp90a-NTD K112A 20 mg/mL, 10 mM cAMP, 500 mM NaCl, 20 mM TRIS, pH 7.5
Resolution 1.48 Å R-free 0.218
6GPP Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112A in complex with ADP Deposited 2018-06-06 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa)
Mutation:K112A MG MAGNESIUM ION × 2 ADP ADENOSINE-5'-DIPHOSPHATE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 6.5;291 K;Precipitant: 25 % wt/vol PEG 2000, 200mM MgCl2, 100 mM sodium cacodylate, pH 6.5 Sample: Hsp90a-NTD K112A 20 mg/mL, 10 mM ADP, 500 mM NaCl, 20 mM TRIS, pH 7.5
Resolution 1.51 Å R-free 0.200
6GPR Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) in complex with cAMP Deposited 2018-06-06 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa)
Not recorded CMP ADENOSINE-3',5'-CYCLIC-MONOPHOSPHATE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 6.5;291 K;Precipitant: 25 % wt/vol PEG 2000, 200mM MgCl2, 100 mM sodium cacodylate, pH 6.5 Sample: Hsp90a-NTD 20 mg/mL, 10 mM cAMP, 500 mM NaCl, 20 mM TRIS, pH 7.5
Resolution 2.35 Å R-free 0.286
6GPT Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) in complex with AMPCP Deposited 2018-06-07 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa)
Not recorded MG MAGNESIUM ION × 1 A12 PHOSPHOMETHYLPHOSPHONIC ACID ADENOSYL ESTER × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 6.5;291 K;Precipitant: 25 % wt/vol PEG 2000, 200mM MgCl2, 100 mM sodium cacodylate, pH 6.5 Sample: Hsp90a-NTD 20 mg/mL, 10 mM AMPCP, 500 mM NaCl, 20 mM TRIS, pH 7.5
Resolution 2.00 Å R-free 0.232
6GPW Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) Deposited 2018-06-07 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa)
Not recorded MG MAGNESIUM ION × 1 CL CHLORIDE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 6.5;291 K;25 % wt/vol PEG 2000, 200mM MgCl2, 100 mM sodium cacodylate, pH 6.5
Resolution 1.60 Å R-free 0.199
6GPY Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) in complex with AMPPNP Deposited 2018-06-07 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa)
Not recorded ANP PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER × 1 MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 6.5;291 K;Precipitant: 25 % wt/vol PEG 2000, 200mM MgCl2, 100 mM sodium cacodylate, pH 6.5 Sample: Hsp90a-NTD 20 mg/mL, 10 mM AMPPNP, 500 mM NaCl, 20 mM TRIS, pH 7.5
Resolution 2.25 Å R-free 0.244
6GQ6 Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) in complex with ADP Deposited 2018-06-07 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa)
Not recorded MG MAGNESIUM ION × 1 ADP ADENOSINE-5'-DIPHOSPHATE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 6.5;291 K;Precipitant: 25 % wt/vol PEG 2000, 200mM MgCl2, 100 mM sodium cacodylate, pH 6.5 Sample: Hsp90a-NTD 20 mg/mL, 10 mM ADP, 500 mM NaCl, 20 mM TRIS, pH 7.5
Resolution 2.25 Å R-free 0.237
6GQR Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) in complex with AMPCPP Deposited 2018-06-08 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa)
Not recorded MG MAGNESIUM ION × 1 APC DIPHOSPHOMETHYLPHOSPHONIC ACID ADENOSYL ESTER × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 6.5;291 K;Precipitant: 25 % wt/vol PEG 2000, 200mM MgCl2, 100 mM sodium cacodylate, pH 6.5 Sample: Hsp90a-NTD 20 mg/mL, 10 mM AMPCPP, 500 mM NaCl, 20 mM TRIS, pH 7.5
Resolution 2.05 Å R-free 0.232
6GQS Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112R in complex with AMPCP Deposited 2018-06-08 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa)
Mutation:K112R A12 PHOSPHOMETHYLPHOSPHONIC ACID ADENOSYL ESTER × 1 MG MAGNESIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 6.5;291 K;Precipitant: 25 % wt/vol PEG 2000, 200mM MgCl2, 100 mM sodium cacodylate, pH 6.5 Sample: Hsp90a-NTD K112R 20 mg/mL, 10 mM AMPCP, 500 mM NaCl, 20 mM TRIS, pH 7.5
Resolution 1.43 Å R-free 0.186
6GQU Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112R in complex with cAMP Deposited 2018-06-08 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa)
Mutation:K112R CMP ADENOSINE-3',5'-CYCLIC-MONOPHOSPHATE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 6.5;291 K;Precipitant: 25 % wt/vol PEG 2000, 200mM MgCl2, 100 mM sodium cacodylate, pH 6.5 Sample: Hsp90a-NTD K112R 20 mg/mL, 10 mM cAMP, 500 mM NaCl, 20 mM TRIS, pH 7.5
Resolution 1.72 Å R-free 0.228
6GR1 Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112R in complex with AMPCPP Deposited 2018-06-08 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa)
Mutation:K112R APC DIPHOSPHOMETHYLPHOSPHONIC ACID ADENOSYL ESTER × 1 MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 6.5;291 K;Precipitant: 25 % wt/vol PEG 2000, 200mM MgCl2, 100 mM sodium cacodylate, pH 6.5 Sample: Hsp90a-NTD K112R 20 mg/mL, 10 mM AMPCPP, 500 mM NaCl, 20 mM TRIS, pH 7.5
Resolution 2.05 Å R-free 0.238
6GR3 Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112R in complex with AMPPNP Deposited 2018-06-08 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa)
Mutation:K112R AN2 AMP PHOSPHORAMIDATE × 1 MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;291 K;Precipitant: 25 % wt/vol PEG 2000, 200mM MgCl2, 100 mM sodium cacodylate, pH 6.5 Sample: Hsp90a-NTD K112R 20 mg/mL, 10 mM AMPPNP, 500 mM NaCl, 20 mM TRIS, pH 7.5
Resolution 1.88 Å R-free 0.214
6GR4 Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112R Deposited 2018-06-08 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa)
Mutation:K112R MG MAGNESIUM ION × 1 CL CHLORIDE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 6.5;291 K;25 % wt/vol PEG 2000, 200mM MgCl2, 100 mM sodium cacodylate, pH 6.5
Resolution 1.50 Å R-free 0.193
6GR5 Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112R in complex with ADP Deposited 2018-06-08 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa)
Mutation:K112R MG MAGNESIUM ION × 1 ADP ADENOSINE-5'-DIPHOSPHATE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 6.5;291 K;Precipitant: 25 % wt/vol PEG 2000, 200mM MgCl2, 100 mM sodium cacodylate, pH 6.5 Sample: Hsp90a-NTD K112R 20 mg/mL, 10 mM ADP, 500 mM NaCl, 20 mM TRIS, pH 7.5
Resolution 1.34 Å R-free 0.169
6HHR Hsp90 in complex with 5-(2,4-Dihydroxy-phenyl)-4-(2-fluoro-phenyl)-2,4-dihydro-[1,2,4]triazole-3-thione Deposited 2018-08-29 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 17–224(208 aa)
Not recorded G5E 3-[2,4-bis(oxidanyl)phenyl]-4-(2-fluorophenyl)-1~{H}-1,2,4-triazole-5-thione × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;Sodium cacodylate, pH 6.5 30% PEG8000 0.2 M ammonium sulfate
Resolution 2.00 Å R-free 0.207
6KSQ Middle Domain of Human HSP90 Alpha Deposited 2019-08-25 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 293–554(262 aa)
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8.5;277 K;0.5 M (NH4)2SO4, 5% Glycerol, 29.5% PEG 3350, PH 8.5
Resolution 2.20 Å R-free 0.232
6LR9 HSP90 in complex with Debio0932 Deposited 2020-01-15 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded EOR 2-[[6-(dimethylamino)-1,3-benzodioxol-5-yl]sulfanyl]-1-[2-(2,2-dimethylpropylamino)ethyl]imidazo[4,5-c]pyridin-4-amine × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;277 K;100 mM Tris-HCl (pH 8.5) 200 mM MgCl2 25% PEG4000
Resolution 2.20 Å R-free 0.209
6LSZ HSP 90 in complex with Ganetespib Deposited 2020-01-20 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded TUH 5-[2,4-dihydroxy-5-(propan-2-yl)phenyl]-4-(1-methyl-1H-indol-5-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;287 K;100 mM Tris-HCl (pH 8.5) 200 mM MgCl2 25% PEG4000
Resolution 1.99 Å R-free 0.208
6LT8 HSP90 in complex with KW-2478 Deposited 2020-01-21 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded ET3 2-[2-ethyl-6-[3-methoxy-4-(2-morpholin-4-ylethoxy)phenyl]carbonyl-3,5-bis(oxidanyl)phenyl]-~{N},~{N}-bis(2-methoxyethyl)ethanamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;277 K;100 mM Tris-HCl (pH 8.5) 200 mM MgCl2 25% PEG4000
Resolution 1.59 Å R-free 0.190
6LTI HSP90 in complex with NVP-AUY922 Deposited 2020-01-22 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded 2GJ 5-[2,4-DIHYDROXY-5-(1-METHYLETHYL)PHENYL]-N-ETHYL-4-[4-(MORPHOLIN-4-YLMETHYL)PHENYL]ISOXAZOLE-3-CARBOXAMIDE × 1 MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;277 K;0.1M Tris-HCl pH8.5 0.2M MgCl2 25% PEG4000
Resolution 1.59 Å R-free 0.195
6LTK HSP90 in complex with SNX-2112 Deposited 2020-01-22 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded E0G 4-[6,6-dimethyl-4-oxidanylidene-3-(trifluoromethyl)-5,7-dihydroindazol-1-yl]-2-[(4-oxidanylcyclohexyl)amino]benzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;277 K;100 mM Tris-HCl (pH 8.5) 200 mM MgCl2 25% PEG4000
Resolution 2.14 Å R-free 0.223
6N8X Hsp90-alpha bound to PU-11-trans Deposited 2018-11-30 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 123–358(236 aa)
Not recorded KFY 9-[(2E)-but-2-en-1-yl]-8-[(3,4,5-trimethoxyphenyl)methyl]-9H-purin-6-amine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;Na Cacodylate pH 6.5, MgCl2, PEG 2000 MME. Incubate with PU-11-trans prior to setup.
Resolution 1.49 Å R-free 0.185
6OLX Hsp90-alpha S52A bound to PU-11-trans Deposited 2019-04-17 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 123–358(236 aa)
Mutation:S52A KFY 9-[(2E)-but-2-en-1-yl]-8-[(3,4,5-trimethoxyphenyl)methyl]-9H-purin-6-amine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;100mM Na Cacodylate pH 6.5 160 mM MgCl2 6% PEG 2000 monomethyl ether
Resolution 1.44 Å R-free 0.181
6TN4 Rapid optimisation of fragments and hits to lead compounds from screening of crude reaction mixtures Deposited 2019-12-05 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain AAA 9–236(228 aa)
Not recorded NLZ 2,4-bis(oxidanyl)benzamide × 1 CL CHLORIDE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;10% PEG3350, 0.1 M sodium cacodylate pH 6.5, 0.2 M MgCl2
Resolution 1.27 Å R-free 0.198
6TN5 Rapid optimisation of fragments and hits to lead compounds from screening of crude reaction mixtures Deposited 2019-12-05 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain AAA 9–236(228 aa)
Not recorded NL8 ~{N}-(4-aminocarbonylphenyl)-~{N}-methyl-2,4-bis(oxidanyl)benzamide × 1 CL CHLORIDE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;10% PEG3350, 0.1 M sodium cacodylate pH 6.5, 0.2 M MgCl2
Resolution 1.17 Å R-free 0.184
6U98 Hsp90a NTD K58R bound reversibly to sulfonyl fluoride 6 Deposited 2019-09-06 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 2–236(235 aa)
Mutation:K58R Q2D 3-{[(3R)-3-({6-amino-8-[(6-iodo-2H-1,3-benzodioxol-5-yl)sulfanyl]-9H-purin-9-yl}methyl)piperidin-1-yl]methyl}benzene-1-sulfonyl fluoride × 1 K POTASSIUM ION × 1 NA SODIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;20% PEG-3350, 0.2 M MgCl2, 0.1 M HEPES pH 7.5
Resolution 1.50 Å R-free 0.205
6U99 Hsp90a NTD covalently bound to sulfonyl fluoride probe 1 at K58 Deposited 2019-09-06 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 2–236(235 aa)
Not recorded Q2J 3-{[(3-{6-amino-8-[(6-iodo-2H-1,3-benzodioxol-5-yl)sulfanyl]-9H-purin-9-yl}propyl)amino]methyl}benzene-1-sulfinic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;20% PEG-3350, 0.2 M MgCl2, 0.1 M sodium acetate, pH 5.6
Resolution 1.60 Å R-free 0.204
6U9A Hsp90a NTD K58R bound reversibly to sulfonyl fluoride 5 Deposited 2019-09-07 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 2–236(235 aa)
Mutation:K58R Q2A 3-{[(3S)-3-({6-amino-8-[(6-iodo-2H-1,3-benzodioxol-5-yl)sulfanyl]-9H-purin-9-yl}methyl)piperidin-1-yl]methyl}benzene-1-sulfonyl fluoride × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;20% PEG-3350, 0.2 M MgCl2, 0.1 M sodium acetate, pH 5.8
Resolution 1.65 Å R-free 0.228
6U9B Hsp90a NTD covalently bound to sulfonyl fluoride 5 at K58 Deposited 2019-09-07 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 2–236(235 aa)
Not recorded Q2A 3-{[(3S)-3-({6-amino-8-[(6-iodo-2H-1,3-benzodioxol-5-yl)sulfanyl]-9H-purin-9-yl}methyl)piperidin-1-yl]methyl}benzene-1-sulfonyl fluoride × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;20% PEG-3350, 0.2 M MgCl2, 0.1 M sodium acetate, pH 5.6
Resolution 1.75 Å R-free 0.222
7DMC Dipyridamole binds to the N-terminal domain of human Hsp90A Deposited 2020-12-03 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 16–224(209 aa)
Not recorded H9F 2-[[2-[bis(2-hydroxyethyl)amino]-4,8-di(piperidin-1-yl)pyrimido[5,4-d]pyrimidin-6-yl]-(2-hydroxyethyl)amino]ethanol × 1 CL CHLORIDE ION × 2 MG MAGNESIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;291 K;0.1 M Tris pH8.7, 0.2M MgCl2, 22% PEG3350
Resolution 2.34 Å R-free 0.244
7H9K PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr12478 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AW3 (1s,5s)-N-hydroxybicyclo[3.3.1]nonane-1-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.66 Å R-free 0.204
7H9L PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr14229 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AW6 (1s,5s)-bicyclo[3.3.1]nonane-1-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.42 Å R-free 0.172
7H9M PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr13527 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AW8 (1m)-1-(2,4-difluorophenyl)-4-methylpiperidine-2,6-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.49 Å R-free 0.180
7H9N PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr13347 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AXZ 3-(2-phenylethyl)-2-sulfanylideneimidazolidin-4-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 2.35 Å R-free 0.251
7H9O PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr13146 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AXA {4-[(oxan-4-yl)oxy]phenyl}methanol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.55 Å R-free 0.178
7H9P PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr12541 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded HX8 4-phenoxyphenol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.64 Å R-free 0.191
7H9Q PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr13944 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AX0 5-fluoro-2-methylbenzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.51 Å R-free 0.188
7H9R PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr14452 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AX2 N-(3-ethynylphenyl)acetamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.69 Å R-free 0.182
7H9S PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with FS-3027 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AXJ [2-(4-ethylpiperazin-1-yl)phenyl]methanol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 2.17 Å R-free 0.204
7H9T PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr12599 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AXL (5-methyl-1-phenyl-1H-pyrazol-4-yl)methanol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 2.48 Å R-free 0.277
7H9U PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr12864 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded 8K2 5-chloranylthiophene-2-sulfonamide × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.94 Å R-free 0.230
7H9V PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr12319 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AXO 8-carbamoyl-1-benzopyran-1-ium × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.52 Å R-free 0.187
7H9W PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr12314 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded SLS 3,4-dihydro-2~{H}-chromene-6-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.64 Å R-free 0.218
7H9X PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr14128 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AXD 3,4-dimethylbenzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.47 Å R-free 0.179
7H9Y PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with NH-0224 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AXF 1-[5-chloro-4-(difluoromethyl)pyridin-2-yl]piperazine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 2.11 Å R-free 0.218
7H9Z PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr12500 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AXH N-[(1R,2S,4S)-bicyclo[2.2.1]heptan-2-yl]-N'-methylthiourea × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 2.06 Å R-free 0.261
7HA0 PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr12546 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded 54F 3-(pyridin-2-yloxy)aniline × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.47 Å R-free 0.184
7HA1 PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with FL0092 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AX6 5-bromo-3,3-dimethyl-1,3-dihydro-2H-indol-2-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.46 Å R-free 0.196
7HA2 PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr14256 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AX8 3-amino-4-methylbenzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.73 Å R-free 0.203
7HA3 PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr14259 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AW0 3-ethyl-2-sulfanylidene-1,3-thiazolidin-4-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.98 Å R-free 0.201
7HA4 PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr14240 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AW1 2-chloro-4-(trifluoromethyl)benzene-1-sulfonamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.61 Å R-free 0.217
7HA5 PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with PS-3550 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AW2 1-[(4-bromophenyl)methyl]-1,4-diazepane × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.53 Å R-free 0.187
7HA6 PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with DH-0718 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AW5 6-bromo-1-methyl-3,4-dihydroquinolin-2(1H)-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.80 Å R-free 0.218
7HA7 PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with PS-5947 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AW7 4-bromo-3-[(dimethylamino)methyl]phenol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 2.27 Å R-free 0.234
7HA8 PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr14439 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AXY N-[(1R,2S,4R)-bicyclo[2.2.1]heptan-2-yl]-N'-[2-(pyridin-2-yl)ethyl]thiourea × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 2.22 Å R-free 0.249
7HA9 PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr13551 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AW9 N-[(1R,2S,4R)-bicyclo[2.2.1]heptan-2-yl]-N'-[(2S)-1-hydroxybutan-2-yl]thiourea × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 2.00 Å R-free 0.230
7HAA PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr13279 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AXB N-(5-chloro-2-methoxyphenyl)thiourea × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.67 Å R-free 0.180
7HAB PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr12700 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AXC (morpholin-4-yl)(phenyl)methanone × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.50 Å R-free 0.185
7HAC PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr13324 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AX1 3-(4-tert-butylphenyl)-3-oxopropanamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.68 Å R-free 0.202
7HAD PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr14363 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AX3 2,3-dimethylbenzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.59 Å R-free 0.191
7HAE PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr13215 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AXK N-[(1R,2R,4S)-bicyclo[2.2.1]hept-5-en-2-yl]-N'-(2-hydroxyethyl)thiourea × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.73 Å R-free 0.228
7HAF PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr13854 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AXM (2M)-2-(1H-imidazol-1-yl)benzonitrile × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.61 Å R-free 0.219
7HAG PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr14186 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AXN (3M)-3-(1H-imidazol-1-yl)benzonitrile × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.53 Å R-free 0.186
7HAH PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with PS-5160 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AXP [4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]methanol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.60 Å R-free 0.180
7HAI PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with PS-5525 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AXQ 2-(3-bromophenyl)-5-methyl-1,3,4-oxadiazole × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.65 Å R-free 0.194
7HAJ PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with PS-4122 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AXE 1-methyl-1H-indole-6-carboxylic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.57 Å R-free 0.189
7HAK PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with PS-6793 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AXG 8-fluoro-2-methylquinolin-4-ol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.72 Å R-free 0.216
7HAL PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr12580 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AX4 2-(piperidin-1-yl)pyridine-4-carbonitrile × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.65 Å R-free 0.194
7HAM PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr14242 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AX5 (1P)-1-(3-fluorophenyl)-1H-imidazole × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.77 Å R-free 0.206
7HAN PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with PS-3286 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AX7 (2P)-2-(1H-pyrazol-4-yl)pyrazine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.61 Å R-free 0.192
7HAO PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr13777 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AX9 (3M)-3-(1H-pyrazol-1-yl)benzonitrile × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.83 Å R-free 0.210
7HAP PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr13088 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded FMQ [1-(4-fluorophenyl)-5-methyl-1H-pyrazol-4-yl]methanol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 2.35 Å R-free 0.248
7HAQ PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr13428 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AYU 2-phenyl-5-(trifluoromethyl)-1,2-dihydro-3H-pyrazol-3-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.55 Å R-free 0.197
7HAR PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr12616 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AYW 4-(morpholin-4-yl)benzonitrile × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.77 Å R-free 0.195
7HAS PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr12355 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AYY [6-(pyrrolidin-1-yl)pyridin-2-yl]methanol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 2.08 Å R-free 0.212
7HAT PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr12860 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AY5 (furan-2-yl)(thiomorpholin-4-yl)methanone × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 2.04 Å R-free 0.219
7HAU PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr13098 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AYA [2-(4-methylpiperazin-1-yl)phenyl]methanol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.75 Å R-free 0.212
7HAV PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr12879 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AY0 3-amino-5-tert-butylthiophene-2-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 2.45 Å R-free 0.235
7HAW PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr12961 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AYD N-(2,4-difluorophenyl)-N'-methylthiourea × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.65 Å R-free 0.186
7HAX PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr13909 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AYF (3aR,7aS)-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 2.29 Å R-free 0.222
7HAY PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr14271 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AYH N-(2-{[(4-chlorophenyl)methyl]sulfanyl}ethyl)furan-2-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 2.27 Å R-free 0.238
7HAZ PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr12919 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AYI (2-phenoxyphenyl)methanol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.68 Å R-free 0.211
7HB0 PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr12780 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AYK 2-[(oxan-4-yl)oxy]aniline × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.78 Å R-free 0.199
7HB1 PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr12936 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A7Q (6-phenoxypyridin-3-yl)methanol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.66 Å R-free 0.193
7HB2 PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with FL0184 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AY2 2-methoxy-7,7-dimethyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.67 Å R-free 0.180
7HB3 PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr13043 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AYM N-(3-chloro-4-fluorophenyl)thiourea × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 2.34 Å R-free 0.237
7HB4 PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr14472 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AXV N-(3-methylphenyl)thiourea × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.87 Å R-free 0.188
7HB5 PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr13078 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded 6RO ~{N}-(4-chlorophenyl)methanesulfonamide × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.80 Å R-free 0.193
7HB6 PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr13755 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded 72R 5-fluoranyl-1~{H}-indole-2,3-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 2.09 Å R-free 0.250
7HB7 PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr12696 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded WP1 2,2-dimethyl-2,3-dihydro-1-benzofuran-7-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 2.98 Å R-free 0.280
7HB8 PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr13480 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AXS N-[(1R,2R,4S)-bicyclo[2.2.1]hept-5-en-2-yl]-N-methylthiophene-2-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.85 Å R-free 0.188
7HB9 PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr13464 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AYN 2,5-dichlorothiophene-3-sulfonamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.89 Å R-free 0.183
7HBA PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr13425 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AYO 4-(4,5-dichloro-1H-imidazol-1-yl)aniline × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 2.15 Å R-free 0.213
7HBB PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr13430 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AY4 3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazole-6-sulfonamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.84 Å R-free 0.198
7HBC PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr13229 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AYV 2-oxo-2,3-dihydro-1,3-benzoxazole-6-sulfonamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.86 Å R-free 0.201
7HBD PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr12810 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AYX N-(3-chlorophenyl)-2-cyanoacetamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.80 Å R-free 0.192
7HBE PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr12771 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AYZ 5-methyl-2-(trifluoromethyl)furan-3-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.79 Å R-free 0.186
7HBF PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr12938 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AY6 {3-[(pyridin-2-yl)oxy]phenyl}methanol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.97 Å R-free 0.219
7HBG PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr13237 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AYB N-methyl-1-{4-[(pyridin-2-yl)oxy]phenyl}methanamine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.69 Å R-free 0.176
7HBH PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr13518 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AYC (5-tert-butylthiophen-2-yl)(pyrrolidin-1-yl)methanone × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.80 Å R-free 0.208
7HBJ PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr13498 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AYE 6-(4-chloro-3-methylphenoxy)pyridin-3-amine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 2.65 Å R-free 0.265
7HBK PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr13232 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AYG 6-(2,3-dimethylphenoxy)pyridin-3-amine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 2.14 Å R-free 0.231
7HBL PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr12214 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded 9TW 3-chloranyl-4-fluoranyl-benzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.65 Å R-free 0.196
7HBM PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr13278 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AYJ N-cycloheptyl-N'-(2-hydroxyethyl)thiourea × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 2.21 Å R-free 0.238
7HBN PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr13145 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1ABL {2-[(oxan-4-yl)oxy]phenyl}methanol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.99 Å R-free 0.205
7HBO PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr13368 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AY1 N-[(1S,2S,4S)-bicyclo[2.2.1]hept-5-en-2-yl]-N'-butyl-N-methylurea × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 2.07 Å R-free 0.218
7HBP PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with Fr13188 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AYL N-(3,4-difluorophenyl)cyclobutanecarboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.91 Å R-free 0.201
7HBQ PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with FS-2731 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AXU 5-bromo-2-(1H-pyrazol-1-yl)pyrimidine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 2.73 Å R-free 0.265
7HBR PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with AS-5576 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AXW 4-(4-fluorophenyl)-1H-pyrazole × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.91 Å R-free 0.261
7HBS PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with 10X-0806 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AXX (5P)-2-chloro-5-(1,3-oxazol-5-yl)pyridine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.38 Å R-free 0.179
7HBT PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with PS-3621 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AXR [3-(4-methylphenyl)-1H-pyrazol-1-yl]acetic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.38 Å R-free 0.183
7HBU PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with CC-0741 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded KXQ 1~{H}-indole-7-carboxylic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.44 Å R-free 0.179
7HBV PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with PS-4833 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AXT 7-methoxy-1H-pyrrolo[2,3-c]pyridine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.56 Å R-free 0.189
7HBW PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with PS-4774 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AY3 3-bromo-1H-pyrazolo[3,4-c]pyridine × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.91 Å R-free 0.222
7HBX PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with AS-5591 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AY7 (3-methyl-5-phenyl-1,2-oxazol-4-yl)methanol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 2.25 Å R-free 0.256
7HBY PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with 9R-0342 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AYP N-[(4-fluorophenyl)methyl]-1H-pyrrole-2-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.82 Å R-free 0.208
7HBZ PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with 6R-0009 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AYQ (4R)-5-chloro-3-ethyl[1,2,4]triazolo[4,3-a]pyridine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.44 Å R-free 0.187
7HC0 PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with 4W-0801 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AYR 3-(3-bromothiophen-2-yl)-1H-pyrazole × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.66 Å R-free 0.197
7HC1 PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with 10T-0263 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AYS (3M)-3-(3-fluoro-4-methoxyphenyl)-4-methyl-1H-pyrazole × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 2.13 Å R-free 0.237
7HC2 PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with 2X-5009 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AW4 N-(pyridin-4-yl)cyclopropanecarboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 1.60 Å R-free 0.193
7HC3 PanDDA analysis group deposition -- Crystal structure of HSP90N in complex with 3T-0629 Deposited 2024-07-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded A1AYT 2,3-dimethylpyrido[2,3-b]pyrazine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;100mM Tris-HCl pH 8.5, 22% PEG4000, 200mM MgCl2
Resolution 2.22 Å R-free 0.293
7KRJ The GR-Maturation Complex: Glucocorticoid Receptor in complex with Hsp90 and co-chaperone p23 Deposited 2020-11-20 Assembly 1 Protein heterocomplex Heteromer;Protein × 4 PDB declaration: tetrameric(4) Consistent with protein count
Chain A 1–732(732 aa)
Chain B 1–732(732 aa)
Not recorded ATP ADENOSINE-5'-TRIPHOSPHATE × 2 MG MAGNESIUM ION × 2 DEX DEXAMETHASONE × 1 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.5
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.56 Å
7KW7 Atomic cryoEM structure of Hsp90-Hsp70-Hop-GR Deposited 2020-11-30 Assembly 1 Protein heterocomplex Heteromer;Protein × 6 PDB declaration: hexameric(6) Consistent with protein count
Chain A 1–732(732 aa)
Chain B 1–732(732 aa)
Not recorded ADP ADENOSINE-5'-DIPHOSPHATE × 2 MG MAGNESIUM ION × 2 K POTASSIUM ION × 2 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.5
cryo-EM vitrification conditions Cryogen ETHANE-PROPANE
Resolution 3.57 Å
7L7I Cryo-EM structure of Hsp90:FKBP51:p23 closed-state complex Deposited 2020-12-28 Assembly 1 Protein heterocomplex Heteromer;Protein × 4 PDB declaration: tetrameric(4) Consistent with protein count
Chain A 1–732(732 aa)
Chain B 1–732(732 aa)
Not recorded ANP PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER × 2 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.5
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.30 Å
7L7J Cryo-EM structure of Hsp90:p23 closed-state complex Deposited 2020-12-28 Assembly 1 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric(3) Consistent with protein count
Chain A 1–732(732 aa)
Chain B 1–732(732 aa)
Not recorded ANP PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER × 2 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.5
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.10 Å
7LSZ Hsp90a N-terminal inhibitor Deposited 2021-02-18 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–293(293 aa)
Not recorded ONG {3-[(2,3-dihydro-1,4-benzodioxin-6-yl)sulfanyl]-4-hydroxyphenyl}(1,3-dihydro-2H-isoindol-2-yl)methanone × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;277 K;23% PEGMME 2,000, 0.2 M magnesium chloride, 0.1M sodium cacodylate pH 6.5
Resolution 1.70 Å R-free 0.188
7LT0 Hsp90a N-terminal inhibitor Deposited 2021-02-18 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–293(293 aa)
Not recorded ONJ (1,3-dihydro-2H-isoindol-2-yl){3-[(3,4-dimethylphenyl)sulfanyl]-4-hydroxyphenyl}methanone × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;277 K;23% PEGMME 2,000, 0.2 M magnesium chloride, 0.1M sodium cacodylate pH 6.5
Resolution 1.70 Å R-free 0.204
7RXZ human Hsp90_MC domain structure Deposited 2021-08-24 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 293–714(422 aa)
Chain B 293–714(422 aa)
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;293 K;0.1M NaAc PH 6.0, 12 % PEG3350
Resolution 3.15 Å R-free 0.248
7RXZ human Hsp90_MC domain structure Deposited 2021-08-24 Assembly 2 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain C 293–714(422 aa)
Chain D 293–714(422 aa)
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;293 K;0.1M NaAc PH 6.0, 12 % PEG3350
Resolution 3.15 Å R-free 0.248
7RXZ human Hsp90_MC domain structure Deposited 2021-08-24 Assembly 3 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain E 293–714(422 aa)
Chain F 293–714(422 aa)
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;293 K;0.1M NaAc PH 6.0, 12 % PEG3350
Resolution 3.15 Å R-free 0.248
7RY0 human Hsp90_MC domain structure Deposited 2021-08-24 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 293–714(422 aa)
Chain B 293–714(422 aa)
Mutation:W320A Mutation:W320A DMS DIMETHYL SULFOXIDE × 3 GOL GLYCEROL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;293 K;0.1M Hepes PH 7.5, 20% PEG 400
Resolution 2.20 Å R-free 0.254
7RY1 human Hsp90_MC domain structure Deposited 2021-08-24 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 293–714(422 aa)
Chain B 293–714(422 aa)
Not recorded MDC N-[2-(1-MALEIMIDYL)ETHYL]-7-DIETHYLAMINOCOUMARIN-3-CARBOXAMIDE × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;293 K;0.1M Succinic acid PH 6.5, 12% PEG3350, 20mM CaCl2
Resolution 3.52 Å R-free 0.272
7RY1 human Hsp90_MC domain structure Deposited 2021-08-24 Assembly 2 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain C 293–714(422 aa)
Not recorded MDC N-[2-(1-MALEIMIDYL)ETHYL]-7-DIETHYLAMINOCOUMARIN-3-CARBOXAMIDE × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;293 K;0.1M Succinic acid PH 6.5, 12% PEG3350, 20mM CaCl2
Resolution 3.52 Å R-free 0.272
7S8Y Cryogenic apo Human Hsp90a-NTD Deposited 2021-09-20 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa)
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;291 K;100 mM HEPES, pH 7 and 1.6 M sodium citrate dihydrate
Resolution 1.59 Å R-free 0.191
7S8Z Room-temperature apo Human Hsp90a-NTD Deposited 2021-09-20 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa)
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;291 K;100 mM HEPES, pH 7 and 1.6 sodium citrate dihydrate
Resolution 1.64 Å R-free 0.168
7S90 Cryogenic Human Hsp90a-NTD bound to adenine Deposited 2021-09-20 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa)
Not recorded ADE ADENINE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;291 K;1.8 Malic acid, pH 7
Resolution 1.79 Å R-free 0.214
7S95 Room-temperature Human Hsp90a-NTD bound to adenine Deposited 2021-09-20 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa)
Not recorded ADE ADENINE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;291 K;1.8 M Malic acid, pH 7
Resolution 1.71 Å R-free 0.191
7S98 Cryogenic Human Hsp90a-NTD bound to N6M Deposited 2021-09-20 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa)
Not recorded N6M N-METHYL-9H-PURIN-6-AMINE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;291 K;1.8 M Malic acid, pH 7
Resolution 1.90 Å R-free 0.216
7S99 Room-temperature Human Hsp90a-NTD bound to N6M Deposited 2021-09-20 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa)
Not recorded N6M N-METHYL-9H-PURIN-6-AMINE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;291 K;1.8 M Malic acid, pH 7
Resolution 1.52 Å R-free 0.181
7S9F Cryogenic Human Hsp90a-NTD bound to BIIB021 Deposited 2021-09-20 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa)
Not recorded 94M 6-chloro-9-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-9H-purin-2-amine × 1 MG MAGNESIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;291 K;1.8 M Malic acid, pH 7
Resolution 2.30 Å R-free 0.246
7S9G Room-temperature Human Hsp90a-NTD bound to BIIB021 Deposited 2021-09-21 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa)
Not recorded 94M 6-chloro-9-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-9H-purin-2-amine × 1 MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;291 K;1.8 M Malic acid, pH 7
Resolution 1.79 Å R-free 0.196
7S9H Cryogenic Human Hsp90a-NTD bound to EC144 Deposited 2021-09-21 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa)
Not recorded 7PP 5-{2-amino-4-chloro-7-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-methylpent-4-yn-2 -ol × 1 MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;291 K;1.8 M Malic acid, pH 7
Resolution 1.45 Å R-free 0.184
7S9I Room-temperature Human Hsp90a-NTD bound to EC144 Deposited 2021-09-21 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa)
Not recorded 7PP 5-{2-amino-4-chloro-7-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-methylpent-4-yn-2 -ol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;291 K;1.8 M Malic acid, pH 7
Resolution 1.75 Å R-free 0.191
7UR3 Hsp90 alpha inhibitor Deposited 2022-04-21 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–293(293 aa)
Not recorded OJ3 (5-fluoro-1,3-dihydro-2H-isoindol-2-yl){4-hydroxy-3-[(2S)-2-hydroxy-5-phenylpentan-2-yl]phenyl}methanone × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;293 K;25% PEGMME 2000, 0.2 M magnesium chloride, and 0.1 M sodium cacodylate pH 6.5
Resolution 1.60 Å R-free 0.189
8AGI Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) in complex with JMC31 Deposited 2022-07-20 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa)
Not recorded M0U 1-[2,4-bis(oxidanyl)-5-propan-2-yl-phenyl]-5-[4-[(cyclohexylmethylamino)methyl]phenyl]-~{N}-ethyl-1,2,3-triazole-4-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;281 K;25% wt/vol PEG-4000, 200 mM magnesium chloride and 100 mM TRIS-HCl, pH 8.5
Resolution 2.10 Å R-free 0.276
8AGI Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) in complex with JMC31 Deposited 2022-07-20 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–236(236 aa)
Not recorded M0U 1-[2,4-bis(oxidanyl)-5-propan-2-yl-phenyl]-5-[4-[(cyclohexylmethylamino)methyl]phenyl]-~{N}-ethyl-1,2,3-triazole-4-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;281 K;25% wt/vol PEG-4000, 200 mM magnesium chloride and 100 mM TRIS-HCl, pH 8.5
Resolution 2.10 Å R-free 0.276
8AGJ Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112A in complex with JMC31 Deposited 2022-07-20 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa)
Mutation:K112A M0U 1-[2,4-bis(oxidanyl)-5-propan-2-yl-phenyl]-5-[4-[(cyclohexylmethylamino)methyl]phenyl]-~{N}-ethyl-1,2,3-triazole-4-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 6.5;281 K;25% wt/vol PEG-2000, 200 mM magnesium chloride and 100 mM sodium cacodylate, pH 6.5
Resolution 2.32 Å R-free 0.284
8AGJ Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112A in complex with JMC31 Deposited 2022-07-20 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–236(236 aa)
Mutation:K112A M0U 1-[2,4-bis(oxidanyl)-5-propan-2-yl-phenyl]-5-[4-[(cyclohexylmethylamino)methyl]phenyl]-~{N}-ethyl-1,2,3-triazole-4-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 6.5;281 K;25% wt/vol PEG-2000, 200 mM magnesium chloride and 100 mM sodium cacodylate, pH 6.5
Resolution 2.32 Å R-free 0.284
8AGL Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112R in complex with JMC31 Deposited 2022-07-20 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa)
Mutation:K112R M0U 1-[2,4-bis(oxidanyl)-5-propan-2-yl-phenyl]-5-[4-[(cyclohexylmethylamino)methyl]phenyl]-~{N}-ethyl-1,2,3-triazole-4-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;281 K;25% wt/vol PEG-4000, 200 mM magnesium chloride and 100 mM TRIS-HCl, pH 8.5
Resolution 2.20 Å R-free 0.297
8AGL Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112R in complex with JMC31 Deposited 2022-07-20 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–236(236 aa)
Mutation:K112R M0U 1-[2,4-bis(oxidanyl)-5-propan-2-yl-phenyl]-5-[4-[(cyclohexylmethylamino)methyl]phenyl]-~{N}-ethyl-1,2,3-triazole-4-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;281 K;25% wt/vol PEG-4000, 200 mM magnesium chloride and 100 mM TRIS-HCl, pH 8.5
Resolution 2.20 Å R-free 0.297
8FFV Cryo-EM structure of the GR-Hsp90-FKBP52 complex Deposited 2022-12-10 Assembly 1 Protein heterocomplex Heteromer;Protein × 4 PDB declaration: tetrameric(4) Consistent with protein count
Chain A 2–732(731 aa)
Chain B 2–732(731 aa)
Not recorded ATP ADENOSINE-5'-TRIPHOSPHATE × 2 MG MAGNESIUM ION × 2 DEX DEXAMETHASONE × 1 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.5
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.01 Å
8FFW Cryo-EM structure of the GR-Hsp90-FKBP51 complex Deposited 2022-12-10 Assembly 1 Protein heterocomplex Heteromer;Protein × 4 PDB declaration: tetrameric(4) Consistent with protein count
Chain A 2–732(731 aa)
Chain B 2–732(731 aa)
Not recorded ATP ADENOSINE-5'-TRIPHOSPHATE × 2 MG MAGNESIUM ION × 2 DEX DEXAMETHASONE × 1 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.5
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.23 Å
8JR6 Hsp90a N-terminal domain Deposited 2023-06-16 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–237(237 aa)
Not recorded No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 7;298 K;Ionic strength (raw mmCIF value) 100;Pressure 1
NMR sample composition 300 uM [U-13C; U-15N; U-2H] protein, 90% H2O/10% D2O | 90% H2O/10% D2O
Resolution not provided
8JR7 N-terminal domain of Hsp90 mutant Deposited 2023-06-16 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–237(237 aa)
Mutation:T36E No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 7;298 K;Ionic strength (raw mmCIF value) 100;Pressure 1
NMR sample composition 300 uM [U-13C; U-15N; U-2H] protein, 90% H2O/10% D2O | 90% H2O/10% D2O
Resolution not provided
8JRA N-terminal domain of Hsp90a mutant Deposited 2023-06-16 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–237(237 aa)
Mutation:T115E No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 7;298 K;Ionic strength (raw mmCIF value) 100;Pressure 1
NMR sample composition 0.3 mM [U-13C; U-15N; U-2H] protein, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition 0.5 mM [U-13C; U-15N] protein, 90% H2O/10% D2O | 90% H2O/10% D2O
Resolution not provided
8KI4 Crystal structure of human HSP90 in intermediate state Deposited 2023-08-22 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded EDO 1,2-ETHANEDIOL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8.5;277 K;100 mM Bis-Tris, pH 8.5, 20% PEG 3350, 200 mM NaF
Resolution 1.55 Å R-free 0.208
8KI4 Crystal structure of human HSP90 in intermediate state Deposited 2023-08-22 Assembly 2 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain B 9–236(228 aa)
Not recorded EDO 1,2-ETHANEDIOL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8.5;277 K;100 mM Bis-Tris, pH 8.5, 20% PEG 3350, 200 mM NaF
Resolution 1.55 Å R-free 0.208
8SBT Structure of human Hsp90-alpha bound to purine inhibitor PU-H36 Deposited 2023-04-04 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 123–358(236 aa)
Mutation:none MG MAGNESIUM ION × 1 ZUY 9-(pent-4-yn-1-yl)-8-[(2,4,6-trimethylphenyl)sulfanyl]-9H-purin-6-amine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277 K;PEG 2000 MME, Magnesium Chloride, Sodium Cacodylate
Resolution 1.50 Å R-free 0.197
8W4V Crystal structure of human HSP90 in complex with compound 4 Deposited 2023-08-25 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded MG MAGNESIUM ION × 2 Q9O 4-[2-[(dimethylamino)methyl]phenyl]sulfanylbenzene-1,3-diol × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.1;277 K;100 mM HEPES, pH 7.2, 200 mM MgCl2, 20% PEG 2000 MME
Resolution 1.81 Å R-free 0.195
8W8K Crystal structures of HSP90 and the compound Ganetespid in the "closed" conformation Deposited 2023-09-03 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded TUH 5-[2,4-dihydroxy-5-(propan-2-yl)phenyl]-4-(1-methyl-1H-indol-5-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one × 2 MG MAGNESIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8.5;277 K;100 mM Bis-Tris, pH 8.5, 20% PEG 3355, 200 mM NaF
Resolution 2.25 Å R-free 0.220
8W8K Crystal structures of HSP90 and the compound Ganetespid in the "closed" conformation Deposited 2023-09-03 Assembly 2 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain B 9–236(228 aa)
Not recorded TUH 5-[2,4-dihydroxy-5-(propan-2-yl)phenyl]-4-(1-methyl-1H-indol-5-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8.5;277 K;100 mM Bis-Tris, pH 8.5, 20% PEG 3355, 200 mM NaF
Resolution 2.25 Å R-free 0.220
8X2R The Crystal Structure of HSP 90-alpha from Biortus. Deposited 2023-11-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–236(236 aa)
Mutation:S52A GOL GLYCEROL × 4 EDO 1,2-ETHANEDIOL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;277 K;(Index-H6) 0.2M Sodium formate, 20% PEG 3350
Resolution 1.45 Å R-free 0.156
9AUU Hsp90 NTD in complex with compound 6 Deposited 2024-02-29 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 2–236(235 aa)
Not recorded A1AG2 3-{[(3R)-3-({6-amino-8-[(6-iodo-2H-1,3-benzodioxol-5-yl)sulfanyl]-9H-purin-9-yl}methyl)piperidin-1-yl]methyl}-6-fluoro-2-hydroxybenzaldehyde × 1 MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.2;293 K;20% PEG-3350, 0.2 M MgCl2, 0.1 M Bis-Tris pH 6.2
Resolution 2.00 Å R-free 0.222
9IMW Crystal structure of N-terminal domain of human Hsp90 Deposited 2024-07-04 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;277 K;20-25% (w/v) PEG 4000, 200mM magnesium chloride, 100mM Tris-HCl, pH 6.5
Resolution 1.53 Å R-free 0.181
9IMW Crystal structure of N-terminal domain of human Hsp90 Deposited 2024-07-04 Assembly 2 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 9–236(228 aa)
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;277 K;20-25% (w/v) PEG 4000, 200mM magnesium chloride, 100mM Tris-HCl, pH 6.5
Resolution 1.53 Å R-free 0.181
9KMR Human Hsp90-PINK1 complex Deposited 2024-11-17 Assembly 1 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric(3) Consistent with protein count
Chain A 1–732(732 aa)
Chain B 1–732(732 aa)
Not recorded ADP ADENOSINE-5'-DIPHOSPHATE × 2 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.98 Å
9KOX human Hsp90-FKBP51-PINK1 complex Deposited 2024-11-21 Assembly 1 Protein heterocomplex Heteromer;Protein × 4 PDB declaration: tetrameric(4) Consistent with protein count
Chain A 1–732(732 aa)
Chain B 1–732(732 aa)
Not recorded ADP ADENOSINE-5'-DIPHOSPHATE × 2 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 4.43 Å
9KQN Hsp90-Cdc37-PINK1 complex Deposited 2024-11-26 Assembly 1 Protein heterocomplex Heteromer;Protein × 4 PDB declaration: tetrameric(4) Consistent with protein count
Chain A 1–732(732 aa)
Chain B 1–732(732 aa)
Not recorded ADP ADENOSINE-5'-DIPHOSPHATE × 2 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.84 Å
9QQU Crystal structure of an engineered TPR domain in complex with the HSP90 peptide MEEVD Deposited 2025-04-02 Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain B 728–732(5 aa)
Non-standard monomer:Yes (specific site not provided by mmCIF) SO4 SULFATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 5;293 K;0.1M Sodium Acetate, pH 5.0 2.0 M Ammonium sulphate
Resolution 2.13 Å R-free 0.256
9X6X Hsp90a N-terminal domain Deposited 2025-10-16 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–237(237 aa) Fragment:N-terminal domain
Not recorded No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 7;298 K;Ionic strength (raw mmCIF value) 50;Pressure 1
NMR sample composition 300 uM [U-100% 15N] Hsp90a NTD, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition 300 uM [U-100% 13C; U-100% 15N] Hsp90a NTD, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition 300 uM [U-100% 13C Val,Thr,Leu,Met,Ala,Ile] Hsp90a NTD, 90% H2O/10% D2O | 90% H2O/10% D2O
Resolution not provided
9X70 Hsp90a T36E N-terminal domain Deposited 2025-10-16 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–237(237 aa) Fragment:N-terminal domain
Mutation:T36E No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 7;298 K;Ionic strength (raw mmCIF value) 50;Pressure 1
NMR sample composition 300 uM [U-100% 15N] Hsp90a T36E NTD, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition 300 uM [U-100% 13C-Leu,Val,Thr,Met,Ala,Ile] Hsp90a T36E NTD, 90% H2O/10% D2O | 90% H2O/10% D2O
Resolution not provided
9X71 the closed-form Hsp90a NTD Deposited 2025-10-16 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–237(237 aa) Fragment:N-terminal domain
Not recorded No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 7;298 K;Ionic strength (raw mmCIF value) 50;Pressure 1
NMR sample composition 300 uM [U-100% 15N] Hsp90a NTD, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition 300 uM [U-100% 13C; U-100% 15N] Hsp90a NTD, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition 300 uM [U-100% 13C Leu,Thr,Val,Ala,Ile,Met] Hsp90a NTD, 90% H2O/10% D2O | 90% H2O/10% D2O
Resolution not provided
9X72 closed-form Hsp90a T36E N-terminal domain Deposited 2025-10-16 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–237(237 aa) Fragment:N-terminal domain
Mutation:T36E No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 7;298 K;Ionic strength (raw mmCIF value) 50;Pressure 1
NMR sample composition 300 uM [U-100% 15N] Hsp90a T36E NTD, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition 300 uM [U-100% 13C Leu,Val,Ile,Thr,Met,Ala] Hsp90a T36E NTD, 90% H2O/10% D2O | 90% H2O/10% D2O
Resolution not provided
9X73 Hsp90a T115E N-terminal domain Deposited 2025-10-16 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–237(237 aa) Fragment:N-terminal domain
Mutation:T115E No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 7;298 K;Ionic strength (raw mmCIF value) 50;Pressure 1
NMR sample composition 300 uM [U-100% 15N] Hsp90a T115E NTD, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition 300 uM [U-100% 13C; U-100% 15N] Hsp90a T115E NTD, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition 300 uM [U-100% 13C-Leu,Met,Val,Ala,Thr,Ile] Hsp90a T115E NTD, 90% H2O/10% D2O | 90% H2O/10% D2O
Resolution not provided
9XZ1 KRAS(G12C)-RNK07311-HSP90(N-terminus) Deposited 2025-08-26 Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 123–358(236 aa)
Not recorded BTB 2-[BIS-(2-HYDROXY-ETHYL)-AMINO]-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 1 CA CALCIUM ION × 1 GDP GUANOSINE-5'-DIPHOSPHATE × 1 A1CRY (5M)-4-{4-[(4-{4-[2-({7-(8-chloronaphthalen-1-yl)-4-[(3S)-3-(cyanomethyl)-4-propanoylpiperazin-1-yl]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl}oxy)ethyl]piperazine-1-carbonyl}piperidin-1-yl)methyl]phenyl}-5-[2,4-dihydroxy-5-(propan-2-yl)phenyl]-4H-1,2,4-triazole-3-carboxamide × 1 MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 6.5;293.15 K;KRAS(G/C)-RNK07311-HSP90a complex was crystallized by sitting drop with vapor diffusion against 0.05M CaCl2, 0.1M Bis-Tris pH6.5, 30% PEGMME550 (drop size: 200 nl protein + 180nl reservoir + 20nl lysozyme seed).
Resolution 1.96 Å R-free 0.249